Allosteric Regulation of the First Enzyme in Histidine Biosynthesis by Livingstone, Emma Kathrine
 
 Allosteric Regulation of the 




A thesis submitted in partial fulfilment of the requirements for the 
degree of 
 
Master of Science with Honours in Chemistry 
 
In the Department of Chemistry 
At the University of Canterbury 
 






























The ATP-PRTase enzyme catalyses the first committed step of 
histidine biosynthesis in archaea, bacteria, fungi and plants.1 As the 
catalyst of an energetically expensive pathway, ATP-PRTase is subject 
to a sophisticated, multilevel regulatory system.2 There are two 
families of this enzyme, the long form (HisGL) and the short form 
(HisGS) that differ in their molecular architecture. A single HisGL 
chain comprises three domains. Domains I and II house the active site 
of HisGL while domain III, a regulatory domain, forms the binding site 
for histidine as an allosteric inhibitor. The long form ATP-PRTase 
adopts a homo-hexameric quaternary structure.3,4 HisGS comprises a 
similar catalytic core to HisGL but is devoid of the regulatory domain 
and associates with a second protein, HisZ, to form a hetero-octameric 
assembly.5   
 
 This thesis explores the allosteric regulation of the short form 
ATP-PRTase, as well as the functional and evolutionary relationship 
between the two families. New insight into the mode allosteric 
inhibition of the short form ATP-PRTase from Lactococcus lactis is 
reported in chapter two. A conformational change upon histidine 
binding was revealed by small angle X-ray scattering, illuminating a 
potential mechanism for the allosteric inhibition of the enzyme. 
Additionally, characterisation of histidine binding to HisZ by 
isothermal titration calorimetry, in the presence and absence of HisGS, 
provided evidence toward the location of the functional allosteric 
binding site within the HisZ subunit. 
 
 iv 
Chapter three details the extensive effort towards the 
purification of the short form ATP-PRTase from Neisseria menigitidis, 
the causative agent of bacterial meningitis. This enzyme is of 
particular interest as a potential target for novel, potent inhibitors to 
combat this disease. The attempts to purify the long form ATP-PRTase 
from E. coli, in order to clarify earlier research on the functional 
multimeric state of the enzyme, are also discussed.  
 
 Chapter four reports the investigation of a third ATP-PRTase 
sequence architecture, in which hisZ and hisGS comprise a single open 
reading frame, forming a putative fusion enzyme. The engineering of 
two covalent linkers between HisZ and HisGS from L. lactis and the 
transfer of the regulatory domain from HisGL to HisGS, is also 
discussed, in an attempt to delineate the evolutionary pathway of the 
ATP-PRTase enzymes. Finally, the in vivo activity of each functional 
and putative ATP-PRTase was assessed by E. coli BW25113ΔhisG 
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ACT domain – regulatory domain with a βαββαβ fold 
AICAR – 5’-phosphoribosyl-4-carboxamide-4-aminoimidazole 
AMP – adenosine monophosphate 
ATP – adenosine triphosphate 
ATP-PRTase – adenosine triphosphate phosphoribosyl transferase 
Cje – Campylobacter jejuni 
CjeACT – the ACT domain from Campylobacter jejuni 
Dmax – maximum dimension of the particle 
DNA – deoxyribonucleic acid 
Eco – Escherichia coli  
EDTA – ethylenediaminetetraacetic acid 
gDNA – genomic DNA 
GST – glutathione S-transferase 
HisGcore – domains I and II of HisGL 
HisGL – the long form ATP-PRTase 
HisGS – the catalytic subunit of the short form ATP-PRTase 
HisZ – the regulatory subunit of the short form ATP-PRTase 
HisZGS – the short form ATP-PRTase 
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The catalytic power of enzymes makes nature an exceptional 
chemist. Unravelling the secrets of how these large biomolecules 
control metabolic and cellular signalling pathways is necessary to 
understand the chemistry of life. This thesis explores the structure and 
function of the first enzyme in histidine biosynthesis, an enzyme that 
initiates a metabolically essential but energetically expensive reaction 
sequence. Understanding the tight regulation and diverse structures of 
this enzyme will help to probe the different modes of allosteric 
regulation and provide insight into the evolution of enzymes. 
 
1.1  L-Histidine Biosynthesis 
 
L-Histidine (hereafter referred to as histidine) is an essential amino 
acid that often plays a critical role in enzyme active sites. The 
imidazole side chain of histidine can be reversibly protonated at 
physiological pH, a property that allows it to act as a proton shuttle. 
Histidine residues often function as metal co-ordinating ligands in 
metallo-proteins and the free amino acid is able to be decarboxylated to 
form histamine, a neurotransmitter. The histidine biosynthetic 
pathway is present in archaea, bacteria, plants, and some lower 
eukaryotes. The absence of this pathway from mammalian metabolism 
highlights it as a potential target for herbicide6 and antibiotic design.7,8  
 
 2 
There are eight or nine genes that encode the enzymes that catalyse 
the ten reactions of histidine biosynthesis.2,9 These genes are usually 
arranged in an operon, referred to as the his operon. Early 
investigation into the histidine biosynthetic pathway aided the 
definition and refinement of operon theory10 and has unravelled some 
fundamental biological processes, including attenuation and feedback 
inhibition.2 Three of the genes of the his operon (hisD, hisB, and hisI) 
encode bifunctional enzymes and two (hisH and hisF) or sometimes 
four (hisZ and hisGS – discussed later) encode single polypeptide 
chains that assemble into a heteromeric enzyme that catalyses a single 
reaction.2 
 
The substrates of the first committed step of histidine biosynthesis, 
adenosine triphosphate (ATP) and 5-phosphoribosyl 1-pyrophosphate 
(PRPP) play a key role in intermediary and energy metabolism. Using 
ATP and PRPP, the first product N’-[5-phosphoribosyl]-ATP (PR-ATP) 
is formed via a phosphoribosyl transferase reaction (Figure 1.1). This 
step is followed by hydrolysis, resulting in N’-[5-phosphoribosyl]-AMP 
(PR-AMP). Hydrolytic opening of the adenosine ring results in the 
production of N’-[(5’-phosphoribosyl)-formimino]-5-aminoimidazole-4-
carboxamide-ribonucleotide (ProFAR). This intermediate undergoes 
ribose ring opening via an Amadori rearrangement to produce 
5’-phosphoribosyl-4-carboxamide-4-aminoimidazole (AICAR) and 
imidazole glycerol phosphate (IGP). Glutamine is deaminated to 
provide the ammonia required for this step. IGP is further dehydrated 
to give imidazole acetolphosphate (IAP). After transamination to 
histidinol phosphate and dephosphorylation, histidinol undergoes two 
sequential oxidation steps to produce histidine. The histidine 
biosynthetic pathway is closely linked to the biosynthesis of 
tryptophan, folates, pyrimidines, and is also linked to purine 
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biosynthesis via the AICAR cycle. The focus of this thesis is the 
phosphoribosyl transferase enzyme that catalyses the first committed 
step of this pathway, ATP-phosphoribosyl transferase (ATP-PRTase).2  
 
 
Figure 1.1 The histidine biosynthetic pathway. The names of the enzymes that catalyse each step are 























































































































1.2  Phosphoribosyl Transferases 
 
Phosphoribosyl transferase (PRTase) enzymes are of critical 
metabolic importance as they catalyse essential reactions in the 
biosynthesis of purines, pyrimidines, and the amino acids, tryptophan 
and histidine.11,12 These enzymes are structurally diverse and are 
organised into four classes based on their protein fold (Figure 1.2).4,11,13 
PRTases are characterised by the attack of a nitrogenous and generally 
aromatic base on PRPP, an activated form of ribose 5-phosphate. 
PRTase reactions require a divalent metal ion for catalysis and proceed 
with inversion of stereochemistry at the anomeric centre.12 The 
diversity of sequence and structure between the four types of PRTase 
suggests a convergent evolution of this enzyme family. 
 
The type I PRTases are the most well defined class of PRTase and 
are typically involved in nucleotide synthesis and salvage pathways. 
These include adenine, orotate, and hypoxanthine PRTase.  Type I 
PRTases generally consist of four domains: a core region that binds 
both PRPP and the nucleotide substrate, a flexible loop that closes over 
PRPP, a variable hood domain that recognises the specific nucleotide 
substrate, and a C-terminal region that facilitates dimerisation.9,10 
Type I PRTases comprise a parallel β-sheet catalytic fold flanked by 
α-helices and they are identified by a 13 amino acid PRPP binding 
motif that includes two acidic amino acids, four hydrophobic amino 
acids, and seven variable amino acids that usually include glycine and 
threonine.13,14 
 
The type II PRTases lack the distinct PRPP binding motif, which is 
limited to the type I PRTases. Type II PRTases include quinolate 
PRTase15 and nicotinic acid PRTase16 and are formed from a mixed α/β 
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N-terminal domain that resembles an open β-sandwich, and a β7α6 
C-terminal barrel.15 The quaternary structures of the type II PRTases 
vary from the hexameric Homo sapiens quinolate PRTase17 to the 
monomeric nicotinic acid PRTase of Saccharomyces cerevisiae,16 
although many exist as dimers.15 
 
The tryptophan biosynthetic enzyme, anthranilate PRTase, is an 
example of a type III PRTase. Anthranilate PRTase consists of a large 
mixed α/β C-terminal domain linked to a smaller N-terminal α-helical 
domain via a hinge region. The quaternary structure of anthranilate 
PRTase is described as a head-to-head dimer.18 The type IV PRTase 
enzymes are represented solely by ATP-PRTase. These enzymes 
consist of a mixed α/β bilobal catalytic domain with a PRPP binding 
motif that is conserved within the ATP-PRTase family and differs from 
that of the type I PRTases (Figure 1.3).3,4,19,20  
 
Figure 1.2 The array of PRTase protein folds. Single chains of each of the four PRTases are coloured by 
secondary structure with the PRPP binding regions coloured yellow. The type I PRTases are represented 
by hypoxanthine PRTase from Trypanosoma cruzi (PDB 1TC2). Quinolate PRTase from Mycobacterium 
tuberculosis represents the type II PRTases (PDB 1QPR). M. tuberculosis anthranilate PRTase (PDB 
3QSA) and Lactococcus lactis ATP-PRTase (HisGS) (PDB 1Z7M) represent the type III and type IV 
PRTases respectively. 
 6 
Several PRTases have complex quaternary structures and 
sophisticated regulatory mechanisms, including glutamine PRPP 
amidotransferase, which catalyses the first committed step of purine 
biosynthesis,21 and ATP-PRTase.22,23 Both of these enzymes exhibit 
pathway end product inhibition and regulation by metabolites that 
reflect cellular energy levels, although the mechanism of this 
regulation is not well understood for either enzyme. 
 
Figure 1.3 Multiple sequence alignment of several ATP-PRTase enzymes. An asterisk indicates conserved 
residues and a colon indicates residues with conserved functionality. The PRPP binding motif is coloured 
yellow. Organism names are as follows: Eco – Escherichia coli, Mtu – Mycobacterium tuberculosis, Cje – 
Campylobacter jejuni, Lla – Lactococcus lactis, Tma – Thermotoga maritima, Nme – Neisseria 
meningitidis. The sequence identity across this family is typically 20-30%. 
 
1.3 ATP-Phosphoribosyl Transferase 
 
 The ATP-phosphoribosyl transferase enzyme (ATP-PRTase, 
HisG) encoded by the hisG gene is responsible for initiating histidine 
biosynthesis.1,23 ATP-PRTase catalyses the reversible Mg2+-dependent 
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condensation of PRPP and ATP to yield PR-ATP and inorganic 
pyrophosphate (Figure 1.4).23 ATP-PRTase has been studied since the 
1950s and this early effort, predominantly by Martin et al., resulted in 
a basic understanding of its reaction chemistry.1,22 Kinetic 
characterisation of the ATP-PRTase enzymes from Escherichia coli, 
Salmonella typhimurium, Lactococcus lactis and Mycobacterium 
tuberculosis revealed that the reaction follows an ordered bi-bi kinetic 
mechanism with ATP binding first and PR-ATP leaving last.3,24-26 The 
mechanistic details of the substitution reaction are yet to be deduced. 
ATP-PRTase has also been shown to be feedback regulated 
competitively by adenosine monophosphate (AMP) and allosterically by 
histidine.22,27 
 
 The enzymes of histidine biosynthesis are potential 
pharmaceutical targets for a wide range of pathogens including 
Neisseria meningitidis, the causative agent of bacterial meningitis, and 
M. tuberculosis, which causes tuberculosis. The essentiality of the 
ATP-PRTase reaction and the histidine biosynthetic pathway to the 
survival of M. tuberculosis has been confirmed by high resolution 
transposon mutagenesis28 and by genetic knockouts of other enzymes 
in the pathway.29 Furthermore, the absence of this pathway from 
mammalian metabolism may indicate no a priori toxicity associated 
with potential inhibitors targeting these enzymes. There are two 
distinct subfamilies of ATP-PRTase that differ in their molecular 
architecture,3,20 and an understanding of the structure and function of 





Figure 1.4 The reaction catalysed by the ATP-PRTase enzyme.  
 
1.3.1 The Long Form of ATP-PRTase 
 
The long form of ATP-PRTase (HisGL) is present in most 
bacteria, as well as fungi and plants.2 A single polypeptide chain of 
HisGL consists of 280-310 amino acids and comprises three 
domains (Figure 1.5 A).3 Domains I and II form the catalytic core of 
HisGL, with Domain II topographically inserted into Domain I (Figure 
1.5 C).  
 
The active site lies in the cleft between Domains I and II and 
includes a conserved PRPP binding motif.13 Domain III is a regulatory 
domain that adopts the classic βαββαβ ACT domain fold30 and forms 
the binding site for histidine as an allosteric inhibitor.3 The ACT 
domain is a common regulatory motif found in many enzymes involved 
in amino acid metabolism.31 The ACT domain was named after the 
three enzymes in which it was first discovered: aspartate kinase, 
chorismate mutase, and TyrA (prephenate dehydrogenase).32 X-ray 
crystal structures have revealed a homo-hexameric quaternary 
structure of the long form ATP-PRTase (Figure 1.5B).3,4 The long form 
ATP-PRTase enzymes from M. tuberculosis,33 E. coli,4 and 


























encodes two isozymes of HisGL, which share 82% sequence identity, but 
the structure and function of these isozymes is not well understood.35.36 
 
Figure 1.5 A) Single HisGL chain from M. tuberculosis (PDB 1NH8) with domain I coloured blue, domain II 
coloured green, and domain III coloured red. The PRPP binding motif is coloured yellow and AMP is shown 
bound in the active site. B) The hexameric quaternary structure with a single chain of HisGL coloured by 
domain, a second chain of HisGL coloured purple to show the dimer interface, and the remaining four 
chains shown in grey. C) A schematic of the HisGL amino acid sequence with M. tuberculosis HisGL 
numbering shown. 
 
1.3.2 The Short Form of ATP-PRTase 
 
The short form, denoted HisGS to illustrate its relationship to 
HisGL, is approximately 80 amino acids shorter than HisGL at the 
C-terminus of the protein (Figure 1.6).5,37 HisGS is restricted to 
proteobacteria and some bacteria and bioinformatic analysis has 
indicated that it is likely to be the phylogenetically older form of 
ATP-PRTase.19,37 Structural characterisation of the short form 
enzymes from L. lactis and Thermotoga maritima has been 
reported.19,20 HisGS has approximately 25 % sequence identity to HisGL 
and consists of two domains comparable to domains I and II of HisGL, 
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but is devoid of the ACT regulatory domain (Figure 1.6 B). 
Surprisingly, HisGS appears to be catalytically inactive on its 
own19,20,38 and instead forms a non-covalent complex with a second 
protein, HisZ, to generate a functional enzyme.5  
 
 
Figure 1.6 A) Two views of the HisZGS complex from L. lactis (PDB 1Z7M). One HisGS chain is coloured by 
domain, the remaining four HisGS chains are shown in cyan and the four HisZ chains are coloured red. B) 
A single HisGS chain coloured by domain. The cleft between domains I (blue) and II (green) houses the 
active site and the conserved PRPP binding region is shown in yellow. PRPP is shown bound in the active 
site. C) Schematic of the HisGS polypeptide chain coloured by domain and numbered according to the 
L. lactis sequence. 
 
HisZ is a paralogue of class II histidyl-tRNA synthetase.5 
Aminoacyl-tRNA synthetases are enzymes responsible for correctly 
matching amino acids with their cognate tRNA to maintain the fidelity 
of the genetic code. This relationship reflects a clear evolutionary link 
between the synthesis of proteins and their amino acid building 
blocks.5 The correlation between the absence of the ACT domain and 
the presence of HisZ, as well as the evolutionary relationship between 
HisZ and histidyl-tRNA synthetase, suggests that HisZ plays a role in 
the allosteric regulation by histidine.19,20 HisZ from L. lactis does 
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exhibit non-specific RNA binding properties but this no longer appears 
to be functionally significant.5 Although HisZ does not display 
phosphoribosyl transferase activity itself, it is believed to be required 
for catalysis, as an E. coli hisG knockout strain required 
co-transformation of plasmids containing both hisGS and hisZ from 
L. lactis in order to grow on histidine deficient media.5 The molecular 
basis for this requirement is unknown. The HisZ and HisGS complex 
from L. lactis and T. maritima adopts a hetero-octameric quaternary 
structure (Figure 1.6A).19,20,39  
 
1.3.3 Catalytic Mechanism 
 
The ATP-PRTase reaction follows an ordered bi-bi kinetic 
mechanism with ATP binding first and PR-ATP leaving last.24 
Pre-steady state kinetics showed that product release, rather than 
chemical reaction, is likely to be rate-limiting.33 The reaction was 
initially believed to proceed via the formation of a covalent 
intermediate, however, detailed kinetic analysis has refuted the 
involvement of such an intermediate.40  
 
The reaction chemistry is a nucleophilic substitution that 
proceeds with inversion of stereochemistry.41 The mechanism of the 
ATP-PRTase reaction is yet to be determined, although two 
mechanisms can be proposed (Figure 1.7). The reaction may proceed 
via a dissociative (SN1-like) mechanism in which the pyrophosphate 
leaving group of PRPP dissociates first, resulting in an oxocarbenium 
ion intermediate. This is followed by nucleophilic attack of the 1-N of 
the adenosine ring of ATP on the oxocarbenium ion. Alternatively, the 
reaction may proceed via an associative (SN2-like) mechanism in which 
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nucleophilic attack and dissociation of the leaving group occur in the 
same step, without the formation of a discrete intermediate. The 
degree of SN1-like or SN2-like character can be discerned by 
determining the structure of the transition state. The transition state 
structure is likely to vary between enzymes of different organisms.42 
 
Parsons et al. have used kinetic isotope effects to study the 
mechanism of all four classes of PRTase from S. typhimurium, 
including ATP-PRTase.43 Types I, II and III PRTases were clearly 
shown to follow an SN1-like mechanism, with large 3H kinetic isotope 
effects observed, consistent with the formation of an oxocarbenium ion 
intermediate. The results of the analysis for ATP-PRTase also 
indicated an SN1-like mechanism, however these results were less 
conclusive due to the reverse reaction potentially supressing the 
overall kinetic effect. It is probable that, in accordance with the other 
three classes of PRTase, ATP-PRTase proceeds via an SN1-like 
reaction, however the observation that ATP binds first, and that the 
mechanism is sequential, means that possible participation of the ATP 
nucleophile cannot be excluded.  
 
 







































1.3.4 ATP-PRTase Structure 
 
The HisGL and HisGS chains both possess a bilobal catalytic 
domain that is homologous to the periplasmic binding proteins that 
bind sulfate, phosphate, and other small molecules.44,45 Early 
biochemical work on ATP-PRTase focused on the relationship of the 
quaternary structure to the catalysis and regulation of the 
enzyme.23,46-48 There are a total of 12 crystal structures available in the 
protein data bank (PDB).49 These include the long form structures from 
E. coli (PDB 1Q1K and 1H3D),4 M. tuberculosis (PDB 1NH7 and 
1NH8),3 and Methanobacterium thermoautotrophicum (PDB 2VD3), 
the short form complex from L. lactis (PDB 1Z7M and 1Z7N)20 and 
Thermotoga maritima (PDB 1USY),19 and the HisGS dimer from 
Bacillus subtilis (PDB 2VD2) and Thermus thermophilus (PDB 1VE4) .  
 
Long Form ATP-PRTase Structure 
 
In 2003 Cho et al. provided the first glimpse of the ATP-PRTase 
structure with the publication of two X-ray crystal structures of the 
enzyme from M. tuberculosis (MtuHisGL).3 MtuHisGL was solved to 
1.8 Å in the presence of the inhibitors AMP and histidine (PDB 1NH8), 
and to 2.7 Å in the absence of ligands (PDB 1NH7). This was quickly 
followed by the publication of a 2.7 Å crystal structure of the AMP 
bound ATP-PRTase from E. coli (EcoHisGL) (PDB 1H3D), and a second 
EcoHisGL structure at a resolution of 2.9 Å with the product, PR-ATP, 
partially modelled into the active site* (PDB 1Q1K).4 A single chain of 
MtuHisGL (PDB 1NH7) aligns to EcoHisGL (PDB 1H3D) with an RMSD 
of 1.6 Å, reflecting a high degree of similarity between the overall folds 
the two structures. As described in section 1.3.1, the monomeric unit of 
                                            
* The ribosyl-triphosphate could not be resolved. 
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HisGL consists of three domains.3 Domain I is formed from an 
antiparallel β-sheet flanked by four α-helices, one of which links to 
domain III, the ACT regulatory domain. Domain II consists of a 
twisted β-sheet core, surrounded by α-helices. Domains I and II are 
connected by a twisted β-ribbon and the crevice between the two 
domains houses the active site, which includes the conserved PRPP 
binding motif (Figure 1.8 A).  
 
Early biochemical work on EcoHisGL suggested that the long 
form ATP-PRTase adopts an active dimeric structure (Figure 1.8 B), 
and that binding of histidine, as an allosteric inhibitor, facilitates the 
transition to an inactive hexameric species.46 This dimer-hexamer 
model was supported by analytical size exclusion chromatography, 
performed by Cho et al., on the long form enzyme from M. tuberculosis, 
although the experimental data were not presented.3 This model 
persisted despite the revelation of the hexameric crystal structures of 
ATP-PRTase from both organisms in the absence of ligands and in the 
presence of PR-ATP, histidine, and AMP (Figure 1.9).3,4 Lohkamp et al. 
attributed the hexameric crystal structure to the high concentration of 
protein in the crystal, citing the propensity of the enzyme to aggregate 
at high concentrations.4,50 Recent work by Pedreno et al.,33 on the 
ATP-PRTase from M. tuberculosis, has challenged the dimer-hexamer 
model of the long form ATP-PRTase and has been supported by further 
studies, using a variety of biophysical techniques, on HisGL from 
Campylobacter jejuni (Gerd Mittelstädt personal communication). 
Contrary to previous reports, it appears more likely that the active and 
inactive states are both hexameric. Koshland et al. in 1974, also 
suggested that the physiologically relevant form of ATP-PRTase from 
S. typhimurium is hexameric, although a variety of oligomeric states 
were observed.51  
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 The dimer interface of HisGL is antiparallel, with domain I of 
one chain of HisGL interacting with domain II of the second HisGL 
chain (Figure 1.8 B). Domain I joins the ACT domain via a loop 
connected to a long α-helix. Interestingly, this loop is unresolved in the 
MtuHisGL crystal structures, suggesting that this region is quite 
flexible. The contacts responsible for formation of the homo-hexameric 
quaternary structure are almost exclusively between the ACT domains. 
 
Figure 1.8 A) A single chain of MtuHisGL (PDB 1NH7) coloured by secondary structure. The active site is 
situated in the cleft between domains I and II and the PRPP binding motif is coloured yellow. B) Two 
chains of MtuHisGL coloured by domain with the dimer interface indicated by a dotted line. 
 
Figure 1.9 The hexameric quaternary structure of MtuHisGL coloured by chain. 
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Short Form ATP-PRTase Structure 
 
X-ray crystal structures of the short form ATP-PRTase from 
L. lactis (LlaHisZGS) and T. maritima (TmaHisZGS) have revealed a 
hetero-octameric quaternary structure that is unusual among both the 
phosphoribosyl transferases and the aminoacyl-tRNA synthetases.19,20 
Despite the similarity in the folds of the individual chains, the 
TmaHisZGS complex (PDB 1USY) aligns to LlaHisZGS (PDB 1Z7M) 
with an RMSD of 20 Å. It is unclear whether this difference is due to 
ligand-induced conformational changes, crystal packing, or sequence 
differences. The comparison of LlaHisZGS and TmaHisZGS is explored 
further in chapter two. 
 
The short form complex consists of four subunits of HisZ 
arranged in an X-shaped core with two large cavities, each of which 
binds two subunits of HisGS  (Figure 1.11). HisZ typically consists of 
300-350 amino acids and comprises a seven-stranded antiparallel 
β-sheet flanked by α-helices. HisZ features the three domains 
characteristic of histidyl-tRNA synthetases52 and class II 
aminoacyl-tRNA synthetase paralogues,53,54 but possesses an α-helical 
distal domain with a different topology (Figure 1.10).19 In the absence 
of HisGS, TmaHisZ has been reported to exist as a dimer-tetramer 
equilibrium in solution, however no data were shown to support this 
observation.19  HisZ usually lacks the anticodon binding domain of the 
histidyl-tRNA synthetase and is therefore devoid of amino acylation 
activity.5 The HisZ proteins from the Geobacter clade, however, are 
formed from approximately 550 amino acids and sequence analysis has 
attributed the additional amino acids to the retention of the anticodon 
binding domain.38  
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The bacteria of the Geobacter clade are the only organisms 
reported to date whose genome encodes both a long and short form 
ATP-PRTase. Gene knockout studies demonstrated that the short form 
is the predominant ATP-PRTase, while the long form functions mainly 
under nitrogen fixation conditions.38 Surprisingly, Aklujkar et al. also 
observed that HisZ is essential to the survival of Geobacter 
sulfurreducens, both in the presence and absence of an exogenous 
source of histidine. This unexpected result may be due to a poorly 
constructed knockout or could potentially indicate another essential 
function of HisZ in the cell.38 
 
 
Figure 1.10 A) A single chain of TmaHisZ (PDB 1USY) coloured by domain. B) TmaHisZ aligned with the 
histidyl-tRNA synthetase (grey) from Thermus thermophilus (PDB 1H4D) with an RMSD of 4.108 Å. 
TmaHisZ is coloured by domain as in A. The folds of the core and proximal domains are similar. The distal 
subdomain, responsible for interaction between HisZ and HisGS, differs in topology. TmaHisZ also lacks 
the anticodon binding domain.  
 
It has been noted that HisZ is required for catalysis, despite 
HisGS housing the active site, however, the molecular details that 
account for this activation are unclear. The crystal structures of HisGS 
from B. subtilis (PDB ID 2VD2) and T. thermophilus (PDB ID 1VE4) 
reveal a dimeric structure of the protein in the absence of HisZ.  Both 
of these structures readily superimpose with the HisGS chains from the 
LlaHisZGS hetero-octameric complex, indicating no major 
conformational changes of HisGS in the presence or absence of HisZ 
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(Figure 1.12). Further research into the structure and dynamics of the 
short form ATP-PRTase is required to determine the role of HisZ in 
catalysis and to understand how this catalytic activity evolved via 
collaborative adaptation of two distinct ancestral proteins. 
 
 
Figure 1.11 A) Two views of the TmaHisZ core (PDB 1USY). One chain of HisZ is coloured by domain, a 
second HisZ chain is coloured purple to show the dimer interface, and the remaining two chains are 
coloured grey. B) The TmaHisZGS hetero-octameric complex. The HisZ subunits are coloured as in A and 
oriented as shown on the RHS. The four HisGS chains are coloured cyan.  
 
Figure 1.12 LlaHisZGS hetero-octameric structure (PDB 1Z7N) with a single chain of LlaHisGS (coloured 
by domain) aligned with the HisGS crystal structure from T. thermophilus (PDB 1VE4), coloured grey 
(RMSD 1.3 Å). 
 19 
1.4  Regulation of ATP-PRTase 
 
Histidine biosynthesis is one of the most energetically expensive 
metabolic pathways and ATP-PRTase, as the catalyst of the first 
committed step of this pathway, represents the commitment of 41 ATP 
equivalents to the synthesis of one molecule of histidine. Cells that 
exhibit unregulated histidine biosynthesis have been shown to 
dissipate up to 2.5% of metabolic energy.55 As a result; ATP-PRTase is 
subject to an elaborate multilevel regulatory system.  
 
1.4.5 Regulation on the Level of Transcription 
 
A high concentration of histidine inhibits the transcription of the 
histidine operon, mediated by the attenuation effect of histidyl-tRNA, 
thereby preventing the synthesis of the histidine biosynthetic 
enzymes.2 Promoter substitution in Corynebacterium glutamicum, 
whereby the histidine promoter region was exchanged for the stronger 
tac promoter, disrupted transcriptional regulation, resulting in 
increased levels of histidine biosynthesis.56  
 
1.4.6 Feedback Inhibition  
 
Adenosine monophosphate (AMP) and adenosine diphosphate 
(ADP) act as competitive inhibitors of ATP-PRTase with respect to both 
ATP and PRPP (Figure 1.13).27 AMP and ADP reflect a low overall 
energy status of the cell and a need to down regulate energetically 
expensive pathways such as histidine biosynthesis. The product 
PR-ATP also inhibits the enzyme, as does inorganic pyrophosphate, 
and ATP when it is present in excess.25  HisGL also loses specific 
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activity at high protein concentrations, although this may reflect a 
tendency of the enzyme to aggregate at high concentrations – a 
phenomenon that is unlikely to be biologically significant.50 The most 
prominent control of ATP-PRTase activity is the overall synergistic 
inhibition by AMP and the allosteric inhibitor histidine.27  
 
 
Figure 1.13 Crystal structure of MtuHisGL (1NH8) with AMP bound in the active site. The PRPP binding 
motif is coloured yellow. AMP is shown to partially occupy both the ATP and PRPP binding regions, which 
provides a molecular basis for the competitive nature of the inhibition with respect to both substrates. 
 
1.4.7 Allosteric Regulation by Histidine 
 
The two families of ATP-PRTase differ significantly in their 
quaternary structure and likely transition between active and inactive 
states via two very different mechanisms.  
 
Long Form of ATP-PRTase 
 
The X-ray crystal structure of the histidine and AMP-bound 
MtuHisGL (PDB 1NH8), reveals the location of the histidine binding 
sites at the cleft between two ACT domains in the hexamer, 
approximately 30 Å from the active site.3 One histidine molecule binds 
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per ACT domain, for a total of six in the hexamer. The interaction of 
histidine with conserved residues suggests that these binding sites are 
likely to be biologically functional (Figure 1.14). Although Cho et al. 
attributed the mode of regulation to oligomerisation from an active 
dimer to an inactive hexamer, facilitated by histidine binding, recent 
work has suggested a more subtle mechanism of allosteric regulation.33 
It appears that with a combination of AMP and histidine MtuHisGL 
exists as a tight hexamer, caused by a slight twist in the ACT domains 
relative to domains I and II (Figure 1.15). Domains I and II of the 
unliganded and histidine/AMP bound MtuHisGL crystal structures 
align with an RMSD of 1.4 Å, whereas the relative positioning of the 
ACT domains differs by approximately 13 Å, indicative of a 
conformational change. This is consistent with the observation of Tebar 
et al. that the radius of the EcoHisGL enzyme decreases in the presence 
of histidine.57 Further research is required to determine how this 
allosteric inhibition is communicated. Tightening of the hexamer may 
not be enough to attribute inhibition to steric hindrance, as there 
remains a cavity of sufficient size for substrate and product diffusion. 
To this end, molecular dynamics simulations may prove to be 
invaluable, as it has been well established that dynamics and 
conformational changes are both important for allosteric signal 
transduction.58  
 
The proposed histidine binding residues have been supported by 
recent work on C. glutamicum HisGL. Schendzielorz et al. developed a 
method for the in vivo identification of mutant strains that over 
produce histidine.59 In the process they discovered that the HisGL 
mutants GT233HQ, N216R, and N216I had significantly impaired 
histidine inhibition. Homology modelling and mutagenesis by Zhang et 
al. demonstrated that N216, L231, T235, and A271 play a role in 
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histidine inhibition in C. glutamicum and possibly serve as histidine 
binding residues.60 pH dependence of allosteric inhibition of MtuHisGL 
has also been observed. Pedreno et al. measured histidine binding to 
MtuHisGL using saturation transfer difference NMR. A neutral 
α-amino group was shown to achieve the tightest binding to the 
enzyme, however superior inhibition is achieved with a neutral 
imidazole group and an ionised α-amino group.33 
 
 
Figure 1.14 The histidine binding site of MtuHisGL (PDB 1NH8) between two ACT domains (coloured red 
and blue). Hydrogen bonds are indicated by purple dotted lines. 
 
 
Figure 1.15  Crystal structures of MtuHisGL depicting A) the unliganded hexamer (PDB 1NH7), and B) the 
histidine and AMP bound hexamer (PDB 1NH8). The ACT domain interfaces are shown (truncated at the 
dotted lines) to demonstrate the transition from unliganded (C) to histidine bound (D) structures.  
 23 
Short Form of ATP-PRTase 
 
The mode of allosteric inhibition of the short form ATP-PRTase 
is unclear. Analytical ultracentrifugation experiments on LlaHisZGS 
showed a change in the sedimentation coefficient in the presence of 
histidine.39 This may be interpreted as a change in the conformation or 
subunit composition of the protein. In contrast, dynamic light 
scattering on TmaHisZGS indicated that histidine binding had no effect 
on the hydrodynamic radius of the protein.19 
 
The X-ray crystal structure of TmaHisZGS has been solved in 
the presence of histidine to 2.5 Å.19 Eight histidine binding sites, 
located at each of the HisZ-HisGS interfaces, are shown in the 
hetero-octamer (Figure 1.16). It was later revealed that mutation of 
conserved residues in LlaHisZ, homologous to the active site of the 
histidyl-tRNA synthetase, resulted in a loss of allosteric inhibition 
without affecting phosphoribosyl transferase activity.26 This 
observation cast doubt on the biological relevance of the histidine 
binding sites reported in the T. maritima structure. It should be noted 
that it was the loss of histidine inhibition that was detected, as 
opposed to the loss of histidine binding; therefore mutation of these 
residues may have interfered with transmission of the allosteric signal 
rather than histidine binding. Nevertheless, any of the three potential 
binding sites represents a different mode of allosteric inhibition to the 
long form ATP-PRTase. The discrepancy between the histidine binding 




Figure 1.16 Crystal structure of TmaHisZGS with histidine bound (PDB 1USY). The HisZ chains are 
shown in red, HisGS chains in blue, and the bound histidine ligands are coloured yellow. A) The hetero-
octameric structure with the histidine ligands shown as spheres. B) Two histidine binding sites at the 
interface of HisZ and HisGS. 
 
1.5  Objectives of this Thesis 
 
The aim of this research is to investigate the allosteric 
regulation of the short form ATP-PRTase by histidine and to explore 
the functional and evolutionary relationship between the two families 
of ATP-PRTase. Chapter two describes the cloning, expression, and 
purification of the short form ATP-PRTase from L. lactis and the use of 
small angle X-ray scattering and isothermal titration calorimetry to 
characterise the allosteric regulation of the enzyme.  
 
Chapter three details the attempts to clone, express, and purify 
the short form ATP-PRTase from N. meningitidis, the causative agent 
of meningitis, as an understanding of the structure and function of this 
enzyme could inform the design of antibiotics to combat this disease. 
The attempts to clone, express, purify and characterise the long form 
ATP-PRTase from E. coli, with the intent of clarifying the previous 
work on the dimer-hexamer model of allosteric inhibition, are also 
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described, as is the synthesis of a truncation mutant that is devoid of 
the ACT regulatory domain.  
 
Chapter four reports the first study of a third molecular 
architecture of ATP-PRTase from Leuconostoc mesenteroides, in which 
HisZ and HisGS are covalently linked. This architecture was 
investigated both by cloning, expression and homology modelling of the 
wild-type fused enzyme and by engineering a covalent linker between 
HisZ and HisGS from L. lactis. The transfer of the ACT domain from 
HisGL of C. jejuni to HisGS of L. lactis is also reported, in the attempt 
to model the domain transfer event that conferred both allosteric 
regulation and phosphoribosyl transferase activity to the short form 











Chapter Two  
 




Allostery, whereby ligand binding at one site affects catalysis at 
another remote functional site, is a common feature of key metabolic 
enzymes. A spectrum of general allosteric mechanisms has been 
proposed, ranging from the traditional paradigm of large 
conformational changes, to perturbations of backbone and side chain 
dynamics, to local unfolding of the protein.58 Histidine acts as an 
allosteric inhibitor of ATP-PRTase. The histidine binding sites at the 
interfaces of the ACT domains in the long form ATP-PRTase have been 
well established, and an allosteric mechanism involving subtle 
conformational changes has been proposed.3,33,56 A lack of structural 
information has precluded the development of a convincing model for 
the allosteric inhibition of the short form ATP-PRTase. The HisZGS 
complexes from L. lactis and T. maritima represent the only 
structurally characterised short form enzymes, and discrepancies exist 
between the reported response to histidine binding and the location of 
the functional allosteric sites within the two enzymes (Figure 
2.1).19,20,26,39 
 
Analytical ultracentrifugation experiments, reported by Bovee et 
al., indicated a change in the sedimentation coefficient of LlaHisZGS 
upon the addition of histidine.39 This may be interpreted as a change in 
the subunit composition or the conformation of the protein. In contrast, 
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Vega et al. reported that dynamic light scattering suggested the 
hydrodynamic radius of TmaHisZGS was unaffected by histidine 
binding, although no data were shown to support this observation.19  
 
 
Figure 2.1 The crystal structure of LlaHisZGS (PDB 1Z7N) with each of the three proposed histidine 
binding sites shown. The active site is indicated by a yellow dot. Histidine (green) is shown modelled into 
each of the three potential binding sites. Site 1 is the binding site proposed by Champagne et al., 
equivalent to the active site of histidyl-tRNA synthetase,20 while the remaining two sites are proposed 
based on comparison with the TmaHisZGS structure (PDB 1USY).19 
 
The TmaHisZGS crystal structure (PDB 1USY) revealed two 
histidine binding sites at each HisZ-HisGS interface, a total of eight in 
the hetero-octamer.19 The histidine binding residues at the HisZ-HisGS 
interfaces are not conserved among the short form ATP-PRTase family, 
which is unusual for an important functional binding site. Champagne 
et al. reported that the mutation of highly conserved residues in 
LlaHisZ, equivalent to the histidine binding residues of histidyl-tRNA 
synthetase from T. thermophilus, disrupted allosteric inhibition of 
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LlaHisZGS without impacting catalysis.20 This represents an entirely 
different histidine binding site to those observed in the TmaHisZGs 
crystal structure, and leads to the question of which site(s) is the 
functional allosteric site? (Figure 2.1) Mutation of the histidine binding 
residues proposed by Champagne et al. may have simply disrupted the 
communication pathway between the allosteric and active sites. 
Alternatively, the lowest energy state of TmaHisZGS, stabilised by the 
crystal lattice, may not represent the biologically relevant inhibited 
state.  
 
Champagne et al. drew comparisons between the TmaHisZGS 
and LlaHisZGS crystal structures in an attempt to develop a model for 
the allosteric activation and inhibition of the enzyme.20 The 
TmaHisZGS structure was assigned to the inhibited state, as the 
enzyme was purified in the presence of the synergistic inhibitors 
histidine (0.4 mM) and AMP (0.6 mM), and the RMSD of the alignment 
between TmaHisGS and histidine-bound MtuHisGL (PDB 1NH8, 
RMSD 1.15 Å) was lower than the RMSD of the alignment with the apo 
MtuHisGL structure (PDB 1NH7, RMSD 1.35 Å). Similarly, both 
crystal structures of LlaHisZGS were assigned to the active state based 
on co-crystallisation with ATP or its analogue N-1-methyl-ATP and 
PRPP, and alignment with the apo and histidine bound MtuHisGL 
structures (RMSD of 1.24 Å and 1.27 Å respectively). This assignment 
is tentative and illustrates the requirement for crystal structures of the 
active and inactive HisZGS enzymes from the same organism, to 
distinguish sequence differences from ligand-induced conformational 
changes.  
 
Champagne et al. noted the presence of an interstitial phosphate 
ion at two of the four LlaHisZ-LlaHisGS interfaces that is absent from 
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the histidine-bound TmaHisZGS structure.20 It should be noted that 
phosphate buffers were used in the purification of both TmaHisZGS 
and LlaHisZGS. However, a Tris-HCl buffer was employed for the 
crystallisation of both enzymes.19,20 The phosphate binding residues 
are conserved among the HisZGS enzyme family, which suggests that 
the presence of the phosphate ion is not merely a crystallisation 
artefact.20 The switch between inhibited and active states was 
proposed to involve the rearrangement of the HisGS dimer interface, 
driven by binding of the interstitial phosphate ion and histidine 
dissociation. The interstitial phosphate ion was proposed to operate in 
concert with HisZ to cause this rearrangement, which is believed to 
recruit catalytic residues to the active site.20 Notably, an inorganic 
phosphate has also been implicated in the activation of both bacterial 
and mammalian PRPP synthetases, which are similar in structure to 
the type I PRTases.61,62 Champagne et al. suggested that an inorganic 
phosphate ion may represent a cellular signal to stimulate energy 
requiring pathways, although the origin of such a phosphate in vivo 
was not discussed.20  
 
The RMSD of the alignment between the hetero-octameric 
LlaHisZGS and TmaHisZGS is 20 Å, which reflects a significant 
conformational difference (Figure 2.2). Alignment of the HisZ and 
HisGS components individually suggests that conformational 
differences in HisZ may be the largest contributor to structural 
differences between the complexes (Table 2.1), although it is unclear 
what, if any, the functional significance of these differences is. The 
debate that has arisen over the functionality of the histidine binding 
sites in the TmaHisZGS crystal structure calls into question the 
relevance of this comparison. If histidine is not bound in the functional 
allosteric sites, does this structure truly represent the inhibited form of 
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HisZGS? The inhibited conformation may be stabilised, fortuitously, by 
crystal lattice interactions, or the lowest energy state in the crystal 
lattice may not represent the inhibited form of HisZGS.  
 
Table 2.1 RMSD of the Structural Alignment Between Chains of LlaHisZGS 
(PDB 1Z7N) and TmaHisZGS (PDB 1USY) 
 
Alignment Chain RMSD (Å) 
LlaHisGS-TmaHisGS (monomer) 1.9 
LlaHisGS-TmaHisGS (dimer) 2.1 
LlaHisZ-TmaHisZ (monomer) 7.2 
LlaHisZ-TmaHisZ (dimer) 5.9 
LlaHisZ-TmaHisZ (tetramer) 9.3 




Figure 2.2 Alignment of LlaHisZGS (PDB 1Z7N) and TmaHisZGS (PDB 1USY). TmaHisZ and TmaHisZGS 
are shown in dark pink and dark blue respectively whilst LlaHisZ and LlaHisGS are coloured light pink 
and light blue. Interstitial phosphate ions are shown as yellow spheres. 
 
The formation of a definitive model for the allosteric regulation 
of the short form ATP-PRTase requires an understanding of the crystal 
structure, solution behaviour, and dynamics of the active and inhibited 
enzyme. This chapter reports the determination of the solution 
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structure of both the active and inhibited LlaHisZGS and further 
evidence towards the definition of the functional histidine binding 
sites. 
 
2.2 Cloning, Expression and Purification of 
LlaHisZGS 
 
The purification method of LlaHisZGS described by Bovee et al. 
reported that co-expression of LlaHisZ and LlaHisGS results in a 
decreased expression level of LlaHisGS relative to LlaHisZ.39 The work 
towards the purification of HisZGS from N. meningitidis, detailed in 
chapter three, supports this observation. To this end the decision was 
made to utilise the approach taken by Vega et al. who expressed 
TmaHisZ and TmaHisGS separately, and purified the TmaHisZGS 
hetero-octameric complex by co-lysing the combined cell pellets.19 
Furthermore, the observation by Sissler et al. that the untagged 
LlaHisGS protein co-purified with (His)6-tagged LlaHisZ, via 
immobilised metal affinity chromatography (IMAC), was exploited in 
the development of this purification scheme.5 
 
2.2.1 Cloning of LlahisZGS 
 
Synthetic genes encoding LlaHisGS and LlaHisZ, codon 
optimised for expression in E. coli, were purchased from Epoch Life 
Science. The synthetic genes were provided in standard pBSK vectors 
and sequence verified prior to delivery. LlahisGS and LlahisZ were 
subcloned into pET expression vectors using the In-Fusion® HD 
Cloning Kit (Clontech). The In-Fusion® enzyme catalyses the 
recombination of a linearised vector and a PCR product by the precise 
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recognition of a 15 base pair overlap sequence, complementary to the 
sequence of the vector (Figure 2.3).  
 
 
Figure 2.3 Schematic of the In-Fusion® HD cloning protocol. The destination vector can be linearised by 
restriction enzyme digest or by inverse PCR. The gene of interest is amplified with primers that include a 
sequence of 15 base pairs complementary to the vector sequence (represented here by red and yellow 
extensions). The In-Fusion® enzyme (green) recombines the PCR product with the linearised vector, 
resulting in the formation of a recombinant plasmid. The In-Fusion® reaction mixture is then transformed 
into competent E. coli cells and plated on agar plates containing the appropriate media and antibiotics. 
 
LlahisZ and LlahisGS amplified beautifully from their respective 
pBSK vectors, using primers designed to include the 15 base pair 
recombination sequence. LlahisZ was subcloned into pET-28a, 
linearised with EcoRI and NdeI, to produce a construct with an 
N-terminal (His)6-tag. The recognition site for tobacco etch virus (TEV) 
protease was incorporated into the synthetic gene sequence of LlahisZ, 
to allow subsequent cleavage of the (His)6-tag. LlahisGS was subcloned 
into pET-21a, digested with NdeI and XhoI, to form an untagged 
construct. LlahisGS was also subcloned into pET-28a with an 
N-terminal (His)6-tag, to allow purification of the protein by IMAC in 
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the absence of LlaHisZ. Each of the clones that were screened via 
colony PCR was found to be positive. The linearised vectors were gel 
purified prior to incubation with the In-Fusion® enzyme, and 
religation of the vector in the absence of insert is unlikely, as the 
In-Fusion® system is a ligase-free cloning procedure.  
 
2.2.2 Expression and Purification of the LlaHisZGS Complex 
 
 An appreciable yield of soluble LlaHisZ was obtained from 
expression in E. coli BL21*(DE3) cells, in the absence of LlaHisGS. In 
contrast, LlaHisGS was predominantly found in the cellular debris 
following cell lysis. A common strategy for improving the solubility of 
recombinant proteins is co-expression with chaperonins, to promote 
chaperone-mediated folding of the protein.63,64 Expression of LlaHisGS 
in E. coli BL21*(DE3) pBB540/pBB542 (Chaperone 3) cells led to a 
significant improvement in the yield of soluble protein. Chaperone 3 
cells contain plasmid-borne genes encoding groESL, clpB, grpE, dnsK, 
and dnaJ. Cultures of both LlaHisGS and LlaHisZ were grown at 37 °C 
until an optical density of 0.4-0.6. At this point, protein expression was 
induced by the addition of isopropyl-1-thiol-β-D-galactopyranoside 
(IPTG) to a final concentration of 0.5 mM. Following induction, the 
cultures were incubated at 23 °C overnight and harvested by 
centrifugation. 
 
The buffers utilised in the purification of the LlaHisZGS complex 
were adapted from the previously published protocol. † ,39 The 
LlaHisZGS complex was purified by the combination of cell pellets of 
LlaHisZ and LlaHisGS in a 1:1 (v/v) ratio of cell cultures. 
                                            
† For a detailed description of this and other methods, refer to chapter six. 
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Unsurprisingly, ATP-PRTase activity was detected in the cell lysate of 
the combined LlaHisZ and LlaHisGS but was absent from the cell 
lysate of LlaHisGS expressed independently. This finding is consistent 
with previous reports that HisZ is required for catalysis.5 
 
 The supernatant was applied to an IMAC column and the 
(His)6-tagged LlaHisZGS enzyme eluted, as a single peak, with an 
imidazole gradient. TEV protease was employed to cleave the (His)6-
tag from LlaHisZ. Several attempts were made to cleave the (His)6-tag, 
varying both the temperature (4 °C to 37 °C) and duration (1 hour to 2 
days) of the incubation, as well as the ratio of TEV protease to 
LlaHisZGS. Cleavage of the tag was incomplete under all conditions 
tested and the resulting mixture of tagged and untagged protein could 
not be resolved by IMAC or size exclusion chromatography (SEC). The 
decision was made to omit the (His)6-tag cleavage step and proceed 
directly to SEC, the final polishing step of the purification. The 
presence of the (His)6-tag had no impact ATP-PRTase activity (section 
2.3). 
 
SEC separates proteins based on size, with large proteins 
eluting earlier than small proteins. LlaHisZGS elutes as three peaks 
from the preparative SEC (Figure 2.4). SDS-PAGE analysis showed 
that the first and second peaks both contain LlaHisZ and LlaHisGS in 
approximately equal proportion (Figure 2.4). The first peak is unlikely 
to represent a biologically relevant species. The early elution volume is 
consistent with a complex significantly larger than the hetero-octamer, 
which is believed to be the physiological form. In addition, the band at 
60 kDa on the SDS-PAGE gel indicates the presence of a stoichiometric 
amount of a chaperonin protein, suggesting that LlaHisZGS may be 
misfolded, as chaperonins have a high affinity for misfolded 
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proteins.65,66 The third peak corresponds to an excess of LlaHisZ, 
however the presence of trace amounts of LlaHisGS prohibited the use 
of this protein for the independent characterization of LlaHisZ. The 
first and third peaks were excluded from the purification and the 
fractions corresponding to the second peak were pooled to yield 
50-100 mg of LlaHisZGS per litre of cell culture.   
 
 
Figure 2.4 SEC trace of LlaHisZGS (left) showing three peaks. Note that the A260nm trace is shown instead 
of A280nm, which exceeded the detection limit of the instrument. An SDS-PAGE gel (right) shows the 
fractions corresponding to each peak on the SEC trace. Lane A is a molecular weight standard, lanes C-E 
show peak 1, lanes F-H represent peak 2, and lanes I and F correspond to peak 3. The band corresponding 
to 60 kDa in lanes C-E is indicative of a chaperonin protein, which suggests that LlaHisZGS is not correctly 
folded. The high molecular weight band present in lanes F-H is due to the presence of HisZ dimer, caused 
by insufficient heat treatment of the sample. 
 
2.2.3 Expression and Purification of LlaHisZ 
  
The purification of LlaHisZ was relatively facile (Figure 2.5). 
The same methodology was employed as for LlaHisZGS, described in 
section 2.2.2, with the omission of LlaHisGS. The final yield of LlaHisZ 




Figure 2.5 SDS-PAGE gel showing the purified LlaHisZ protein. The higher molecular weight band visible 
in lanes C-J corresponds to HisZ dimer, due to insufficient heat treatment of the sample. 
 
2.2.4 Attempted purification of LlaHisGS 
 
 The purification of LlaHisGS was attempted both untagged, via 
anion exchange chromatography, and with an N-terminal (His)6-tag via 
IMAC. Chromatography was performed both at room temperature and 
at 4 °C and the composition of the purification buffers was varied by 
altering the concentration of NaCl (0-500 mM), TCEP (200 µM – 
1 mM), and by the addition of glycerol (5 % v/v). The protein 
precipitated during the first chromatography step under all conditions 
tested. Optimisation of the purification protocol was not pursued due to 
time constraints.  
 
2.3 Kinetic Characterisation of LlaHisZGS 
 
Kinetic characterisation of LlaHisZGS was performed using an 
established enzyme assay that detects the formation of PR-ATP at 
290 nm.26 The KMPRPP, KMATP, and kcat values determined for this 
preparation are comparable to the kinetic parameters reported by 
Champagne et al. (Table 2.2) (Figure 2.6).26  The specific activity was 
also evaluated in the presence of varying concentrations of histidine, 
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and was found to be consistent with the KiHis value of 81 µM reported 
by Champagne et al (Figure 2.7).26  
 
Table 2.2 Kinetic Parameters of LlaHisZGS 
 KMATP (mM) KMPRPP (µM) kcat (s-1) Reference 
LlaHisZGS 2.9 ± 0.4 16 ± 3 2.5 ± 0.2 This work 
LlaHisZGS 2.7 ± 0.3 18 ± 4 2.7 ± 0.3 Champagne et al.26 
 
 
Figure 2.6 Michaelis-Menten curves of LlaHisZGS. The KMATP (left) was determined by holding the [PRPP] 
constant at 100 µM while varying the [ATP]. To determine the KMPRPP (right) the [ATP] was held constant 
at 10 mM and the [PRPP] was varied. The Lineweaver-Burk plots are shown as inserts. 
 
Figure 2.7 The variation in the specific activity of LlaHisZGS with the addition of the allosteric inhibitor 
histidine. The [PRPP] and [ATP] were held constant at 50 µM and 10 mM respectively.  
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2.4 Determination of the Quaternary Structure of 
LlaHisZGS and LlaHisZ by Analytical SEC 
 
Analytical SEC is a common technique for determining the 
molecular weight of proteins in solution.67 The protein standards 
thyroglobulin (669 kDa), apoferritin (443 kDa), β-amylase (200 kDa), 
conalbumin (75 kDa), and ovalbumin (44 kDa) were used to construct a 
calibration curve by plotting the log of the molecular weight against 
the normalised elution volume (VN) (Figure 2.8). VN is equal to the 
quotient of the elution volume of the sample and the void volume of the 
column, defined by the elution volume of blue dextran (2,000 kDa). 
 
Figure 2.8 Analytical SEC calibration curve formed by plotting the log of the molecular weight against the 
normalised elution volume of the protein standards. 
 
2.4.1 Characterisation of LlaHisZGS by Analytical SEC 
 
In the absence of ligands, LlaHisZGS eluted as two peaks. The 
main peak has a molecular weight consistent with the LlaHisZGS 
hetero-octamer, with a small shoulder, corresponding to a HisZ dimer 
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(Table 2.3) (Figure 2.9).  To determine whether the presence of the 
shoulder reflects an equilibrium between oligomeric states, the protein 
corresponding to the hetero-octamer was collected and reapplied to the 
column, without dilution or concentration. The sample eluted as a 
single peak, consistent with the LlaHisZGS hetero-octamer (Figure 
2.9). Thus the presence of the HisZ dimer was attributed to a slight 
excess of HisZ in the purification due to overlapping peaks in the 
preparative SEC. This could potentially be alleviated by the addition of 
a third chromatography step, such as hydroxyapatite chromatography.  
 
Table 2.3 LlaHisZGS Analytical SEC Data 
 Ve (mL) VN LogMw Mw (kDa) Oligomeric State 
LlaHisZGS main peak 11.3 1.47 2.35 224 Hetero-octamer 
LlaHisZGS shoulder  13.4 1.74 1.94 88.0 HisZ dimer 
LlaHisZGS collected main peak 11.3 1.47 2.35 222 Hetero-octamer 
LlaHisZGS + Histidine 11.4 1.49 2.33 214 Hetero-octamer 
 
 
Figure 2.9 Analytical SEC trace of LlaHisZGS at a concentration of 1mg/mL (solid line). The fractions 
corresponding to the main peak were reapplied to the column, and eluted as a single species (dashed line). 
 
 In the presence of 1 mM histidine, LlaHisZGS eluted as a single, 
hetero-octameric species. Comparison with the data collected in the 
absence of histidine revealed a slight shift in the peak (Table 2.3) 
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(Figure 2.10). This suggests that histidine binding may induce a 
conformational change, without affecting the subunit composition of 
the protein.   
 
 
Figure 2.10 Analytical SEC traces of LlaHisZGS (1mg/mL) in the presence (solid line) and absence (dashed 
line) of 1 mM histidine. A slight shift in the peak suggests that histidine binding cause a slight 
compression of the LlaHisZGS complex relative to the unliganded species. 
 
2.4.2 Characterisation of LlaHisZ by Analytical SEC 
 
 Contrary to previous reports of a TmaHisZ dimer-tetramer 
equilibrium, described by Vega et al.,19 LlaHisZ eluted as a single 
species, consistent with a HisZ dimer, at concentrations of both 
1 mg/mL and 4 mg/mL (Table 2.4) (Figure 2.11). This supports the 
previous proposal by Sissler et al.5 of a dimeric LlaHisZ and suggests 
that the X-shaped core of four LlaHisZ chains, found in the hetero-
octameric structure, is stabilised only in the presence of LlaHisGS.  
 
Table 2.4 LlaHisZ Analytical SEC Data 
 Ve (mL) VN LogMw Mw (kDa) Oligomeric State 
LlaHisZ (1mg/mL) 13.2 1.72 1.98 94.6 Dimer 




Figure 2.11 Analytical SEC trace of LlaHisZ at a concentration of 4mg/mL (solid line) and 1 mg/mL 
(dashed line). Note that the A260nm trace is shown as the A280nm trace for the 4 mg/mL sample exceeded the 
detection limit, resulting in a flattened peak. There is no evidence of a tetrameric species observed in 
either sample. 
 
2.5 Characterisation of LlaHisZGS by Small Angle 
X-ray Scattering 
 
 Small angle X-ray scattering (SAXS) was employed to verify the 
solution structure of LlaHisZGS (1 mg/mL) in the presence and absence 
of 1 mM histidine. SEC-SAXS was performed to ensure that the 
scattering data was collected from the hetero-octameric species. 
Guinier analysis of the LlaHisZGS scattering profile in the absence of 
histidine revealed a radius of gyration (Rg) of 41.4 ± 0.2 Å.68 The pair 
distribution (P(r)) function was determined via indirect Fourier 
transformation. The Rg and the maximum dimension (Dmax) of the 
particle were defined by P(r) as 41.0 ± 0.2 Å and 146 Å respectively. 
The particle volume defined by the Porod invariant (Porod volume) was 
equal to 435000 Å3. 
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Overlay of the SAXS scattering profiles revealed a notable 
difference in the presence of histidine (Figure 2.12). The Rg of the 
LlaHisZGS + histidine scattering profile was calculated to be 
40.9 ± 0.2 Å by Guinier approximation and 40.4 ± 0.1 Å by the P(r) 
function. The protein in the presence of histidine has a Dmax of 117 Å 
and a Porod volume of 323000 Å3. This is consistent with the histidine 
induced change observed by analytical SEC (Section 2.4.1). 
 
 
Figure 2.12 Overlay of the SAXS scattering profiles of LlaHisZGS in the presence (red) and absence (blue) 
of 1 mM histidine. 
. 
2.5.1 Crysol Fitting of the LlaHisZGS SAXS Profiles to the X-ray 
Crystal Structure 
 
 The difference between the protein conformation in the presence 
and absence of histidine is more pronounced when compared to the 
X-ray crystal structure. Crysol was used to deduce the theoretical 
scattering curve from the X-ray crystal structure of LlaHisZGS (PDB 
1Z7N) and calculate the fit to the experimentally determined SAXS 
profiles.69  In the absence of histidine, the LlaHisZGS scattering profile 
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fits the theoretical scattering profile calculated from the X-ray crystal 
structure (PDB 1Z7N, χ2 = 1.1) (Figure 2.13). This suggests that the 
X-ray crystal structure is a reasonable representation of the 
conformation adopted by aqueous LlaHisZGS (1 mg/mL) in the absence 
of ligands.  
 
 
Figure 2.13 (left) Crysol fit of the LlaHisZGS SAXS profile (blue circles) to the theoretical scattering profile 
calculated from the crystal structure (PDB 1Z7N) (black line). The χ2 value of 1.1 indicates a good fit. The 
P(r) function of the LlaHisZGS SAXS profile is shown on the right.  
 
 
Figure 2.14 (left) Crysol fit of the LlaHisZGS + histidine SAXS profile (red circles) to the theoretical 
scattering profile calculated from the crystal structure (PDB 1Z7N) (black line). The χ2 value of 10.6 
demonstrates that the crystal structure is not good representation of the histidine-inhibited LlaHisZGS. 
The P(r) function of the LlaHisZGS + histidine SAXS profile is shown on the right.  
 
In the presence of histidine, however, the experimental 
scattering profile of LlaHisZGS differs significantly to the theoretical 
scattering curve calculated from the crystal structure (χ2 = 10.6) 
(Figure 2.14). This observation is consistent with a conformational 
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change in response to histidine binding, and hints at a potential 
mechanism for allosteric inhibition of the enzyme. 
 
 Slight differences in the LlaHisZGS scattering data compared to 
the crystal structure may be attributed to the presence of an 
N-terminal (His)6-tag on LlaHisZ.  It must also be noted that the 
crystal structure is incomplete, as the first five N-terminal and last 
five C-terminal residues are missing from LlaHisZ. The structure 
reported by Champagne et al. also has three mutations in LlaHisGS 
(A51P, D86Y, and R110H) and four in LlaHisZ (N73K, H174Q, E209G, 
and V303F) compared to the reported sequence of LlaHisZGS from 
L. lactis subsp. lactis KF147, from which the genes were originally 
cloned. The synthetic genes provided by Epoch Life Sciences are 
consistent with the reported sequence of HisZGS from L. lactis subsp. 
lactis KF147.  
 
The experimental SAXS data was also compared to the other 
LlaHisZGS crystal structure (PDB 1Z7M) as well as the TmaHisZGS 
structure (PDB 1USY) (Table 2.5). ‡  The results suggest that the 
available LlaHisZGS crystal structures are reasonable representations 
of the LlaHisZGS envelope in the absence of histidine, but are unlikely 
to reflect the structure adopted by histidine bound LlaHisZGS. The 
histidine bound TmaHisZGS structure resembles neither the average 




                                            
‡ See Appendix I for plots of these fits. 
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Table 2.5 χ2 Values Obtained by Fitting the LlaHisZGS SAXS Data to the 
Available HisZGS Crystal Structures 
 
Crystal Structure (PDB) LlaHisZGS LlaHisZGS + Histidine 
LlaHisZGS (1Z7N) 1.1 11 
LlaHisZGS (1Z7M) 0.87 6.8 
TmaHisZGS (1USY) 5.5 6.2 
 
 
2.5.2 Ab Initio Modelling to the LlaHisZGS + Histidine SAXS 
Data 
 
 In lieu of a histidine bound LlaHisZGS crystal structure, ab 
initio modelling was performed to glean information about the shape of 
the protein in the presence of histidine. Ab initio modelling generates 
low resolution envelope structures by optimising the agreement 
between the experimental data and the theoretical scattering curves 
(or P(r) functions), calculated from the proposed models.70 In order to 
reduce the search space, the shape of the protein is modelled as a 
continuous object.  
 
 Gasbor was used to generate ab initio models of the histidine 
bound LlaHisZGS. The ab initio models produced by Gasbor comprise 
chain-line ensembles of dummy residues, whose spatial positioning 
approximates the Cα atoms of the protein backbone.71 20 ab initio 
models with P1 symmetry were generated by Gasbor. These models 
were averaged with the Damaver program suite.72 Supcomb was used 
to superimpose the crystal structure of LlaHisZGS (PDB 1Z7N) on to 
the most typical model; identified by Damaver as having the lowest 
normalised spatial discrepancy (Figure 2.15).73 The process was 
repeated to generate models with P2 and P4 symmetry, as imposing 
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symmetry on ab initio models may improve the quality of the model.70 
Crysol was employed to compare the average models to the scattering 
profile of LlaHisZGS + histidine (Figure 2.16). Crysol fits indicated no 
significant difference between the models generated with P1 
(χ2 = 0.35), P2 (χ2 = 0.36), or P4 symmetry (χ2 = 0.29), and the low 
χ2 values indicate a requirement for further refinement.  
 
 
Figure 2.15 Ab initio models of histidine bound LlaHisZGS generated with Gasbor and averaged using 
Damaver (grey surface representation). The LlaHisZGS crystal structure (PDB 1Z7N) is shown 
superimposed on these models (cartoon representation with four LlaHisGS chains coloured blue and four 
LlaHisZ chains coloured red). 
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Figure 2.16 Crysol fits of the Gasbor models of P1 symmetry (red), P2 symmetry (blue) and P4 symmetry 
(green) to the experimental scattering (black circles).  
 
2.5.3 Rigid Body Modelling to the LlaHisZGS + Histidine SAXS 
Data 
 
 The difference between the proposed shapes of the histidine 
bound LlaHisZGS, and the unliganded enzyme, may reflect a change in 
the relative orientation of the LlaHisZ and LlaHisGS subunits. Atomic 
resolution structures of the LlaHisZ and LlaHisGS chains are 
available; therefore the relative position of these chains could 
potentially be resolved by rigid body modelling. The general method is 
reminiscent of ab initio modelling, whereby the final model is 
calculated by optimising the agreement between the experimental 
scattering and the theoretical scattering from the proposed 
structures.70 In rigid body modelling, however, the atomic resolution 
structures are used in place of dummy residues. These structures are 
considered to be static objects and only their relative spatial 
arrangement is altered.  
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Coral was used to construct models of the histidine bound 
LlaHisZGS.74 Individual PDB files of each of the eight chains in the 
LlaHisZGS crystal structure were created and the LlaHisZ and 
LlaHisGS dimer interfaces were fixed. These interfaces are strong, 
ΔG = −102 kJmol-1 and −58 kJmol-1 respectively, as calculated by 
PDBePISA.75 It is a reasonable first assumption that these interfaces 
remain largely intact upon histidine binding, although slight 
conformational changes at this interface are possible. The most likely 
conformations of LlaHisZGS were obtained by running Coral with P1 or 
P2 symmetry (Figure 2.17) as imposing P4 symmetry resulted in 
disruption of the LlaHisZGS complex and χ2 values greater than 10 
when fitted to the experimental data. Analytical SEC revealed that, 
under the conditions of the SAXS experiment, the hetero-octameric 
complex remains intact upon histidine binding. 
 
Figure 2.17 The four best models of histidine-bound LlaHisZGS generated by Coral. The LlaHisZ chains 
are coloured red and the LlaHisGS chains are coloured blue. 
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Figure 2.18 Crysol fitting of the rigid body models produced by Coral to the experimental scattering of 
LlaHisZGS. The best fit defined by Coral is Model 1 (pink, χ2 = 0.79) followed by Model 3 (green, χ2 = 0.47), 
Model 4 (red, χ2 = 0.42) and Model 2 (blue, χ2 = 11).  
 
Crysol revealed a large variation in the quality of the fit of the 
theoretical scattering profiles to the experimental data, between each 
of the four models (Figure 2.18). This signifies that, while rigid body 
modelling has proved successful for the structural characterisation of 
many proteins,70 further information is required to construct a 
convincing model of the histidine bound LlaHisZGS. Model 2 most 
closely resembles the known conformation of the hetero-octameric 
HisZGS, however the fit to the experimental data is poor, as evidenced 
by a χ2 value of 11. The model that best reflects the experimental data, 
model I (χ2 = 0.79), indicates a possible change in the relative position 
of the LlaHisZ subunits, as well as a change in the LlaHisZ-LlaHisGS 
interface. This is consistent with elongation of the protein complex in 
response to histidine binding, however significant disruption of 
protein-protein interfaces unlikely. Rigid body modelling does not 
account for conformational changes within the individual protein 
subunits in response to ligand binding and work towards 
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understanding the conformational response to histidine binding is 
continuing. 
 
2.6 Induced Fit Docking of Histidine into Three 
Potential Binding Sites on LlaHisZGS 
 
Three distinct histidine binding sites have been proposed for 
LlaHisZGS. The first (designated site one) is located in a region highly 
conserved between HisZ and histidyl-tRNA synthetase. Champagne et 
al. used mutagenesis to attribute histidine binding to three conserved 
residues at this site (Glu130, Tyr268 and Tyr269).20 Whether these 
represent the histidine binding residues, or if mutation of these 
residues disrupted the allosteric signal transduction pathway, is yet to 
be deduced. Sites two and three reside at the interface between 
LlaHisZ and LlaHisGS and were proposed based on comparison with 
the histidine-bound crystal structure of TmaHisZGS (PDB 1USY).19 
Induced fit docking of histidine into each of the three potential binding 
sites on the LlaHisZGS complex was performed by Dr Wanting Jiao, 
with the intention of identifying the biologically relevant histidine 
binding sites(s). An ensemble of histidine poses was generated and 
Prime structure prediction was used to accommodate the ligand by 
reorienting side chains in the proposed binding site. The ligand was 
then re-docked into the lowest energy protein structure and poses were 
ranked by their Glide docking score. The Glide score is an empirical 
measure that approximates the free energy of ligand binding.76,77 




2.6.1 Histidine Docking into Site One of LlaHisZGS  
 
 Preparation of the LlaHisZGS complex for induced fit docking 
resulted in Glu130 being assigned to a neutral state, instead of the 
negatively charged state expected of this residue. It is unclear why this 
occurred, therefore the induced fit docking of histidine into site one 
was evaluated under both negative and neutral charge states. The top 
scored pose of histidine docked into site one with a neutral Glu130 has 
a Glide docking score of −6.009. This pose reveals no significant 
interaction between histidine and the histidine-binding residues 
proposed by Champagne et al.20 (Figure 2.19). The Tyr268 and Tyr269 
side chains both orient away from the bound histidine. Glu130 lies in 
close proximity to histidine, however there is no evidence to suggest 
that this residue is involved in stabilisation of the ligand in the binding 
pocket. This pose highlights Lys265, Asp84, and Tyr291 as potential 
histidine binding residues. The carboxylate group of histidine forms 
both a hydrogen bond and a salt bridge with the Lys265 side chain. A 
salt bridge is also formed between the amino group of histidine and the 
side chain of Asp84 and pi-pi stacking interactions are established with 




Figure 2.19 The highest scored docking pose of histidine in site one of LlaHisZGS with a neutral Glu130. 
The proposed histidine binding residues determined by mutagenesis (yellow sticks) show no interaction 
with the histidine ligand (green). Grey sticks are used to show the histidine binding residues in this pose. 
The cartoon structure of LlaHisZ is coloured red. 
 
 When histidine was docked into site one with a negative Glu130, 
the highest scored pose had a docking score of −6.041. Histidine adopts 
a different conformation in this pose, compared to the previously 
described pose, which suggests that this site is sufficiently spacious to 
accommodate histidine binding in different orientations (Figure 2.20). 
The imidazole ring of histidine forms pi-pi stacking interactions with 
Tyr291 and the side chain of Asp84 forms a salt bridge with the 
histidine amino group, as described previously. The carboxylate group 
of histidine also interacts with the side chains of Lys265 and Gln126. 
The three proposed histidine binding residues again show no 




Figure 2.20 The highest scored docking pose of histidine docked into site one with a negative Glu130. 
LlaHisZ is coloured red, the previously proposed histidine binding residues are shown in yellow, and grey 
sticks represent the histidine binding residues. 
 
2.6.2 Histidine Docking into Site Two of LlaHisZGS 
 
 Docking of histidine into potential binding site two of 
LlaHisZGS, at the interface of LlaHisZ and LlaHisGS, resulted in a 
pose with a docking score of -8.071 (Figure 2.21). Hydrogen bonding is 
observed between the carboxylate group of histidine and the side 
chains of Lys213 and Asn196 from LlaHisZ. The backbone amino group 
of Lys213 also appears to stabilise the imidazole group of histidine by 
hydrogen bonding. The amino group of histidine forms salt bridges 
with Glu200 and Glu203 from LlaHisGS. 
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Figure 2.21 Histidine (green) docked into potential binding site two at the interface of LlaHisGS (blue) and 
LlaHisZ (red). The histidine binding residues are coloured grey.  
 
2.6.3 Histidine Docking into Site Three of LlaHisZGS 
 
 Docking of histidine into potential binding site three of 
LlaHisZGS, also located at the LlaHisZ−LlaHisGS interface, resulted in 
a pose with a docking score of -5.813 (Figure 2.22). In this pose, the 
amino group and the imidazole group of histidine establish hydrogen 
bonds with the side chain of Asp191 from LlaHisZ. The Glu83 and 
Lys70 of LlaHisGS also form salt bridges with the carboxylate group of 
histidine.  
 
Figure 2.22 Histidine (green) docked into potential binding site three at the interface of LlaHisGS (blue) 
and LlaHisZ (green). The histidine binding residues are represented as grey sticks. 
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2.6.4 Where Does Histidine Bind? 
 
 Induced fit docking of histidine into potential binding site two, 
at the interface of LlaHisZ and LlaHisGS, gave the best (most negative) 
docking score. This binding site, along with potential binding site 
three, was identified by comparison with the histidine-bound 
TmaHisZGS crystal structure. It is tempting to conclude that this is the 
functional allosteric site and that the Glu130, Tyr268 and Tyr269 
residues of site one are critical for allosteric signal transmission, but 
not involved in ligand binding. Induced fit docking, however, was 
performed on the unliganded LlaHisZGS structure and binding of 
histidine has been shown to trigger a conformational change of the 
protein. The algorithm used for induced-fit docking compensates for 
changes in side chain positioning but does not account for the large 
conformational changes observed by SAXS.  
 
2.7 Characterisation of Histidine Binding to 
LlaHisZGS by Isothermal Titration Calorimetry 
 
 Isothermal titration calorimetry (ITC) provides a direct measure 
of the heat changes associated with binding events in solution. ITC was 
employed to assess histidine binding to both the LlaHisZGS complex, 
and the LlaHisZ protein independently, in order to identify the 
functional allosteric site. 
 
2.7.1 Histidine Binding to the LlaHisZGS Complex 
 
 When a 2 mM solution of histidine was titrated into 50 µM 
LlaHisZGS, the resulting binding curve fit a one-site model with a 
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KD = 26.0 ± 0.9 µM and stoichiometry of 1.13 ± 0.02 (Figure 2.23). 
LlaHisZ and LlaHisGS were treated as a combined unit in the 
determination of concentration; therefore the stoichiometry reveals a 
total of four histidine binding sites in the hetero-octameric complex.   
 
 
Figure 2.23 ITC data of histidine binding to the LlaHisZGS complex. The stoichiometry is 1.13 ± 0.02 sites 
and KD = 26.0 ± 0.9 µM. ΔH = -41.4 ± 0.8 kJmol-1 and ΔS = -50.6 Jmol-1K-1  
 
2.7.2 Histidine Binding to LlaHisZ 
 
 LlaHisZ is a histidyl-tRNA synthetase paralogue, and the 
sequence of proposed histidine binding site one is highly conserved 
(Figure 2.30). If LlaHisZ houses the histidine binding site, then it is 
conceivable that histidine may bind to LlaHisZ in the absence of 
LlaHisGS. A 0.8 mM solution of histidine was titrated into 47 µM 
LlaHisZ, and the resulting binding curve fit a one-site model with a 
KD = 16 ± 1 µM and stoichiometry of 0.46 ± 0.03. The concentration was 
determined per LlaHisZ chain; therefore the stoichiometry suggests 
one histidine molecule binds for every two chains. This could be due to 
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the low sigmoidicity of the curve, which may be improved by optimising 
the relative concentrations of protein and ligand. LlaHisZ is dimeric in 
solution; therefore the observed stoichiometry could alternatively 
indicate that histidine binds to only one chain of each dimer. Further 
investigation using SAXS is required to determine the conformational 
response of LlaHisZ upon histidine binding. 
 
 
Figure 2.24 ITC data of histidine binding to LlaHisZ in the absence of LlaHisGS. The stoichiometry is 
0.46  ± 0.03, KD = 16 ± 1, ΔH = -39 ± 3 kJmol-1 and ΔS= -40 Jmol-1K-1 
 
The observation that LlaHisZ binds histidine in the absence of 
LlaHisGS and the similarity in the KD values obtained for histidine 
binding to LlaHisZ and LlaHisZGS provides strong evidence to support 





2.8 Crystallisation Trials of LlaHisZGS + Histidine 
  
 The complementarity of SAXS and X-ray crystallography has 
been well documented, and the availability of high-resolution protein 
crystal structures has proved invaluable to the identification of 
allosteric mechanisms.70 Numerous attempts were made to obtain an 
X-ray crystal structure of the histidine-bound LlaHisZGS. Adaptation 
of the conditions reported for the apo-LlaHisZGS, along with 
replication of the conditions reported for the histidine-bound 
TmaHisZGS proved unsuccessful. A variety of commercial screens were 
employed to detect conditions under which the protein crystallised. 
Crystals were tested for diffraction and the most promising conditions 
were optimised, via hanging drop vapour diffusion, by systematically 
varying the concentration of protein, precipitant, ligand, as well as pH, 
drop volume, temperature, incubation time, and the cryoprotectant. 
Multiple diffraction quality crystals were obtained, however the best 
crystals diffracted to just 4.7 Å on the MX1 beamline at the Australian 
Synchrotron (Figure 2.25).   
 
 
Figure 2.25 Images of the two best diffracting crystals and their corresponding diffraction patterns, taken 




The mechanism of allosteric regulation of LlaHisZGS is still 
unclear, however the results of SAXS and ITC suggest that histidine 
binding at HisZ is associated with a conformational change of the 
protein complex. Site one has been identified as the likely functional 
allosteric site through a combination of the ITC presented here and the 
mutagenesis studies reported by Champagne et al.20 This site is highly 
conserved between HisZ and histidyl-tRNA synthetase (Figure 2.30) 
and serves as the histidine binding site of T. thermophilus histidyl-
tRNA synthetase (Figure 2.26). In contrast, Vega et al. attributed 
functional allostery to the HisZ-HisGS interface sites, as opposed to the 
former histidyl-tRNA synthetase active site, due to the presence of 
eight histidine ligands in the crystal structure, and the location of the 
HisZ active site buried at the core of the protein (Figure 2.27).19 The 
biological relevance of the interface binding sites in TmaHisZGS was 
inferred from the proximity to the active site in HisGS, presumably 
providing direct contacts leading to rearrangement of the active site. It 
has been established that transmission of allosteric signals can occur 
over phenomenal distances and close contact between the allosteric site 
and the active site is unnecessary.78,79  
 
 Induced fit docking favoured histidine binding to potential 
binding site two, an interface site, over site one. The induced fit 
docking algorithm does not account for the conformational change 
observed by SAXS. In addition, docking was performed on the 
unliganded X-ray crystal structure and the histidine-binding site may 
not be properly formed in this structure. Crystal packing may cause 
proteins to adopt conformations that are not biologically relevant.70 
 60 
Allosterically regulated proteins have multiple stable conformations 
that are separated by small energy changes and are particularly 
affected by lattice forces.70 Despite the apparent affinity of the 
interface binding sites for histidine, it appears unlikely that the 




Figure 2.26 Structural alignment of LlaHisZ (pale pink) with histidine-bound histidyl-tRNA synthetase 
from T. thermophilus (PDB 1ADJ). The histidine ligands are shown docked into site one of LlaHisZ (blue 
and yellow sticks) with either a negative or neutral Glu130. Histidine is also shown bound in the histidyl-
tRNA synthetase active site (green). The histidine binding residues (grey sticks) are shown with the 
comparable residues from LlaHisZ (pink).  
 
 Comparison of the LlaHisZ histidine binding site with the 
histidine binding site of histidyl-tRNA synthetase from 
T. thermophilus reveals a striking similarity (Figure 2.26). Although it 
appears that LlaHisZ houses the histidine binding site, the binding 
residues proposed by Champagne et al. have not been confirmed. The 
proposed residues (Glu130, Tyr268 and Tyr269) are highly conserved 
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within both the HisZ and histidyl-tRNA synthetase families and have 
been implicated in histidine binding based on the histidine bound 
T. thermophilus histidyl-tRNA synthetase structure.80 The high 
sequence conservation and confirmed role of these residues in allosteric 
inhibition points to these residues as strong candidates for histidine 
coordination. The induced fit docking experiments, however, 
highlighted additional highly conserved residues as potential histidine 
binding residues (Tyr291, Asp84 and Gln126) that merit further 
investigation. Lys265 was also implicated in histidine binding however 
the lack of conservation of this residue within the HisZ family suggests 
that a crucial function of this residue is unlikely. The definition of the 
histidine-binding residues of this enzyme will require the generation of 
enzymes with loss of function point mutations and characterisation of 
histidine binding by ITC or saturation transfer difference NMR.   
 
 
Figure 2.27 Surface representation of LlaHisZGS with histidine docked into each of the proposed binding 
sites. The four LlaHisZ chains are coloured red and the four LlaHisGS chains are shown in blue. The 
histidine residues are represented as spheres coloured as per the labels indicated in the figure. Sites two 
and three are clearly visible near the surface of the protein whilst site one is buried within the core of the 
protein.  
 
 The solution conformation of LlaHisZGS in the absence of 
histidine resembles the previously published LlaHisZGS crystal 
structure. A change in the SAXS scattering profile in the presence of 
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histidine reflects a conformational change of the enzyme associated 
with allosteric inhibition. In contrast, the SAXS profile of the long form 
ATP-PRTase from C. jejuni is largely unaffected by the addition of 
histidine (Gerd Mittelstädt personal communication). Crysol fitting 
demonstrated that neither the LlaHisZGS nor the histidine-bound 
TmaHisZGS crystal structure adequately represents the shape of the 
inhibited enzyme in solution. This casts doubt on the relevance of the 
comparison between the LlaHisZGS and TmaHisZGS structures to 
devise a model of allosteric regulation. It should be noted that the 
Crysol fit of the LlaHisZGS SAXS scattering profile in the absence of 
histidine to the histidine-bound TmaHisZGS crystal structure was 
better than the same fit with the LlaHisZGS + histidine scattering 
data. The structure adopted by TmaHisZGS may represent a 
conformation accessible to LlaHisZGS, but not the average shape of the 
enzyme in solution.  
 
 The shape of the SAXS profile of histidine-bound LlaHisZGS 
suggests a more elongated structure of the inhibited enzyme. The 
attempts to obtain a crystal structure of the histidine-bound 
LlaHisZGS were unsuccessful and further optimisation is required. In 
lieu of a high resolution structure, both ab initio and rigid body 
modelling methods were employed to extract structural information 
from the SAXS data. The shape of the SAXS envelopes generated by 
Gasbor and the rigid body models generated by Coral are both 
consistent with an extended conformation of the protein, however 
neither method provided sufficient insight into the molecular details of 
the domain rearrangements. Model 2 generated by Coral, which most 
closely resembles the known HisZGS conformations, has the highest χ2 
value when compared to the experimental data. This suggests that 
model 2 is not an accurate representation of the inhibited enzyme. The 
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remaining models appear unlikely to represent an accessible 
conformation, as they would require significant disruption of multiple 
protein-protein interfaces. Analytical SEC, under the same conditions 
as SEC-SAXS, indicated that the inhibited LlaHisZGS complex is 
hetero-octameric. The strongest interfaces in the complex, determined 
by PDBePISA, are the LlaHisZ and LlaHisGS dimer interfaces, with 
estimated ΔG values of -96 kJmol-1 and -54 kJmol-1 respectively. These 
interfaces may undergo a conformational change in response to 
histidine binding, but are unlikely to be significantly disrupted. Rigid 
body modelling works by altering the relative positioning of individual 
domains or subunits and does not account for conformational changes 
within the individual chains. The weakest functional interface in the 
complex is the interface between the four LlaHisZ chains (estimated 
ΔG = -4 kJmol-1). This interface, along with the heteromeric interfaces 
between HisGS and HisZ, is more likely to be susceptible to large 
conformational changes.  
 
The histidyl-tRNA synthetase enzymes from E. coli and 
T. thermophilus are both dimeric in solution, however they crystallise 
with four chains in the asymmetric unit.52,80 Interestingly, the non-
biological interface structurally resembles the interface between the 
four HisZ chains in the LlaHisZGS complex (Figure 2.28). The angle 
between the two histidyl-tRNA synthetase enzymes in the asymmetric 
unit differs significantly from the angle between the four HisZ chains 
in the hetero-octameric crystal structure. This observation may suggest 
that the HisZ proteins rotate relative to each other, like a pair of 
scissors, resulting in an extended conformation of the allosterically 
inhibited enzyme. Future investigation should focus on the interactions 
between the HisZ and HisGS proteins via chemical crosslinking and 
fluorescence resonance energy transfer. 
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Figure 2.28 Alignment of four chains of histidyl-tRNA synthetase from T. thermophilus (Purple) with 
LlaHisZ (red). Note that the anticodon binding domains of histidyl-tRNA synthetase have been omitted for 
clarity.  
 
Notably, HisZ is requiried for catalysis although the molecular 
basis for this requirement is unknown. The interaction between HisZ 
and HisGS may provide contacts that are favourable for catalysis. One 
possible mechanism of allosteric inhibition is that binding of histidine 
to HisZ may disrupt these interactions and inhibit the enzyme. It is 
unclear how histidine binding to HisZ inhibits catalysis, however the 
large, open nature of the active site suggests that it is unlikely to be 
the result of steric hinderance. ITC or saturation transfer difference 
NMR could also be utilised to investigate substrate binding in the 
presence of inhibitory concentrations of histidine. Molecular dynamics 
simulations could also be invaluable to determine dynamic 
contributions to allostery, however the absence of a histidine-bound 
crystal structure complicates the use of this technique.  
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Figure 2.29 Analysis of the LlaHisZGS (PDB 1Z7N) interfaces using PDBePISA reveals asymmetry across 
the HisGS dimer interface, of the interfaces between HisGS domain I and HisZ. Two LlaHisZ-LlaHisGS 
interface interactions are coloured by chain. The larger of the two interfaces has LlaHisGS coloured dark 
blue and LlaHisZ coloured cyan. The second interface has LlaHisGS coloured dark pink and LlaHisZ 
coloured light pink. There is symmetry of the asymmetry, with equivalent interfaces found in the second 
HisGS dimer of the complex.   
 
 Further analysis of the LlaHisZGS crystal structure with 
PDBePISA revealed an asymmetry of the interactions between HisZ 
and domain I of HisGS, across the HisGS dimer interface (Figure 2.29). 
Each pair of HisGS chains has one large HisZ-HisGS interface (1040 Å2) 
and one small HisZ-HisGS interface (760 Å2). The small interface 
provides the binding site for the interstitial phosphate ion that was 
proposed to be involved in activation of HisZGS.20 This may be 
indicative of alternating catalysis, where pairs of HisGS at opposing 
ends of the X-shaped HisZ core are active, while their dimer partners 
are not. Such a mechanism could be investigated by using fluorescence 
techniques in combination with crystallography and computational 
analysis.  
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 In conclusion, investigation into the allosteric regulation of 
LlaHisZGS provided further evidence to support the histidine binding 
site proposed by Champagne et al.20, comparable to the active site of 
histidyl-tRNA synthetase. SAXS revealed a conformational change to a 
more extended structure in response to allosteric inhibition, which may 
be the result of rotation of the HisZ subunits relative to each other. 
Further work is required to understand the nature of this 
conformational change and the role of HisZ in both the allosteric 









Figure 2.30 Sequence alignment of (in order from the top) HisZ from L. lactis, T. maritima, 
N. meningitidis, G. sulfurreducens, B. subtilis, and histidyl-tRNAsynthetase from E. coli, L. lactis, and C. 
jejuni. The histidine binding residues proposed by Champagne et al. are coloured yellow. The site one 
histidine binding residues proposed by induced fit docking experiments are coloured blue, and the histidine 
binding residues corresponding to sites two and three are coloured green.  
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Chapter Three  
 





 Structural and biochemical characterisation of the long form 
ATP-PRTase enzymes from S. typhimurium, M. tuberculosis, and 
E. coli has been progressing since the 1950s.1,4,22 Despite decades of 
research, the mechanistic details of the allosteric regulation of HisGL 
are yet to be fully deduced. Prior to the elucidation of the X-ray crystal 
structures of EcoHisGL and MtuHisGL, investigation focused primarily 
on the quaternary structure of the enzyme in the presence of natural 
substrates and inhibitors.3,4,47,51 A variety of oligomeric states have 
been described for the long form ATP-PRTases.3,23,47 The most widely 
reported model of the allosteric inhibition is the histidine-induced 
oligomerisation from an active dimer to an inactive hexamer, initially 
described by Tebar et al.47 Tebar et al. also noted the presence of a 
tetrameric species of unknown function.  
 
The dimer-hexamer model was supported by Klungsoeyr and 
Kryvi, who reported a change in the sedimentation coefficient of 
EcoHisGL from a 12.6 S species in the absence of ligands to an 8.9 S 
species in the presence of inhibitors,81 as well as the characterisation of 
MtuHisGL by analytical SEC described by Cho et al.3 The dimer-
hexamer model of allosteric inhibition persisted despite the revelation 
of the hexameric crystal structures, as both Lohkamp et al. and Cho et 
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al. attributed the hexameric quaternary structure to crystal packing.3,4 
Recent investigation into MtuHisGL33 and HisGL from C. jejuni 
(CjeHisGL) (Gerd Mittelstädt, unpublished results) has challenged the 
dimer-hexamer model of allosteric inhibition.  
 
Recent investigation has shown that removal of the ACT 
regulatory domain from CjeHisGL results in an active, albeit 
diminished, homodimeric enzyme (Gerd Mittelstädt, unpublished 
results), despite the observation that HisGS proteins only exhibit 
catalytic activity in the presence of HisZ.5 This chapter describes the 
work towards the purification of EcoHisGL with the intent to clarify 
the earlier model of the allosteric regulation, as well as the generation 
of a truncation mutant devoid of the ACT domain to explore whether 
catalytic activity of such a mutant is a general feature of long form 
ATP-PRTases. 
 
 This chapter also reports extensive effort towards the 
purification of ATP-PRTase from N. meningitidis (NmeHisZGS), the 
causative agent of bacterial meningitis. In 2012 there were 1.2 million 
reported cases of meningococcal disease, leading to 135,000 deaths 
worldwide.82 The absence of the histidine biosynthetic pathway from 
mammalian metabolism highlights ATP-PRTase as an attractive drug 
target. Shramm et al. have presented PRTase enzymes as viable 
candidates for the synthesis of transition state analogues that serve as 
highly potent inhibitors targeting these enzymes.12,42 Structural and 
biochemical characterisation of NmeHisZGS may inform the design of 
potent antibiotics to combat this disease. Sequence analysis has 
identified N. meningitidis ATP-PRTase as a short form ATP-PRTase. 
The sequence identities between NmeHisGS and the previously 
characterised TmaHisGS and LlaHisGS are 37% and 39% respectively. 
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NmeHisZ has 20% sequence identity with TmaHisZ and 23 % sequence 
identity with LlaHisZ. Biochemical characterisation of NmeHisZGS has 
not been previously reported. 
 
3.2 Cloning, Expression and Preliminary 
Characterisation of EcoHisGL 
 
 EcohisGL was amplified from E. coli genomic DNA (gDNA) using 
two rounds of nested PCR (Figure 3.1). The first round amplified the 
gene from gDNA and the second installed the TEV protease cleavage 
site and the attB sites for cloning using the Gateway® system (Life 
Technologies). The modified EcohisGL gene was cloned into pDONR221 
using the standard procedure for BP clonaseTM (Figure 3.1). An E. coli 
TOP 10 competent cell line was used for the selection and proliferation 
of positive constructs. LR clonaseTM was employed to subclone the 
sequence verified EcohisGLpDONR221 construct into pDEST-17 with 




Figure 3.1 Schematic of the general protocol for amplification of a gene via nested PCR and cloning of a 
gene into pDONR221 using BP clonaseTM. 
 
 
Figure 3.2 Schematic of the general protocol for cloning into a destination vector using LR clonaseTM. 
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Limited soluble protein was obtained from expression in 
BL21*(DE3) cells. Protein expression conditions were optimised by 
systematically varying the cell line, IPTG concentration, media, 
temperature and duration of incubation. As discussed in chapter two, 
the solubility of EcoHisGL was improved by expression in Chaperone 3 
cells. The purification buffers were adapted from a previously 
published protocol.83 Purification of EcoHisGL was achieved via two 
chromatography steps. The (His)6-tagged protein eluted as a single 
peak from IMAC. The pooled fractions were desalted prior to the 
addition of TEV protease to cleave the N-terminal (His)6-tag. Complete 
cleavage required incubation at 37 °C for one hour, followed by 4 °C for 
three days. Samples were taken throughout the duration of incubation 
to ensure the retention of catalytic activity. The untagged protein was 
then purified via SEC. EcoHisGL eluted from the preparative SEC as a 
single peak, with a small shoulder that likely corresponds to an 
aggregate species (Figure 3.3). Fractions corresponding to the main 
peak were pooled to yield 8 mg of EcoHisGL per litre of cell culture. 
 
Figure 3.3 A280nm trace of tagless EcoHisGL following purification via SEC. Insert: SDS-PAGE gel of 
purified EcoHisGL following SEC. 
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3.3 Determination of the Quaternary Structure of 
EcohisGL by Analytical SEC 
 
 Analytical SEC was used to determine the quaternary structure 
of EcoHisGL (1 mg/mL) in solution. The protein eluted as a single peak 
at the void volume of the column, consistent with a higher order 
species (molecular weight > 669 kDa) (Figure 3.4). There was no 
evidence of a hexameric (267 kDa), tetrameric (133 kDa), or dimeric 
(66.7 kDa) species as previously reported by Tebar et al.47   
 
Figure 3.4 A280nm trace of EcoHisGL following analytical SEC. A single species was observed with an elution 
volume consistent with the void volume of the column. The volume of elution of blue dextran (2000 kDa) 
was 8.05 mL and the elution volume of EcoHisGL was 8.15 mL. The expected molecular weight of the 
hexameric EcoHisGL is 267 kDa. 
 
3.4 Determination of the Quaternary Structure of 
EcoHisGL by SAXS 
 
 In order to confirm the results of analytical SEC, SAXS 
experiments were performed on EcoHisGL in the absence of ligands at 
concentrations of 0.3 mg/mL, 0.75 mg/mL, 1.5 mg/mL and 3 mg/mL. 
SAXS experiments were also conducted with the addition of 1 mM 
ATP, 100 µM PRPP, 1 mM histidine, and the combination of 1 mM 
histidine and 1 mM AMP (Figure 3.5). Each scattering profile was 
consistent with a higher order species. The theoretical Rg values 
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calculated from the hexameric crystal structures were 23.2 Å (PDB 
1H3D) and 22.9 Å (PDB 1Q1K). The Rg values determined from the 
experimental SAXS data by the Guinier approximation and P(r) 
function ranged from 60.4 ± 0.1 Å to 85.2 ± 0.8 Å (Table 3.1). Crysol 
was used to fit the SAXS profiles to each crystal structure, and the fits 
were sufficiently poor that χ2 values could not be determined (Figure 
3.5). 
 
Table 3.1: The Rg, Dmax and Porod Volume Determined for EcoHisGL SAXS 
Data in the Presence and Absence of Natural Substrates and Inhibitors 
 
Sample Rg  (Guinier) (Å) Rg (P(r)) (Å) Porod Volume (Å3) Dmax (Å) 
EcoHisGL 60.4 ± 0.1 62.0 ± 0.1 1045850 242 
EcoHisGL + His + AMP 77.6 ± 0.2 73 ± 1 1292950 241 
EcoHisGL + ATP 77.2 ± 0.1 72.3 ± 0.9 1553690 261 
EcoHisGL + His 77.3 ± 0.3 69 ± 1 1360820 244 




Figure 3.5 Overlay of EcoHisGL SAXS scattering profiles (left). Crysol was used to fit the experimental 
scattering to the theoretical scattering profile from the two available crystal structures (PDB 1Q1K and 
1H3D). The crysol plot for unliganded EcoHisGL is shown on the right, the χ2 values could not be 
determined. 
 
 Investigation into the quaternary structure of HisGL from 
S. typhimurium, E. coli, and M. tuberculosis has revealed the presence 
of dimeric, hexameric, and potentially tetrameric species, which has 
led to debate over the functional oligomeric state(s).3,23,47 In addition, 
higher order oligomers of these enzymes have been reported, however 
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these are unlikely to be biologically significant.46,50 The higher order 
species of EcoHisGL detected by both analytical SEC and SAXS is 
surprising, as the elution volume of EcoHisGL from the preparative 
SEC is consistent with the elution volume of the hexameric C. jejuni 
HisGL from the same column (Gerd Mittelstädt personal 
communication). This suggests that oligomerisation may be the result 
of downstream handling of the protein. Typically EcoHisGL was 
concentrated to 2-10 mg/mL and flash frozen following purification. 
Analysis of EcoHisGL by analytical SEC prior to concentration and 
storage was also consistent with a higher order species. Alteration of 
buffer composition by the variation of the pH, concentration of NaCl (0-
500 mM) and the addition of TCEP and glycerol (5 % v/v) had no effect 
on the oligomeric state of the protein. In addition, chromatography was 
performed at both room temperature and at 4 °C to determine whether 
oligomerisation was temperature dependent.  
 
Preliminary kinetic analysis, using the standard enzyme 
kinetics assay, revealed that the purified EcoHisGL is catalytically 
active following storage at -80 °C, however the estimated specific 
activity (0.2 µmol/min/mg) at 25 °C with 50 µM PRPP and 10 mM ATP, 
was approximately ten fold lower than the previously reported 
activity.50 The estimated kcat (approximately 0.1 s-1) was 10-20 fold 
lower than the kcat reported for the long form ATP-PRTase from 
S. typhimurium.25 The diminished activity suggests that a portion of 
the EcoHisGL is not catalytically active. Time constraints precluded 
optimisation of the purification protocol and further characterisation of 
this protein.  
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3.5 Cloning and Expression of an EcoHisGL 
Truncation Mutant 
 
 In order to explore the function of the regulatory ACT domain in 
EcoHisGL a truncation mutant, devoid of the ACT domain, was 
generated (EcoHisGcore), in parallel with the studies exploring the wild-
type protein. The gene sequence corresponding to domains I and II of 
EcoHisGL up to E225 was amplified using nested PCR, as previously 
described for the wild type EcoHisGL, and cloned into pDEST-17 with 
an N-terminal (His)6-tag using the Gateway system (Figure 3.6). 
Expression trials revealed soluble protein in Chaperone 3 cells, 
however purification and characterisation was not pursued due to the 
absence of wild-type EcoHisGL as a suitable comparison (Figure 3.7). 
The EcohisGcorepDEST-17 construct was shown to express catalytically 
active protein in vivo by E. coli EW25113ΔhisG complementation 
studies reported in chapter four. 
 
Figure 3.6 (Top) A single chain of EcoHisGL (PDB 1H3D) coloured by domain. The PRPP binding motif is 
coloured yellow and AMP is shown bound in the active site. The truncation site to form EcoHisGcore is 
represented by a dashed line. (Bottom) a schematic diagram of the amplification of EcohisGcore via nested 
PCR. Primers were designed to amplify domains I and II of EcohisGL and install a linker (grey), TEV 
protease cleavage site (bright green) and the attB sites for gateway cloning (pink). 
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Figure 3.7 SDS-PAGE gel following expression trial of EcoHisGcore lane A consists of the insoluble fraction 
and lane B is the soluble fraction.  
 
3.6 Cloning, Expression and Purification of ATP-
PRTase from N. meningitidis (NmeHisZGS) 
 
 Numerous attempts were made to clone, express, and purify 
NmeHisZGS, with limited success. The gene encoding NmeHisGS was 
cloned from N. meningitidis gDNA and the NmehisZ gene was 
purchased from Epoch Life Science. Initially the decision was made to 
co-express NmeHisZ and NmeHisGS to allow formation of the 
NmeHisZGS complex in vivo. The observation that HisGS co-purifies as 
a hetero-octameric complex5 was exploited in the development of this 
purification scheme, as discussed in chapter two. NmehisZ was cloned 
into multiple cloning site I of the pRSFDuet-1 vector with an 
N-terminal (His)6-tag and NmehisGS was cloned into multiple cloning 
site II of the NmehisZpRSFDuet-1 vector without a tag. Standard 
methods of restriction enzyme digest followed by ligation using either 
T4 DNA ligase or the Quick Ligation Kit (New England Biolabs) were 
unsuccessful. Various methods of DNA purification were tested 
 78 
including E-Gel® CloneWellTM (Life Technologies), the High Pure® 
PCR Product Purification Kit (Roche) and the Nucleospin® PCR 
Product Cleanup Kit (Clontech) as buffer components, such as ethanol, 
from DNA purification kits are known to inhibit ligation reactions.84 
Ligation was unsuccessful under all conditions tested. The In-Fusion® 
HD Cloning Kit (Clontech) was subsequently employed and both genes 
were cloned sequentially into the pRSFDuet-1 vector using the 
standard procedure described in chapter two.  
 
The expression level of NmeHisZ from the 
NmehisZGSpRSFDuet-1 construct in both BL21*(DE3) and Chaperone 
3 cell lines greatly exceeded the expression level of NmeHisGS (Figure 
3.8 A). Purification of the (His)6-tagged NmeHisZGS complex via IMAC 
followed by SEC, yielded less than 1 mg of per litre of cell culture. 
Optimisation of expression conditions by varying the cell line, IPTG 
concentration, media, temperature, and duration of incubation had no 
effect on the relative expression levels. The protein eluted from the 
preparative SEC as two peaks (Figure 3.9). The NmeHisZGS complex 
eluted as a small peak at the void volume of the column, which 
suggests that the complex exists as a soluble aggregate species. The 
fractions from the second peak, which corresponded to excess 




Figure 3.8A) SDS-PAGE gel following the IMAC purification of NmeHisZGS via expression of the 
NmehisZGSpRSFDuet-1 construct revealed a significantly greater expression level of NmeHisZ (band at 
approximately 40 kDa) relative to NmeHisGS (band at approximately 20 kDa). B) SDS-PAGE gel following 
the purification of NmeHisZGS by co-lysing the pellets of NmehisZpRSFDuet-1 BL21*(DE3) and 
NmehisGSpDEST-14 Chaperone 3. Lanes B and C correspond to the insoluble and soluble fractions 
respectively, lane D is the protein eluted from IMAC, lanes E-K correspond to peak 1 from the preparative 
SEC column and lane L represents purified NmeHisZ. 
 
Figure 3.9 Two SEC traces following NmeHisZGS purification. The dotted line represents the trace 
following early attempts to purify the enzyme and the solid line represents the trace where a small amount 
of hetero-octameric protein was obtained. Peak 1 corresponds to higher order misfolded protein, peak 2 is 
consistent with an NmeHisZGS hetero-octamer, peak 3 represents uncomplexed NmeHisZ and peak 4 is 
consistent with NmeHisGS. 
 
 Alternative approaches to purify the NmeHisZGS complex were 
explored. Attempts were made to purify NmeHisZ and NmeHisGS 
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independently and combine the two proteins in vitro to form the 
complex. This approach potentially had the additional benefit of 
allowing NmeHisZ and NmeHisGS to be characterised independently. 
The Gateway® system (Life Technologies) was utilised to clone 
NmehisGS into pDEST-17 with an N-terminal (His)6-tag, pDEST-15 
with an N-terminal Glutathione S-transferase (GST)-tag, and pDEST-
14 without a tag. Multiple expression trials were performed, varying 
the cell line, IPTG concentration, media, temperature, duration of 
incubation, and the composition of the lysis buffer. Initially the 
(His)6-tagged and untagged proteins were insoluble under all 
conditions tested, however soluble (GST)-tagged protein was obtained 
from Chaperone 3 cells. Purification of the GST-tagged protein was 
attempted, however TEV cleavage of the GST-tag following the first 
chromatography step resulted in precipitation of the protein under all 
conditions tested. Reconstitution of the NmeHisZGS complex was 
attempted by the addition of purified NmeHisZ, in a stoichiometric 
ratio with the GST-tagged NmeHisGS, to the TEV cleavage mixture. 
Samples were tested for catalytic activity using the standard enzyme 
kinetics assay, however ATP-PRTase activity was not detected after 12 
hours incubation at 4 °C and precipitation of the protein was observed. 
It is imperative that the GST tag should be cleaved given its size (25.7 
kDa) relative to the size of NmeHisGS (23.3 kDa) and the propensity of 
the GST-tag to dimerise, which is unlikely to be conducive to formation 
of the hetero-octameric complex.  
 
Optimisation of lysis buffer composition eventually resulted in 
soluble (His)6-tagged NmeHisGS and untagged NmeHisGS, however 
both the tagged and untagged protein precipitated during the first 
chromatography step. This suggests that NmeHisGS is relatively 
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unstable in the absence of NmeHisZ. This observation is consistent 
with the attempted purification of LlaHisGS discussed in chapter two.  
 
 The decision was made to utilise the pellet mixing technique 
described by Vega et al.19, as discussed in chapter two. Cell pellets of 
NmehisZpRSFDuet-1 BL21*(DE3) and NmehisGSpDEST-14 
Chaperone 3 cells were combined and co-lysed via sonication. The 
expression level of NmeHisGS improved in comparison to the 
previously described expression level from the NmehisZGSpRSFDuet-1 
construct. The NmeHisZGS complex, however, eluted at the void 
volume of the preparative SEC (Figure 3.8). As previously reported for 
LlaHisZGS, ATP-PRTase activity was detected in the cell lysate of the 
combined NmeHisZ and NmeHisGS but was absent from the cell lysate 
of NmeHisGS expressed independently. The information gleaned from 
the purification of LlaHisZGS eventually led to the decision to subclone 
NmehisGS into pET-21a. The expression level improved significantly in 
comparison to the pDEST-14 construct. Purification of the NmeHisZGS 
complex was achieved by co-lysing the cell pellets from 
NmehisZpRSFDuet-1 BL21*(DE3) and NmehisGSpET-21a chaperone 
3, followed by IMAC and SEC. A new peak was observed on the 
preparative SEC A280nm trace (Figure 3.8). SDS-PAGE analysis 
revealed an approximately equal ratio of NmeHisZ and NmeHisGS 
(Figure 3.10). The fractions corresponding to this peak were pooled to 
yield 5 mg of NmeHisZGS per litre of cell culture. The detection of a 
fourth peak on the A280nm trace, corresponding to NmeHisGS in the 
absence of HisZ, was also noted and the corresponding fractions were 
pooled to yield 1 mg of NmeHisGS per litre of cell culture.   
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Figure 3.10 A) SDS-PAGE gel of peak 2 from the preparative SEC showing the NmeHisZGS enzyme 
complex. B) SDS-PAGE gel showing the fractions corresponding to peak 1 and peak 4 from the preparative 
SEC. Peak 1 is likely to be an aggregated, misfolded species, indicated by the early elution volume and the 
presence of chaperonin protein (band at approximately 60 kDa). Peak 4 corresponds to purified NmeHisGS.  
 
3.7 Determination of the Quaternary Structure of 
NmeHisZGS by Analytical SEC 
 
3.7.1 Characterisation of NmeHisZGS by Analytical SEC 
 
  
 Analytical SEC was employed to determine the quaternary 
structure of NmeHisZGS in solution. The purified protein from the 
co-lysis of NmehisZpRSFDuet-1 BL21*(DE3) and NmehisGSpDEST-14 
Chaperone 3 cell pellets eluted as two peaks from the analytical SEC. 
The first peak, eluted at the void volume of the column, consistent with 
an aggregate species, whilst the second peak had an elution volume, 
consistent with an NmeHisZ dimer (Figure 3.11). The protein purified 
via the combination of NmehisZpRSFDuet-1 BL21*(DE3) and 
NmehisGSpET-21a Chaperone 3 cell pellets also eluted as two peaks 
(Figure 3.11). The first peak, again corresponded to an aggregate 
species, however the second peak had an elution volume consistent 
with the NmeHisZGS hetero-octamer. This suggests that the protein 
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has a propensity to aggregate and further optimisation of the 
purification and experimental conditions is required.  
 
Figure 3.11 Analytical SEC of NmeHisZGS purified from the combination of NmehisZpRSFDuet-1 
BL21*(DE3) and NmehisGSpDEST-14 Chaperone 3 cell pellets (red line) shows two peaks. The first peak is 
consistent with an aggregate species and the second peak is consistent with an NmeHisZ dimer. The 
analytical SEC trace of NmeHisZGS purified via the combination of NmehisZpRSFDuet-1 BL21*(DE3) and 
NmehisGSpET-21a Chaperone 3 (blue line) also shows two peaks. The first is an aggregate species and the 
second is consistent with the NmeHisZGS hetero-octamer.  
 
 In order to determine whether the in vitro combination of the 
purified NmeHisGS and NmeHisZ to form the hetero-octameric 
NmeHisZGS complex was feasible, 0.04 mM NmeHisZ was combined 
with 0.04 mM NmeHisGS and loaded onto the analytical SEC. This 
protein eluted as two peaks, the first at the void volume of the column, 
consistent with an aggregate species, and the second was consistent 
with an NmeHisZ dimer (Figure 3.12). This protein preparation was 
also catalytically inactive, which suggests that in vitro complex 
formation is not feasible under the conditions tested.   
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Figure 3.12 Analytical SEC following the in vitro combination of purified NmeHisZ and NmeHisGS 
revealed two peaks. The first peak is consistent with a higher order aggregate species and the second is 
consistent with an NmeHisZ dimeric species.  
 
3.7.2 Characterisation of NmeHisZ by Analytical SEC 
 
 
 NmeHisZ eluted from the analytical SEC as a single peak, 
consistent with an NmeHisZ dimer, at concentrations ranging from 0.2 
mg/mL to 9 mg/mL (Figure 3.13). This is in line with the LlaHisZ 
dimeric species discussed in chapter two and contradicts the 
observation of a TmaHisZ dimer-tetramer equilibrium reported by 
Vega et al.19 
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Figure 3.13 Analytical SEC trace of NmeHisZ at concentrations ranging from 0.2 mg/mL to 9 mg/mL 
revealed a single species with a molecular weight consistent with an NmeHisZ dimer.  
 
3.7.3 Analytical SEC Studies on NmeHisGS 
 
 
 NmeHisGS also eluted as a single peak from analytical SEC, 
corresponding to a dimeric species (Figure 3.14). This is consistent 
with the dimeric HisGS crystal structures from T. thermophilus (PDB 
1VE4) and B. subtilis (PDB 2VD2).  
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Figure 3.14 Analytical SEC trace of NmeHisGS (0.5 mg/mL) showing a single species with a molecular 
weight corresponding to a dimer.  
 
3.8 Crystallisation Trials of NmeHisZ 
 
 Multiple commercial screens were employed to determine crystal 
conditions for the NmeHisZ in the absence of NmeHisGS. Several 
crystal conditions were found, however no diffraction quality crystals 
were obtained and further optimisation is required (Figure 3.15). 
 
 
Figure 3.15 Crystals of NmeHisZ obtained from the manual optimisation of conditions from the ProPlex 




3.9 Preliminary Kinetic Analysis 
  
 Preliminary kinetic characterisation of the purified NmeHisZGS 
revealed a KMPRPP value of 18 ± 1 µM, which is consistent KMPRPP value 
of 18 ± 4 µM reported for LlaHisZGS (Figure 3.16).26 The specific 
activity, however, is lower than that of LlaHisZGS. The kcat determined 
for NmeHisZGS (0.91 ± 0.02 s-1) was approximately 3 fold less than the 
kcat of LlaHisZGS (2.7 ± 0.3 s-1). This may reflect a lower catalytic 
activity of NmeHisZGS compared to LlaHisZGS, however this 
observation, in combination with the large aggregate peak observed by 
analytical SEC, suggests that the aggregate species may not be 
catalytically active and further optimisation of the purification protocol 
is required, which precluded further kinetic and biochemical 




Figure 3.16 The KMPRPP for NmeHisZGS determined by holding the [ATP] constant at 10 mM and varying 









 Attempts to clone, express and purify the long form ATP-PRTase 
from E. coli and the short form ATP-PRTase from N. meningitidis 
proved largely unsuccessful due to the tendency of both enzymes to 
aggregate during or following purification. Aggregate species of 
EcoHisGL have previously been described, however the complete 
absence of the biologically relevant oligomeric state(s) of EcoHisGL is 
surprising.47,50 Kryvi and Klungsoyer have reported loss of activity of 
EcoHisGL at high concentration, which they attributed either to 
hexamer formation or to the formation of non-specific aggregates, 
however Dall-Larsen suggested that this inhibition was due to an early 
build up of PR-ATP, thereby inhibiting the enzyme.50,85 Analytical SEC 
and SAXS experiments were consistent with higher order EcoHisGL 
species in the presence and absence of inhibitors. SAXS revealed no 
clear trend in the Rg or Dmax, which suggests that the higher order 
species is not uniform, a further indication that it is not biologically 
functional. Variation of the concentration of NaCl and the addition of a 
reducing agent and glycerol to the purification buffers had no impact 
on aggregation. The buffers used in this purification were adapted from 
the method described by Lohkamp et al., however the published 
method utilised anion exchange chromatography to purify the 
untagged protein, as opposed to the IMAC purification of the 
(His)6-tagged protein described in this chapter.83 Further investigation 
should focus on purification of the untagged protein by anion exchange, 
as it is possible that the presence of the (His)6-tag, or the three day 
incubation required to cleave the tag, may be responsible for 
aggregation of the protein. It should be noted that Lohkamp et al. 
reported significant loss of EcoHisGL during purification due to 
precipitation.83 Further optimisation of the purification scheme could 
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include additional buffer components such as detergents or bovine 
serum albumin, which may help to mitigate aggregation. 
 
 Numerous techniques were employed to clone, express, and 
purify NmeHisZGS, with minimal success. NmeHisZ expressed and 
purified readily whilst the expression level of NmeHisGS was 
significantly lower. NmeHisGS has a tendency to precipitate in the 
absence of NmeHisZ. This suggests that NmeHisZ plays a role in 
stabilising NmeHisGS in the formation of the active hetero-octamer. 
NmeHisZ appears to activate NmeHisGS, as previously reported for 
TmaHisZGS and LlaHisZGS. It is interesting, therefore, that 
truncation mutants of HisGL from both E. coli and C. jejuni, lacking 
the ACT domain, retain diminished catalytic activity. Further 
investigation into the structure, dynamics, and biochemistry of both 
the wild type and mutant proteins is required to understand this 
retention of catalytic activity. 
 
 NmeHisZGS primarily adopts a higher order species during 
purification, a phenomenon that has not been previously reported for 
the short form ATP-PRTase enzymes.19,20,26 Further optimisation of the 
purification procedure is required to minimise aggregation of the 
protein. This could include the purification of the untagged complex, or 
the addition of bovine serum albumin, or detergents to the purification 
buffers. The in vitro combination of purified NmeHisZ and NmeHisGS 
is unlikely to be a viable purification method as it was shown to result 
in inactive protein, whilst the presence of cellular contents during lysis 
of the combined cell pellets appears to promote complex formation. The 
small amount of hetero-octameric NmeHisZGS obtained was likely due 
to the improved expression level of NmeHisGS following subcloning 
into pET-21a. This increase in expression level was unexpected given 
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that pDEST vectors are derived from pET vectors, however it may 
simply be due to the difference between distance of the ribosome 
binding site from the start codon in the two constructs. Although a 
small amount of hetero-octameric NmeHisZGS was eventually 
obtained, the observation of the higher order species by analytical SEC 
and the low kcat value relative to the kcat reported for LlaHisZGS, 
suggests that the higher order species may not be catalytically active. 
Further optimisation of the purification is required before proceeding 
with characterisation of the enzyme.  
 
 Contrary to the reports of a TmaHisZ dimer-tetramer 
equilibrium described by Vega et al.,19 characterisation of the 
quaternary structure of NmeHisZ by analytical SEC revealed a dimeric 
structure of the protein at concentrations ranging from 0.2 mg/mL to 9 
mg/mL. This suggests that the X-shaped HisZ core, assuming that the 
structure of NmeHisZGS is similar to the structures reported for 
TmaHisZGS and LlaHisZGS, is stabilised only in the presence of 
NmeHisGS. NmeHisGS also appears to adopt a dimeric structure in the 
absence of NmeHisZ. This is consistent with the dimeric crystal 
structures of the HisGS proteins from B. subtilis and T. thermophilus, 
however further investigation is required as the low yield following the 
serendipitous NmeHisGS purification precluded in depth biochemical 
characterisation of the protein. 
 
 In conclusion, the tendency of both EcoHisGL and NmeHisZGS to 
aggregate during or following purification precluded extensive 
biochemical characterisation of these proteins. Future investigation 
should focus on optimisation of the purification protocols. NmeHisZGS 
is of particular importance given its identification as a potential target 




4 Cloning and Purification of 
ATP-PRTase from Leuconostoc 
mesenteroides and the Construction 




 Allosteric regulation is a critical feature of metabolism. Binding 
of a ligand at an allosteric site affects activity at a remote functional 
site, exploiting protein flexibility and altering the shape of the protein 
energy landscape.79 The importance of allostery is underpinned by its 
ubiquity and diversity. A myriad of allosteric mechanisms have been 
unravelled, which likely evolved through several independent 
mechanisms.86 Three strategies have been proposed for the 
evolutionary acquisition of functional allostery.86 The first involves the 
structural modification of an existing domain to form an allosteric 
effector site. The second involves the development of homomeric or 
heteromeric assemblies, with the formation of allosteric binding sites 
at the subunit interfaces. Thirdly, allostery may be bestowed by the 
recruitment of a distinct regulatory domain, via gene fusion, to form a 
multidomain protein.  
 
The ATP-PRTase family likely acquired allosteric regulation by 
a combination of all three evolutionary mechanisms. There is 
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unambiguous evidence to support the common ancestry of HisGS and 
HisGL, and the structural and sequential similarity between HisZ and 
the histidyl-tRNA synthetases shows a clear evolutionary relationship 
between histidine biosynthesis and the use of histidine in protein 
synthesis by its cognate tRNA.5,19 Assuming that aminoacyl-tRNA 
synthetases were among the earliest enzymes to emerge, it is plausible 
that the short form ATP-PRTase evolved subsequently. In this 
scenario, HisZ and histidyl-tRNA synthetase share a common 
evolutionary ancestor and the contemporary HisGS emerged 
independently from an unidentified precursor. The subsequent 
recruitment of an ACT domain may have given rise to the HisGL 
family, although how this domain fusion event could confer both 
catalytic activity and allostery to the protein remains to be explored. 
 
 The ACT domain has been identified as a mobile unit of 
allostery.31,32 Most enzymes in which the ACT domain has been 
identified catalyse early reactions in amino acid metabolism, and 
ligand binding is typically associated with the interface of two or more 
ACT domains.32 Recent work has shown that the simple transfer of an 
ACT domain from one protein is sufficient to confer functional allostery 
to its unregulated orthologue from a distinct species. This observation 
suggests that the acquisition of functional allostery may be remarkably 
facile. This chapter reports the formation of a chimeric protein in 
which the ACT domain from HisGL of C. jejuni (CjeACT) was 
transferred to LlaHisGS, in an attempt to replicate the ACT domain 
recruitment event that led to the long form ATP-PRTase.  
 
Two molecular architectures of ATP-PRTase have been 
biochemically characterised, the homo-hexameric long form and the 
hetero-octameric short form.3,4,19,20 A search of the Pfam database 
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revealed a third sequence structure in which hisZ and hisGS constitute 
a single open reading frame, encoding a putative covalently linked 
short form ATP-PRTase (Figure 4.1).87 This chapter describes the 
cloning and purification of such a protein from Leuconostoc 
mesenteroides (LmeHisZGFusion). The generation of two covalently 
linked LlaHisZGS proteins, in an attempt to mimic the gene fusion 




Figure 4.1 Schematic representation of each of the three sequence structures of ATP-PRTase. The short 
form of ATP-PRTase is assembled from the non-covalent association of HisZ (red) and HisGS (blue). The 
long form is composed of HisGL chains, which consist of a similar catalytic domain to HisGS (blue) and a 
regulatory ACT domain (pink). The covalent short form is comprised of HisZ (red) and HisGS (blue) 
domains joined by a short, flexible linker (green). 
 
 
4.2 Cloning, Expression, Purification and Homology 
Modelling of LmeHisZGFusion 
 
 A search of the Pfam database revealed 35 ATP-PRTase 
sequences in which HisZ and HisGS comprise a single open reading 
frame.87 Expression of this open reading frame is expected to generate 
a polypeptide chain with an N-terminal HisZ domain covalently linked 
to a C-terminal HisGS domain. Analysis of the amino acid sequence of 
this hypothetical fusion protein revealed the presence of conserved 
ATP-PRTase motifs, including the PRPP binding motif. The bacterial 
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genomes that possess the HisZGFusion sequence also encode the 
complete his operon. It is therefore a reasonable assumption that these 
organisms are histidine prototrophs and therefore express a functional 
ATP-PRTase.   
 
4.2.1 Homology Model of LmeHisZGFusion  
 
Despite the development of high throughput methods for protein 
crystallography, the rate of protein structure determination has been 
eclipsed by the rapid advancement of genome sequencing.88-90 As a 
result, the number of protein sequences available greatly exceeds the 
availability of structural and biochemical information. Homology 
modelling methods are therefore useful to predict the three 
dimensional structure of a protein from its sequence, using information 
derived from the structure of a homologous protein.91-93 Homology 
models have proven useful for structure-based drug design and for the 
development of biochemical experiments, such as site directed 
mutagenesis, to probe the structure-function relationship.  
 
The Schrödinger program suite was employed by Dr Wanting 
Jiao to construct a homology model of LmeHisZGFusion. The X-ray 
crystal structure of LlaHisZGS (PDB 1Z7M) was used as a template. 
LmeHisZGFusion shares 22 % sequence identity with LlaHisZ (Figure 
4.2) and 39 % sequence identity with LlaHisGS (Figure 4.3). These 
values are consistent with the identities across the short form ATP-
PRTase family.19 The homology model shows the LmeHisZGFusion chains 
arranged in a homo-tetramer, reminiscent of the hetero-octameric 
structure of LlaHisZGS (Figure 4.5). The LmeHisZ and LmeHisGS 
domains are connected by a flexible loop (Figure 4.4). An overlay of the 
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homology model of LmeHisZGFusion and the LlaHisZGS crystal structure 
revealed a similarity in both the histidine binding sites and the 
position of the PRPP binding motif (Figure 4.6). 
 
Figure 4.2 Sequence alignment of LmeHisZGFusion and LlaHisZ. Conserved residues are coloured red and 
conserved functionalities are shown in yellow. The two proteins share 22 % sequence identity. 
 
Figure 4.3 Sequence alignment of LmeHisZGFusion and LlaHisGS. Conserved residues are highlighted in red 
and conserved functionalities are shown in yellow. The sequence identity between LlaHisGS and 
LmeHisZGFusion is 39 %.  
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Figure 4.4A) A single chain of LmeHisZGFusion showing LmeHisGS coloured by domain and LmeHisZ 
coloured grey. The PRPP binding motif is shown in yellow and the linker region is coloured red. B) The 
monomeric unit of LmeHisZGFusion with LmeHisZ coloured by domain, LmeHisGS coloured grey and the 
linker region shown in magenta. Note that the HisZ-HisGS linker is likely to be highly flexible and the 
relative positioning of LmeHisZ and LmeHisGS is due to the constraints imposed by the formation of a 
tetrameric assembly.  
 
 
Figure 4.5 Two views of the tetrameric homology model of LmeHisZGFusion with one HisZ domain coloured 




Figure 4.6 Alignment of a single chain of LmeHisZGFusion coloured by domain, with single chains of LlaHisZ 
and LlaHisGS (grey) (PDB 1Z7M). The PRPP binding motifs of LlaHisGS and LmeHisZGFusion are shown in 
yellow and orange respectively. Conserved residues from the proposed histidine binding site are shown as 
an insert. The LmeHisZGFusion residues are coloured red and the LlaHisZ residues are coloured grey. 
LlaHisZ numbering is shown. Each of the proposed histidine binding residues overlay well with the 
equivalent residues from LlaHisZ, with the exception of Tyr268, which adopts a more favourable 
conformation for histidine binding in the LmeHisZGFusion homology model.  
 
4.2.2 Cloning, Expression and Purification of LmeHisZGFusion 
  
 A synthetic gene encoding LmehisZGFusion, codon optimised for 
expression in E. coli, was purchased from Epoch Life Science. 
LmehisZGFusion was subcloned into pET-28a, with an N-terminal 
(His)6-tag, using the standard procedure for cloning using the 
InFusion® HD cloning kit (Clontech), described in chapter two. 
Expression trials of the sequence verified construct in E. coli 
BL21*(DE3) cells revealed the presence of soluble LmeHisZGFusion, 
however no ATP-PRTase activity was detected in the cellular lysate. 
Purification of LmeHisZGFusion via IMAC (Figure 4.7), followed by SEC 
(Figure 4.8), yielded approximately 20 mg of LmeHisZGFusion per litre of 
cell culture. The elution volume from the preparative SEC is consistent 
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with the elution volume of the hetero-octameric LlaHisZGS from the 
same column. This suggests a tetrameric assembly of LmeHisZGFusion. 
ATP-PRTase activity was not detected in either the eluent from IMAC 
or the purified protein, using the standard enzyme kinetics assay with 
10 mM ATP, 50 µM PRPP and up to 1 mg/mL LmeHisZGFusion. The 
purified LmeHisZGFusion was concentrated to 5 mg/mL and stored 
at -80 °C. Precipitation of the protein precluded the analysis of 
secondary structure via circular dichroism and quaternary structure 
via analytical SEC. It is therefore unclear whether the lack of catalytic 
activity is the result of incorrect folding of the protein or whether 
L. mesenteroides does not express a functional ATP-PRTase. It should 
be noted that co-expression with chaperonins in E. coli Chaperone 3 
cells decreased the yield of LmeHisZGFusion and did not result in 
detectable ATP-PRTase activity. 
 
 
Figure 4.7 SDS-PAGE gel showing the purification of LmeHisZGFusion by IMAC. The first lane is a 
molecular weight marker. The second and third lanes indicate the insoluble fraction; the soluble fraction is 
represented by lanes four and five, and the flow through is shown in the sixth lane. The final four lanes 
correspond to the peak following IMAC. 
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Figure 4.8 A280nm trace and SDS-PAGE gel following purification of LmeHisZGFusion by SEC. The SEC trace 
shows two peaks. Peak 1 corresponds to lanes G and H on the SDS-PAGE gel, which indicates the presence 
of two protein species. The second peak corresponds to lanes A-F on the SDS-PAGE gel and represents 
purified LmeHisZGFusion. There are additional lower molecular weight species present in these lanes. The 
retention time following preparative SEC is similar to the retention time of the hetero-octameric 
LlaHisZGS, which suggests that LmeHisZGFusion may be adopting a tetrameric quaternary structure.  
 
4.3 Engineering a covalent linker between LlaHisZ 
and LlaHisGS 
 
 L. mesenteroides shares a recent common ancestor with 
L. lactis,94 which is known to express a functional short form 
ATP-PRTase. This section reports the engineering of a flexible linker 
between LlaHisZ and LlaHisGS, in an attempt to mimic the domain 
fusion event that may have given rise to the wild-type HisZGFusion 
proteins.  
4.3.1 Linker design 
 
 There is no sequence identity between the linker regions of the 
wild-type HisZGFusion proteins, which is unsurprising given the limited 
number of organisms featuring this sequence architecture. Two 
LlaHisZGFusion constructs were designed, one with a short linker, 
denoted LlaHisZGFusion(Short) and one with a long linker 
(LlaHisZGFusion(Long)). Fusion sites were chosen based on regions of 
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conservation observed in the structure-based sequence alignment of 
the LmeHisZGFusion homology model and the crystal structure of 
LlaHisZGS (PDB 1Z7M) (Figure 4.9). The LlaHisZGFusion(Short) 
construct was formed by the insertion of a ten amino acid 
LmeHisZGFusion sequence between LlaHisZ D26 and LlaHisGS K8. The 
LlaHisZGFusion(Long) construct was generated by inserting a 21 amino 
acid sequence of LmeHisZGFusion between LlaHisZ L315 and LlaHisGS 
K8.  
 
Figure 4.9 Structure-based sequence alignment of a single chain of LmeHisZGFusion with LlaHisZ (1Z7M_A) 
and LlaHisGS (1Z7M_E) generated using the ENDscript server.95 The LlaHisZGS long linker was 
constructed by inserting the LmeHisZGFusion sequence indicated by the red box, between LlaHisZ L315 (red 
arrow) and LlaHisGS K8 (red arrow). The LlaHisZGFusion short linker was constructed by inserting the 
LmeHisZGFusion sequence, shown by the green box, between LlaHisZ D326 (green arrow) and LlaHisGS K8 
(green arrow).  
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4.3.2 Cloning and expression 
 
 The LlahisZ and LlahisGS genes amplified beautifully from their 
respective pBSK constructs. The linker regions were added by the 
stepwise extension of the 3’ end of the LlahisZ PCR product and the 5’ 
end of the LlahisGS PCR product (Figure 4.10), resulting in a 23 base 
pair overlap between LlahisZ and LlahisGS for generation of the 
LlahisZGFusion(Long) PCR product, and a 17 base pair overlap for 
formation of the LlahisZGFusion(Short) PCR product. The final PCR 
reaction installed the 15 base pair recognition sites for cloning using 
the InFusion® HD Cloning Kit (Clontech). Each PCR product was 
cloned into pET-28a with an N-terminal (His)6-tag. Expression of the 
sequence verified constructs in E. coli BL21*(DE3) cells yielded soluble 
protein (Figure 4.11). ATP-PRTase activity was not detected in either 
the cellular lysate or the eluent from IMAC, using the standard 
enzyme kinetics assay with 50 µM PRPP and 10 mM ATP. Purification 
and characterisation of these proteins was not pursued due to the 
paucity of catalytic activity.  
 
Figure 4.10 Schematic representation of the linker formation (green) between LlaHisZ (red) and LlaHisGS 
(blue) via five PCR reactions. The final PCR step installed the 15 base pair recombination sequence for the 
InFusion® reaction (grey). Note that the LlahisZGFusion(Short) PCR product was formed via four PCR 
steps, as the linker region was sufficiently short to generate an overlapping region by a single PCR 
amplification of LlahisZ. 
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Figure 4.11 (left) SDS-PAGE gel following the expression trial of LlaHisZGFusion(Long) in BL21*(DE3) cells. 
Lanes A and B show the insoluble fractions and lanes C and D show the soluble fraction. A band at 
approximately 60 kDa indicates that LlaHisZGFusion(Long) is present in both the soluble and insoluble 
fractions. (right) SDS-PAGE gel following the expression trial of LlaHisZGFusion(Short). Lane A shows the 
insoluble fraction, lane B shows the soluble fraction, lane C shows the flow through from a spin HisTrap 
column, lane D shows the wash step of the spin HisTrap and lane E shows the eluent. A band at 
approximately 60 kDa indicates that LlaHisZGFusion(Short) is predominantly found in the soluble fraction 
and is able to bind the IMAC column.  
 
4.4 Transfer of the ACT regulatory domain from 
CjeHisGL to LlaHisGS 
 
 The ACT domain is a common regulatory motif found in 
enzymes involved in amino acid metabolism.31,32 The simple transfer of 
an ACT domain has been shown to confer functional allostery to an 
unregulated enzyme.96 The HisZGS complex is considered to be the 
phylogenetically older form of ATP-PRTase and HisGL may have 
subsequently evolved via the recruitment of an ACT domain. In order 
to explore this relationship, a chimeric protein was constructed 
whereby the ACT domain of HisGL from C. jejuni (CjeHisGL) was fused 
to the C-terminus of LlaHisGS via PCR. 
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4.4.1 Choice of Fusion Site 
 
 
 The long form ATP-PRTase enzymes from M. tuberculosis,3 
E. coli,4 C. jejuni (Gerd Mittelstädt personal communication) and the 
short form ATP-PRTase enzymes from L. lactis20 and T. maritima19 
have been structurally characterised. Removal of the ACT domain from 
CjeHisGL results in a homo-dimeric enzyme with diminished 
ATP-PRTase activity, and preliminary investigation has suggested 
that the CjeACT domain is trimeric in the absence of the catalytic core 
of CjeHisGL (Gerd Mittelstädt, personal communication). LlaHisGS has 
been structurally characterised as a component of the LlaHisZGS 
complex. Preliminary results from E. coli BW25113ΔhisG 
complementation studies, reported in section 4.5, suggest that 
LlaHisGS may exhibit marginal ATP-PRTase activity in the absence of 
LlaHisZ. LlaHisGS was chosen as the recipient of the ACT domain as it 
is mesophilic, unlike TmaHisGS, which minimises the chance of 
incompatibility of the optimal functional temperature between the 
catalytic core and the ACT domain. CjeHisGL was chosen as the ACT 
domain donor. The observation that the ACT domain may 
independently associate to form a trimer is particularly important, as 
it suggests that transfer of the ACT domain may be sufficient to form a 
hexameric ATP-PRTase.   
 
The overall fold of the LlaHisGS and CjeHisGL catalytic domains 
are very similar.§ The most prominent differences are the unresolved 
β11-α6 loop in CjeHisGL, which is helical in LlaHisGS, and the length 
of the CjeHisGL α6 helix connecting domain I to the ACT domain, 
                                            
§ A single chain of CjeHisGcore aligns to a single chain of LlaHisGS from the LlaHisZGS crystal 
structure with an RMSD of 1.2 Å (PDB 1Z7N) and 1.3 Å (PDB 1Z7N).  
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which is seven residues longer than the equivalent helix in LlaHisGS 
(Figure 4.12). LlaHisGS shares 28 % sequence identity with CjeHisGL 
and the choice of fusion site was informed by a structure-based 
sequence alignment of the two proteins. Two possible fusion sites were 
considered. The first was the replacement of the LlaHisGS sequence 
after β11 with the equivalent CjeHisGL sequence. This would introduce 
the β11-α6 loop sequence from CjeHisGL, in addition to α6 and the ACT 
domain. This method was not pursued due to the possibility that 
introduction of the loop sequence from CjeHisGL in place of the kinked 
helix of LlaHisGS, may result in incorrect protein folding. The decision 
was made to extend α7 of LlaHisGS (equivalent to α6 of CjeHisGL) by 
the addition of the CjeHisGL sequence after residue R202 (R216 in 
CjeHisGL). R216/R202 was chosen as the fusion point due to the 
conservation of this residue. 
 
Figure 4.12 Structure-based sequence alignment of CjeHisGL chain A and LlaHisGS (1Z7M_E) generated 






4.4.2 Cloning and Expression 
 
 
Figure 4.13 Schematic of the construction of the LlaHisGS-CjeACT chimera using PCR. Step 1 amplified 
LlahisGS (blue) from the template vector and partially installed the 5’ sequence corresponding to the TEV 
cleavage site (cyan) and a linker (black) as well as a 3’ extension complementary to the sequence of CjeACT 
(pink). The second reaction installed the remainder of the TEV cleavage site. The third reaction amplified 
CjeACT with a 5’ extension complementary to LlahisGS. The fourth reaction stitched the two products 
together and the fifth installed the recognition sequence for the InFusion enzyme (grey).  
 
 The LlahisGS-CjeACT chimera was constructed using five PCR 
reactions (Figure 4.13). The first reaction amplified LlahisGS from the 
LlahisGSpBSK vector with partial installation of the TEV cleavage site 
at the 5’ end, and a 3’ extension complementary to the sequence of 
CjeACT. The remainder of the TEV cleavage site was incorporated in 
the second PCR reaction. The third step amplified the CjeACT 
sequence from the CjehisGLpDONR221 vector and installed a 5’ 
extension complementary to the LlahisGS sequence. The fourth PCR 
step fused the two genes together and the fifth installed the 15 base 
pair recognition sequence for the InFusion® reaction. The LlahisGS-
CjeACT PCR product was cloned into pET-28a with an N-terminal 
(His)6-tag using the standard procedure for cloning using the 
InFusion® HD cloning kit (Clontech). Expression trials of the sequence 
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verified construct in E. coli Chaperone 3 cells resulted in soluble 
LlaHisGS-CjeACT (Figure 4.14), however catalytic activity was not 
observed in the cellular lysate, or the eluent following IMAC, using the 
standard enzyme kinetics assay with up to 1 mg/mL protein.  
 
Figure 4.14 SDS PAGE gel of the (His)6-tagged LlaHisGS-CjeACT chimeric protein purification via IMAC. 
Lane A corresponds to a molecular weight marker, Lanes G and H show the insoluble and soluble fractions 
respectively, Lane I corresponds to the IMAC flow through, Lane J shows the IMAC wash step and Lane K 
shows the IMAC eluent. The band at approximately 35 kDa corresponds to the (His)6-tagged LlaHisGS-
CjeACT protein. 
 
4.5 E. coli BW25113ΔhisG::kan Complementation 
Studies  
 
 Complementation studies of E. coli BW25113ΔhisG::kan cells 
from the Keio collection97 with plasmids encoding EcoHisGL, CjeHisGL, 
MtuHisGL, LlaHisZGS, NmeHisZGS, EcoHisGcore, CjeHisGcore, 
LmeHisZGFusion, LlaHisGS, NmeHisGS, LlaHisZ+NmeHisGS, 
NmeHisZ+LlaHisGS, LlaHisZGFusion(short), LlaHisZGFusion(long) and 
LlaHisGS-CjeACT were used to probe the ATP-PRTase activity of each 
of these proteins in vivo. The E. coli BW25113ΔhisG::kan cells lack the 
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hisG gene that encodes ATP-PRTase, and are therefore auxotrophic for 
histidine. Growth of these cells is supported only by the addition of 
histidine to the growth medium or by complementation with a plasmid 
encoding a functional ATP-PRTase. Complementation studies allow 
the visualisation of proteins that may exhibit minimal catalytic 
activity, not detected spectroscopically, and are not confounded by 
purification methods or assay conditions.  
 
Table 4.1 Growth of the E. coli BW25113 ΔhisG strain transformed with 
plasmids encoding functional and putative ATP-PRTases on minimal media 
agar plates 
 Detection of Growth 
Protein Encoded By Transformed Plasmid + Histidine + IPTG 
Untransformed Strain ✓ ✗ 
EcoHisGL ✓ ✓ 
CjeHisGL ✓ ✓ 
MtuHisGL ✓ ✓ 
LlaHisZGS ✓ ✓ 
NmeHisZGS ✓ ✓ 
EcoHisGcore ✓ * 
CjeHisGcore ✓ ✗ 
LlaHisGS ✓ * 
NmeHisGS ✓ * 
LmeHisZGFusion ✓ ✗ 
LlaHisZ+NmeHisGS ✓ * 
NmeHisZ+LlaHisGS ✓ * 
LlaHisZGFusion(Short) ✓ ✗ 
LlaHisZGFusion(Long) ✓ ✗ 
LlaHisGS-CjeACT ✓ ✗ 
Key: ✓ indicates definite growth, ✗ indicates no growth, and * indicates marginal 





Figure 4.15 Examples of E. coli EW25113ΔhisG knockout complementation plates showing growth (✓) 
(positive control and EcoHisGL), no growth (✗) (negative control) and marginal growth (*) (EcoHisGcore, 
NmeHisGS, and LlaHisGS). 
 
Transformed and untransformed (control) E. coli 
BW25113ΔhisG::kan cells were plated on M9 minimal medium 
supplemented with the appropriate antibiotics and either IPTG 
(0.1 mM), to induce protein expression, or histidine (13 µM) (Table 4.1) 
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(Figure 4.15). **  Plasmids encoding wild type EcoHisGL, CjeHisGL, 
MtuHisGL, LlaHisZGS, and NmeHisZGS supported growth on histidine 
deficient media, whilst LmeHisZGFusion was unable to rescue the strain. 
This observation, combined with the absence of observed catalytic 
activity of the purified LmeHisZGFusion, suggests that the 
LmehisZGFusionpET-28a construct does not express a functional 
ATP-PRTase. Growth of the cell line was supported by EcoHisGcore but 
not by CjeHisGcore, which is expressed as a GST-tagged construct. 
Interestingly, NmeHisGS and LlaHisGS both appeared to rescue the 
strain, albeit poorly, in the absence of their respective HisZ partners. 
This observation contradicts both the previously reported 
complementation studies, and the absence of ATP-PRTase activity 
detected in vitro.5 Mix and match of HisZ and HisGS from 
N. meningitidis and L. lactis rescued the strain, however neither the 
LlaHisZGFusion proteins nor the LlaHisGS-CjeACT chimera were able to 





 Allostery can arise from the structural modification of a protein 
via the reshaping or repurposing of existing domains, formation of 
multimeric assemblies, or domain recruitment.86 A combination of all 
three mechanisms likely gave rise to the contemporary ATP-PRTases. 
The work described in this chapter aimed to characterise a third 
putative ATP-PRTase architecture and to facilitate the acquisition of 
allostery by mimicking domain fusion events.  
 
                                            
** See Appendix II for figures. 
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The bacteria from which the 35 putative HisZGFusion sequences 
originate are typically associated with the human gut and 
fermentation. Despite colonising a nutrient rich environment, each of 
these organisms encodes the complete histidine biosynthetic pathway. 
Comparative genomics studies on lactic acid producing bacteria, 
including L. mesenteroides and L. lactis, noted a reduction of the 
genome, presumably in response to occupation of a nutrient rich 
ecological niche. It should be noted that L. lactis, has retained a 
functional, metabolically essential ATP-PRTase.5,26,39,98 Few bacterial 
species have been shown to exhibit complete or partial deletion of the 
his operon, which is testament to the essentiality of this pathway.10 
Some bacteria devoid of the genes responsible for histidine 
biosynthesis, such as Mycobacterium genitalium and Helicobacter 
pylori, are able to colonise and persist in a host organism.99-102 Juliao et 
al. observed that strains of Haemophilus influenzae that persist in the 
throat are auxotrophic for histidine, whilst those that colonise the 
nutrient deficient environment of the middle ear express a functional 
histidine biosynthetic pathway.103 Although these organisms are niche 
limited, the energy conservation afforded by histidine auxotrophs may 
be selectively advantageous. To date there have been no bacteria 
reported that are both auxotrophic for histidine and encode the 
complete histidine biosynthetic pathway, however the proportion of 
bacteria that have been studied with respect to histidine biosynthesis 
is limited compared to the number of bacterial species that exist.  
 
Several enzymes involved in histidine metabolism consist of 
multiple domains or multiple subunits, although not all of the 
apparent gene fusion events have resulted in catalytically competent 
enzymes.2,104 Ino et al. observed that in some strains of 
S. typhimurium, hisGL and hisD comprise a single open reading frame 
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that translates to a putative bifunctional enzyme.104 Expression and 
purification of the gene product revealed a protein that displayed 
neither ATP-PRTase (hisGL) nor histidinol dehydrogenase (hisD) 
activity. Ino et al. subsequently proposed that the fusion protein is 
cleaved by endopeptidase activity in vivo. Bifunctional enzymes 
typically catalyse sequential reactions, whilst HisGL and HisD 
represent the first and last steps of the pathway respectively.2,105,106 
The functional integrity of the HisGL-HisD fusion protein is less 
conceivable than that of the HisZGFusion, as the structure of the 
hexameric HisGL differs significantly from the dimeric HisD. HisGL and 
HisD both function independently and association of the two enzymes 
has not been reported. In contrast, HisZ and HisGS are known to 
assemble non-covalently, it a 1:1 ratio, to form a functional 
ATP-PRTase.39 
 
 The observation that LmeHisZGFusion is devoid of ATP-PRTase 
activity, both in vitro and by complementation in vivo is perplexing. 
Sequence alignments revealed that the putative fusion protein 
possesses the known sequence motifs characteristic of the short form 
ATP-PRTase family. LmeHisZGFusion shares 39 % sequence identity 
with LlaHisGS and 22 % sequence identity with LlaHisZ, values that 
are comparable to the identities across the functional short form ATP-
PRTase family. The genome of L. mesenteroides encodes the entire 
cohort of histidine biosynthetic enzymes, however biochemical 
characterisation of this pathway has not been reported. Jin et al. noted 
that addition of histidine to the growth media of L. mesenteroides is not 
essential for proliferation, but appears to enhance the growth rate.107 
Taken together, these observations suggest that L. mesenteroides may 
procure histidine from a nutrient rich environment, however the 
histidine biosynthetic pathway is expected to be functional to support 
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survival of the bacteria in the absence of an exogenous source of 
histidine.   
 
Further investigation is required to understand why the 
LmehisZGFusionpET-28a construct does not appear to express a 
functional ATP-PRTase. Precipitation of the protein following storage 
precluded the analysis of the secondary structure; therefore the 
absence of catalytic activity cannot be definitively attributed to 
inactivity of the HisZGFusion molecular architecture. The elution volume 
from the preparative SEC is consistent with a tetrameric quaternary 
structure, however it is unclear whether the protein was correctly 
folded. Optimisation of the buffer composition may prevent 
precipitation of the protein. Circular dichroism and analytical SEC 
may subsequently be employed to characterise the secondary and 
quaternary structures respectively. There is some evidence to suggest 
that the addition of a (His)6-tag could lead to improper folding and 
diminished catalytic activity of an enzyme.108 E. coli complementation 
studies with a tagless LmehisZGFusion construct may also be used to 
probe the potential impact of the (His)6-tag on catalysis, without being 
confounded by assay conditions. Additionally LmehisZGFusion knockout 
studies may be employed to assess the essentiality of this gene product 
to the survival of the strain. Future work could also assess whether 
fission of LmeHisZGFusion into its constituent HisZ and HisGS subunits 
leads to a functional non-covalent complex, resembling the short form 
ATP-PRTases.   
 
Neither of the engineered LlaHisZGFusion proteins exhibited 
catalytic activity. The choice of fusion site was relatively ambiguous 
due to the low sequence identity between the linker regions of the 
native HisZGFusion proteins and the absence of the five C-terminal 
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LlaHisZ residues from the LlaHisZGS crystal structure. As with 
LmeHisZGFusion it is unclear whether the loss of ATP-PRTase activity is 
the result of improper folding. The wild type LlaHisZ is involved in the 
activation of LlaHisGS via assembly into a hetero-octameric complex, 
although the mechanism for this activation is yet to be deduced. It is 
possible that installation of a covalent linker affected the relative 
domain orientation, the formation of crucial contacts, or the protein 
dynamics that facilitate catalysis. Future work should focus on 
understanding the function of the wild type LlaHisZGS and 
LmeHisZGFusion, which may subsequently inform the construction of a 
chimeric protein.  
 
Previous research has shown that the simple transfer of an ACT 
domain from one enzyme is sufficient to confer functional allostery to 
an unregulated ortholog.96 It is crucial to note that in this instance the 
regulated and unregulated enzymes are catalytically active, adopt 
similar structures, and allostery was conferred by the transfer of a 
distinct domain that is responsible for a large conformational change. 
In contrast, sequence analysis suggests that all ATP-PRTase enzymes 
possess a regulatory element in the form of either an ACT domain or a 
HisZ subunit. The observation of diminished activity of a truncated 
HisGL that has lost the ACT domain, and marginal activity of HisGS in 
the absence of HisZ, suggests that these regulatory elements also 
promote catalysis. The ACT domain is largely responsible for the 
formation of the homo-hexameric quaternary structure of HisGL 
therefore the ACT domain transfer is required to not only confer 
functional allostery but alter the quaternary structure of the HisGS 
protein.3,4 Cross et al. also noted the importance of the choice of fusion 
site.96 One key difference between the available structures of HisGS 
and HisGL is that the β11-α6 linker is unresolved in all HisGL 
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structures, which implies flexibility of this region, whilst the 
equivalent linker in HisGS adopts helical character. Flexibility of this 
region may be required for functionality of the long form ATP-PRTase 
and future work could investigate whether inclusion of this flexible 
region in the engineered chimera could generate a functional ATP-
PRTase.  
 
Complementation of the E. coli BW25113ΔhisG strain with 
plasmids encoding wild type HisGL and HisZGS restored ATP-PRTase 
activity, facilitating growth on minimal media plates supplemented 
with IPTG. The observation that the MtuhisGLpET-24a construct 
rescues the strain is of particular importance as this construct is yet to 
yield catalytically active protein in vitro (Gerd Mittelstädt personal 
communication). This observation suggests that in vivo 
complementation may be used to detect enzymes whose apparent 
inactivity is the result of purification or assay conditions. The lack of 
catalytic activity, both in vivo and in vitro, of the native and 
engineered fusion proteins discussed in this chapter suggests that the 
gene products are completely devoid of ATP-PRTase activity.  
 
Interestingly, NmeHisGS and LlaHisGS both appeared to rescue 
the strain, albeit poorly, in the absence of their respective HisZ 
partners. The untransformed strain failed to proliferate without an 
external source of histidine and the experiments were repeated in 
triplicate, which suggests that the observed growth is not an artefact. 
Sissler et al. reported that an E. coli knockout strain required 
complementation of both LlahisZ and LlahisGS in order to grow on 
histidine deficient media.5 They also observed low expression levels of 
LlaHisGS. One explanation for this discrepancy is that LlaHisGS may 
exhibit marginal catalytic activity in the absence of LlaHisZ and that 
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the increased expression level of the LlahisGSpET-21a construct 
utilised in this experiment was sufficient to rescue the strain. 
Alternatively, HisGS may form an assembly with another protein in 
the cell that fulfils the role of HisZ.   
 
The observed activity of the HisGcore proteins gives credence to 
the hypothesis of a marginally active HisGS. The HisGcore enzymes from 
C. jejuni and E. coli, discussed in chapter three, are truncated forms of 
HisGL that are missing the ACT domain and show diminished ATP-
PRTase activity. CjeHisGcore is homo-dimeric (Gerd Mittelstädt 
personal communication) as is HisGS in the absence of HisZ.39 
Complementation of BW25113ΔhisG cells with EcohisGcorepDEST-17 is 
sufficient to restore ATP-PRTase activity, however CjehisGcorepDEST-
15 was unable to rescue the strain. CjeHisGcore expresses as a fusion 
protein with an N-terminal GST-tag. The inability to complement the 
strain is likely the result of dimerisation of GST, which is a similar size 
to CjeHisGcore, impeding catalysis.  
 
Molecular mix and match between HisZ and HisGS of L. lactis 
and N. meningitidis also appeared to restore ATP-PRTase activity to 
the cell. It is unclear if this is due to the formation of a mixed species 
HisZGS complex or if it is a reflection of HisGS activity in the absence of 
HisZ. Catalytic activity was not observed with a standard kinetic assay 
following the in vitro incubation of LlaHisZ with NmeHisGS, however 
the in vitro combination of NmeHisZ and NmeHisGS also failed to form 
a functional ATP-PRTase (as described in chapter three). Co-
purification of NmeHisZ with LlaHisGS, and vice versa, may be 
employed to determine whether HisZ and HisGS from two genetically 




5  Summary of Thesis and Future 
Work 
 
 This project aimed to further the current understanding of the 
allosteric regulation of ATP-PRTase, and to explore the functional and 
evolutionary relationship between the two molecular architectures of 
this enzyme.   
 
5.1 LlaHisZGS Undergoes a Conformational Change 
in Response to Histidine Binding 
 
 Elucidation of the solution conformation of LlaHisZGS, in the 
presence and absence of histidine, strongly suggested a potential 
mechanism of allosteric regulation involving a conformational change. 
In the absence of ligands, the SAXS envelope is consistent with the 
theoretical scattering calculated from the X-ray crystal structures of 
LlaHisZGS (PDB 1Z7M & 1Z7N), while the arrangement adopted by 
the histidine inhibited enzyme bears little resemblance to any 
available ATP-PRTase structure. Ab initio and rigid body modelling 
revealed elongation of the enzyme in the presence of histidine. 
However a more rigorous approach is required to glean further insight 
into the domain movements associated with this rearrangement. 
 
Histidine binding to LlaHisZ, in the presence and absence of 
LlaHisGS, was demonstrated by ITC. This observation supports the 
allosteric binding site proposed by Champagne et al.,20 over the 
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interface sites proposed by comparison with the TmaHisZGS structure. 
Induced fit docking revealed three additional candidates for the 
histidine binding residues (Tyr271, Asp84, Gln126). Generation of 
point mutants, targeting each of the proposed histidine binding 
residues, coupled with ITC or saturation transfer difference NMR and 
kinetics, is required to confirm the functional histidine binding 
residues. 
 
5.2 Progress Has Been Made Towards the 
Purification and Characterisation of NmeHisZGS 
and EcoHisGL 
 
Purification of NmeHisZGS and EcoHisGL proved difficult due to 
the propensity of each enzyme to adopt higher order multimeric states, 
as evidenced by both analytical SEC and SAXS. Although Numerous 
purification conditions for EcoHisGL were tested, no evidence of a 
hexameric, tetrameric, or dimeric species was observed. Extensive 
effort towards the optimisation of the NmeHisZGS purification 
produced a low yield of hetero-octameric NmeHisZGS, but this species 
could not be reliably separated and may be in equilibrium with a 
higher order species. The tendency of each enzyme to adopt a 
non-biological assembly precluded the biochemical characterisation of 








5.3 L. mesenteroides Encodes a Putative Covalently 
Linked Short Form ATP-PRTase  
 
 A search of the Pfam database87 revealed 35 sequences in which 
HisZ and HisGS comprise a single open reading frame, encoding a 
putative HisZGFusion ATP-PRTase. The bacteria that encode this third 
putative ATP-PRTase architecture possess complete his operons and 
are therefore expected to be prototrophic for histidine. The HisZGFusion 
protein from L. mesenteroides was cloned, expressed, and purified but 
no ATP-PRTase activity was detected using the standard enzyme 
kinetics assay or by in vivo complementation studies.  
 
5.4 Domain Fission Results in an Enzyme with 
Diminished Activity and Domain Fusion is 
Insufficient to Confer Functionality 
 
 It is clear from the E. coli BW25113ΔhisG complementation 
studies of EcoHisGcore, as well as the biochemical characterisation of 
CjeHisGcore (Gerd Mittelstädt, personal communication), that 
truncation of HisGL, to remove the ACT domain, results in a 
catalytically competent ATP-PRTase. This result is surprising in light 
of previous research suggesting that HisGS requires HisZ to 
reconstitute a functional ATP-PRTase. Catalytic activity of NmeHisGS 
and LlaHisGS was not detected in vitro, however the observation that 
both HisGS constructs complement the E. coli BW25113ΔhisG strain, 
albeit poorly, warrants further investigation.  
 
Engineering two covalent linkers between LlaHisZ and 
LlaHisGS, as well as transfer of the ACT domain from CjeHisGL to 
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LlahisGS, was not sufficient to form a functional ATP-PRTase. 
Previous research has shown that such domain transfer events can 
mimic the evolutionary gene fusion events, however the choice of 
fusion site is crucial for functionality.96 Further investigation into the 
structure and function of the wild-type ATP-PRTase enzymes is 
required to inform the construction of functional chimeric enzymes. 
 
5.5 Future Work 
 
Allostery plays an essential role in metabolism and presents a 
promising target for drug design. Understanding allostery at the 
molecular level could shed light on cellular function and may lead to 
new therapeutics to combat a range of diseases. This project has 
opened several avenues for further investigation. The first is the 
maturing model of the allosteric inhibition of LlaHisZGS. Secondly, 
there is scope for the development of potent inhibitors of NmeHisZGS 
that may lead to novel antibiotics to combat bacterial meningitis. 
Finally, the evolutionary origin of the ATP-PRTases and the functional 
relationship between the two families warrants further exploration.  
 
The model of the allosteric regulation of LlaHisZGS described in 
this thesis was developed by comparison of SAXS profiles of LlaHisZGS 
in the presence and absence of histidine. SAXS may be employed to 
characterise the conformational response to substrate binding, as well 
as the synergistic inhibition of AMP and histidine. The 
complementarity of SAXS and small angle neutron scattering (SANS) 
may also be exploited to develop a more rigorous model of the 
conformational change in solution, utilising contrast variation with a 
deuterated LlaHisZ or LlaHisGS. As with SAXS, there are several 
methods to reconstruct protein molecular architectures from SANS 
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profiles, using either ab initio methods or crystallographic data.74,109,110 
Optimisation of the crystal conditions to obtain a structure of the 
inhibited LlaHisZGS should also be pursued in order to gain high-
resolution insight into the histidine-induced structural rearrangement. 
This may inform the design of mutagenesis experiments to probe the 
allosteric signal transduction pathway. Molecular dynamics 
simulations could also be employed to model the transition from the 
active to inhibited state and to understand the role of dynamics in the 
allosteric regulation.  
 
NmeHisZGS is of particular interest as a potential target for 
antibiotic drug design. Linus Pauling proposed that an enzyme binds 
tightest to its transition state, therefore transition state analogues are 
expected to be potent enzyme inhibitors.111,112 Pioneering work by Vern 
Schramm et al. has led to the determination of transition state 
structures and the subsequent development of tight binding inhibitors 
for several PRTases.42,113-115 This technique has recently been employed 
to investigate the transition state of CjeHisGL and may be applied to 
NmeHisZGS in the future. In addition, the allosteric sites may also be 
exploited for the purposes of antibiotic design. 
 
In addition, there is scope for rigorous bioinformatics analysis to 
probe the evolutionary relationships among the ATP-PRTases, 








6 Experimental Methods 
 
6.1 General Methods 
 
6.1.1 Protein Structure Figures 
 
All protein structure figures were created using the PyMOL 
Molecular Graphics System, Version 1.7.4 Schrödinger, LLC.  
 
6.1.2 Amino Acid Sequence Alignments 
 
Amino acid sequence alignments were generated using the 
Clustal Omega server (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Alignment figures 4.2 and 4.3 were constructed using ESPript 3.0 
server (http://espript.ibcp.fr).95 Structure based sequence alignments 
were generated using ENDscript 2.0 (http://endscript.ibcp.fr).95 
  
6.1.3 Purified Water 
 
MilliQ water (referred to as MilliQ), which has been purified 
with a Millipore MilliQ water system, was used in all experimental 






6.1.4 pH Determination 
 
 
 The pH of all buffer solutions was determined at room 
temperature using the Denver UB-10 Ultrabasic pH meter. The pH 
was adjusted by the addition of either NaOH (1 M or 10 M) or HCl (1 M 
or 10 M).  
 
6.1.5 Antibiotic Stocks 
 
 Ampicillin (100 mg/mL), kanamycin (50 mg/mL) and 
spectinamycin (10 mg/mL) stock solutions were prepared in MilliQ 
while chloramphenicol (30 mg/mL) stocks were made up in analytical 
reagent ethanol. All stocks were filter sterilised and stored in 




Super optimal broth with catabolite repression (SOC) media 
(2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2 and 20 mM glucose) was prepared by the addition 
of all components, with the exception of MgCl2 and glucose, to MilliQ 
water, which was subsequently autoclaved at 121 °C, 15 psi for 20 
minutes. The media was separated into 500 µL aliquots in sterile 
microcentrifuge tubes. Filter sterilised glucose and MgCl2 was added 
prior to use. 
 
Cell cultures were grown in Lysogeny Broth (LB) media (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl). LB media was prepared in 
MilliQ and autoclaved at 121 °C, 15 psi for 20 minutes prior to use. 
LB agar plates were made by the addition of agar (25 g/L) to LB (100 
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mL) before sterilisation. Alternatively, LB agar premix (Invitrogen) 
was used. The LB agar was incubated at 60 °C and appropriate 
antibiotics were added immediately before pouring.  
 
6.1.7 Chemically Competent Cells 
 
 Chemically competent cells, with the exception of the 
commercial E. coli StellarTM chemically competent cells (Clontech), 
were prepared using the following procedure. 100 mL of sterile LB was 
inoculated with 5 mL of an overnight preculture of E. coli BL21*(DE3), 
Chaperone 3, TOP 10, or BW25113ΔhisG cells. The LB media was 
supplemented with spectinomycin and chloramphenicol for the growth 
of Chaperone 3 cells and kanamycin for BW25113ΔhisG cell growth. 
The cultures were incubated at 37 °C with shaking (180 rpm) until an 
optical density of 0.4, at which point they were harvested and the 
pellets resuspended in 25 mL of a sterile solution of CaCl2 (25 mM). 
The cells were incubated on ice for 30 minutes, harvested, then 
resuspended in 2.5 mL of the CaCl2 solution and incubated on ice for 
two to four hours before the addition of 15 % (v/v) glycerol. The cells 
were separated into 50 µL aliquots and snap frozen with liquid 
nitrogen prior to storage at -80 °C. All tubes, pipette tips, media, and 




Chemically competent cells (50 µL aliquots) were thawed on ice 
prior to the addition of purified plasmid (2 µL), In-Fusion reaction 
mixture (5 µL), or LR reaction mixture (2 µL). The cells were incubated 
on ice for a further 30 minutes then subjected to a 30-45 second heat 
shock at 42 °C. The cells were incubated on ice for a further 2 minutes 
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prior to the addition of 250 µL of SOC medium and incubated at 37 °C 
for one hour with shaking (180 rpm). 50-200 µL of the culture was 
plated on LB agar supplemented with the appropriate antibiotics and 
incubated at 37 °C over night.  
 
6.1.9 Polymerase Chain Reaction 
 
 PCR reactions, with the exception of colony PCR, were 
performed using the standard procedure for Phusion® High Fidelity 
DNA Polymerase (Thermo Scientific). PCR reaction mixtures (50 µL) 
consisted of 1× HF buffer, 200 µM deoxyribonucleotide triphosphates 
(dNTPs), forward and reverse primers (0.5 µM), Template DNA (50-250 
ng gDNA or 1 pg-10 ng plasmid), and 10 µL of Phusion® High Fidelity 
DNA Polymerase. Each reaction employed either a two-step or three-
step thermocycling protocol.  
 
 Colony PCR was performed using Taq DNA polymerase (New 
England Biolabs). PCR reaction mixtures (50 µL) consisted of 1× 
reaction buffer, 200 µL dNTPs, 0.5 µM gene specific forward primer, 
0.5 µM reverse sequencing primer, and a toothpick scraping of a 
colony. The thermocycling protocol consisted of 94 °C for 5 mins 
followed by cooling to 80 °C at which point the method was paused and 
0.2 µL Taq DNA polymerase was added. The method was subsequently 
resumed. 35 cycles of 94 °C for 45 seconds, 45 °C for 30 seconds, and 72 
°C for 90 seconds preceded a 10 minute extension at 72 °C.  
 
6.1.10  Agarose Gel Electrophoresis 
 
Agarose gels were prepared using a 1% (w/v) solution of LE 
agarose (Seakem) in Tris-acetic acid-EDTA buffer (TAE) (40 mM Tris, 
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20 mM glacial acetic acid, 2 mM EDTA) heated to 60 °C prior to the 
addition of SYBR® Safe DNA Gel Stain (Invitrogen). Samples were 
mixed with 6× loading buffer (60 mM Tris-HCl, 60 mM EDTA, 0.02 % 
(w/v) Orange G, 0.05 % (w/v) xylene cyanol FF, 60 % glycerol). Gels 
were run in 1× TAE buffer using a Mini-sub® Cell GT (Bio-Rad) at 85 V 
for 45 minutes. A Molecular Imager® Gel DocTM XR was used to 
capture images under UV (302 nm). Alternatively, DNA samples were 
separated on an E-Gel® 1.2 % precast agarose gel (Invitrogen) and run 
for 27 minutes using the E-Gel® iBaseTM Power System.  
 
DNA fragments were purified using a self cast agarose gel, 
prepared as above, run in 1× TAE buffer using a Mini-sub® Cell GT 
(Bio-Rad) at 85 V until the dye front migrated sufficiently to separate 
the bands (typically 20 minutes). Images were not captured in order to 
minimise exposure of the samples to DNA damaging UV. The gels were 
visualised with either the Molecular Imager® Gel DocTM XR at 302 nm 
or the E-Gel® Safe ImagerTM Transilluminator at 480 nm. The 
appropriate bands were excised and the DNA was purified using the 
Nucleospin® Gel and PCR Clean-up kit (Clontech). Alternatively, DNA 
fragments were purified with an E-Gel® CloneWellTM 0.8 % precast 
agarose gel (Invitrogen) using the E-Gel® iBaseTM Power System. The 
gel was visualised using the E-Gel® Safe ImagerTM Transilluminator at 
480 nm and a pipette was used to extract DNA when it reached the 
well. 
  
6.1.11  Restriction Enzyme Digest 
 
 Vectors were linearised by digestion with high fidelity 
restriction enzymes (New England Biolabs). 1 µg of plasmid DNA was 
combined with 10 × Cutsmart® Buffer, 1 µL of each restriction enzyme, 
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and MilliQ for a total volume of 50 µL. The restriction enzyme digest 
mixture was incubated at 37 °C for at least one hour followed by 80 °C 
for 20 minutes to denature the restriction enzymes. The digested vector 
was gel purified prior to use.   
6.1.12  In-Fusion® Reaction 
 
 The procedure for the In-Fusion® reaction was adapted from the 
standard protocol in order to utilise half the recommended volume of 
the In-Fusion® HD enzyme premix (Clontech). 1 µL of 5× In-Fusion® 
HD enzyme premix was combined with the purified PCR product (5-
100 ng), purified linearised vector (20-100 ng), and sterile MilliQ for a 
total volume of 5 µL. The reaction mixture was incubated at 50 °C for 
15 minutes and stored on ice prior to transformation into either E. coli 
TOP 10 chemically competent cells or E. coli StellarTM chemically 
competent cells (Clontech). Colonies were screened via colony PCR and 
positive colonies were grown in 5 mL LB cultures, plasmid prepped, 
and sequence verified.  
 
6.1.13   Plasmid Extraction and Purification 
 
 A 5 mL LB preculture, supplemented with the appropriate 
antibiotics, was inoculated with a single colony of E. coli TOP 10 or 
StellarTM chemically competent cells (Clontech) cells that had been 
transformed with the desired plasmid, and incubated at 37 °C with 
shaking (180 rpm) overnight. The cells were harvested and the 
plasmids extracted using the High Pure Plasmid Isolation Kit (Roche), 
the ChargeSwitch®-Pro Plasmid Miniprep Kit (Invitrogen) or the 
Nucleospin® Plasmid Easy Pure kit (Clontech).  The concentration of 
purified plasmid was determined by measuring the absorption at 260 
nm with a Nanodrop-1000 spectrophotometer.  
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6.1.14  DNA Sequencing 
 
 Either Canterbury Sequencing and Genotyping or the Massey 
Genome service provided DNA sequencing services. Approximately 250 
ng of plasmid and 3.2 µM sequencing primers were supplied for the 
sequencing reactions.   
 
















6.1.15  Glycerol Stocks 
 
 Glycerol stocks were prepared by combining a sample of an 
overnight preculture with 20 % (v/v) glycerol (sterile) in a sterile 
1.5 mL microcentrifuge tube. The stocks were snap frozen in liquid 
nitrogen prior to storage at -80 °C.  
 
6.1.16  E. coli Culture Growth 
 
 For the preparation of an overnight preculture 50 mL LB media, 
supplemented with the appropriate antibiotics, was inoculated with a 
scraping from a glycerol stock and incubated at 37 °C with 180 rpm 
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shaking overnight. The 50 mL preculture was used to inoculate 1 L LB 
media supplemented with antibiotics. Cultures were grown in baffled 
flasks at 37 °C with 180 rpm shaking until mid-logarithmic growth 
phase (OD 0.4-0.8). The pDEST, pET, and pRSFDuet plasmids are 
under control of the lac promotor and are therefore induced by lactose. 
To induce protein expression IPTG, a synthetic analogue of lactose that 
is not metabolised by the cell, was added to a final concentration of 0.5. 
Note that 0.1 mM IPTG was used for EcoHisGL cultures as induction 
with higher IPTG concentrations resulted in insoluble protein. 
Following induction cultures, with the exception of EcoHisGL, were 
incubated at 23 °C with 180 rpm shaking overnight. EcoHisGL cultures 
were incubated at 37 °C following induction and harvested after four 
hours. Cells were harvested by centrifugation at 12,000 g for 15 
minutes and the pellets were stored at -80 °C. 
 
6.1.17  Cell Lysis 
 
Cells were lysed by sonication using an Omni-Ruptor 4000 
Ultrasonic Homogenizer. Cell pellets were resuspended in 20-40 mL of 
lysis buffer and sonicated on ice with 4-6 repetitions of 5 minutes at 
80% power and 40 % pulsar. Cell debris was removed by centrifugation 
at 24,000 g or 40,000 g and 4 °C for 30 minutes. The supernatant was 
incubated with 2 µL Benzonase® Nuclease (Sigma Aldrich) for 5 
minutes before the first chromatography step.   
 
6.1.18  Fast Protein Liquid Chromatography 
 
 An ÄKTApurifierTM (GE Healthcare) or a Bio-Rad Biologic 
Protein Chromatography system at 4 °C was employed to purify the 
proteins used in this project. All buffers and solvents were filtered 
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using a 0.2 µm filter (Millipore). Protein samples were also filtered 
prior to loading onto a 10 mL or 50 mL SuperloopTM (GE Healthcare). 
Proteins with an N-terminal (His)6-tag were purified by running a 5 
mL HisTrap or a 5 mL HiTrap Talon Column (GE Healthcare) with a 
gradient of 20 mM to 500 mM imidazole (HisTrap) or 5 mM to 250 mM 
imidazole (HiTrap Talon). 2 mL fractions were collected in a 96 well 
plate. Fractions that displayed absorbance at 280 nm were analysed by 
SDS-PAGE. Fractions corresponding to the correct protein were buffer 
exchanged and loaded onto a Superdex S200 26/60 (GE Healthcare) 
column for size exclusion chromatography.  
 
6.1.19  Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
 
 SDS-PAGE was performed using a Bolt® 10 % Bis-Tris Plus 
precast protein gel (Invitrogen) run in a Mini Gel Tank (Invitrogen). 
Samples were boiled before application to the gel. Novex® Sharp 
prestained protein standards (Invitrogen) were used as a molecular 
weight marker. Gels were run in either MES (HisZGS or HisGL) or 
MOPS buffer (HisZGFusion). Gels were run at 165 V for either 35 
minutes (MES) or 45 minutes (MOPS) and stained with a solution of 
Coomassie Brilliant Blue R250 in 50 % (v/v) methanol, 10 % (v/v) acetic 
acid for approximately 15 minutes. Gels were then destained by the 
addition of 40 % (v/v) methanol and 10 % (v/v) acetic acid for 30 
minutes. 
 
6.1.20  Concentration and Buffer Exchange of Protein 
 
 Proteins were concentrated before and after SEC using a 
VivaspinTM 20 mL, 2 mL or VivaspinTM Turbo 15 mL 10 kDa molecular 
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weight cut off centrifugal concentrator (Sartorius Stedim Biotech). All 
concentrators were washed with 2-3 volumes of MilliQ before use. 
Proteins were buffer exchanged by alternating concentration followed 
by dilution with the desired buffer.   
 
6.1.21  Determination of Protein Concentration 
 To determine the concentration of a purified protein a 2 µL 
protein sample was applied to the Nanodrop-1000 spectrophotometer 
and the absorbance at 280 nm was detected. The extinction coefficient 
was determined from the amino acid sequence using the ExPASy 
ProtParam tool (http://web.expasy.org/protparam/). 
 
6.1.22  Protein Storage 
 
 Following purification, proteins were separated into aliquots of 
50 µL, 100 µL, or 200 µL, snap frozen in liquid nitrogen and stored 
at -80 °C.  
 
6.1.23  Enzyme Kinetics Assay 
 
 ATP-PRTase activity was monitored using a standard enzyme 
assay.24 The formation of PR-ATP was monitored at 290 nm (ε= 
3600 M-1 cm-1) at 25 °C using a Varian Cary 100 UV Visible 
Spectrophotometer. Measurements were made in triplicate using a 
quartz cuvette with a 1 cm pathlength. Stock substrate solutions 
contained 250 mM ATP + 250 mM MgCl2 and 10 mM PRPP + 10 mM 
MgCl2. The standard assay buffer consisted of 100 mM Tris-HCl pH 8.5 
with 150 mM NaCl, 10 mM MgCl2, and 200 µM tris (2-carboxyethyl) 
phosphine (TCEP) and was made with Chelex-treated MilliQ. An 
inorganic pyrophosphatase (PPase) from E. coli was added in excess 
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(0.026 mg/mL) to ensure the reaction went to completion. Assay buffer, 
ATP, ATP-PRTase and PPase were incubated at 25 °C before the 
reaction was initiated by the addition of PRPP. Initial rates were 
determined by least squares fitting across the initial rate data. KM and 
kcat values were determined by fitting initial rates to the Michaelis-
Menten equation using the Grafit software (Erithacus).  
 
6.1.24  Determination of Substrate Concentration 
 
 The enzyme kinetics assay was used to determine the 
concentration of PRPP and ATP stock solutions. For example, the 
concentration of PRPP was determined, in duplicate, by incubating an 
assay mixture with a saturating concentration of ATP at 25 °C and the 
reaction was initiated with PRPP of unknown concentration. The 
reaction was allowed to go to completion and the ΔA290nm was 
determined. The Beer-Lambert Law was then applied with ε= 3600 M-1 
cm-1 and path length 1 cm to determine the concentration of PR-ATP 
formed (and therefore the concentration of PRPP, the limiting reagent, 
in the cuvette). The concentration of the PRPP stock was then 
determined.  
 
6.2 Chapter Two Methods 
6.2.1  PCR Amplification and Cloning of LlahisGS and LlahisZ 
 
 LlahisGS was amplified from the LlahisGSpBSK vector 
purchased from Epoch Life Science. Primers were designed to 
incorporate the 15 base pair overlap for cloning into pET-21a digested 
with NdeI and XhoI using the InFusion enzyme. A three-step 
thermocycling protocol was employed with a 60 °C annealing 
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temperature and an extension time of 30 seconds. The pET-21a vector 






LlahisZ was amplified from the LlahisZpBSK vector purchased 
from Epoch Life Science. Primers were designed to incorporate the 15 
base pair overlap for cloning into pET-28a digested with NdeI and 
EcoRI using the InFusion system. A three-step thermocycling protocol 
was employed with a 65 °C annealing temperature and an extension 
time of 60 seconds. The pET-28a vector was digested with NdeI-HF 






 LlahisZ was also cloned into multiple cloning site I of the 
pRSFDuet-1 vector for use in the E. coli BW25113ΔhisG 
complementation studies. The LlahisZpBSK vector was used as a 
template for amplification with InFusion primers using a three-step 
thermocycling protocol with 60 °C annealing and a 30 second extension 
time. The pRSFDuet-1 vector was digested with BamHI-HF and 
HindIII-HF (New England Biolabs).  
 
Primers used to subclone LlahisZ into pRSFDuet-1: 




 LlahisGS was also amplified from the LlahisGSpBSK vector 
using primers designed to partially install the TEV protease cleavage 
sequence at the 5’ end of the PCR product (reaction 1). The purified 
PCR product was used as a template for installation of the remainder 
of the TEV cleavage site as well as the recognition sequence for the 
InFusion reaction.  A three-step thermocycling protocol with 60 °C 
annealing was used for both amplifications. The pET-28a vector was 
digested with EcoRI-HF and NdeI-HF (New England Biolabs).  
 
Primers used to amplify LlahisGS for cloning into pET-28a: 
Reaction 1 






6.2.2 Purification of LlaHisZGS 
 
 The LlaHisZGS complex was purified by combining the cell 
pellets from 500 mL cultures (1 L cultures were harvested in two 500 
mL batches and stored as separate pellets) of LlahisZpET-28a in 
BL21*(DE3) and LlahisGSpET-21a in Chaperone 3 cells. The combined 
pellets were resuspended in 20 mL lysis buffer (50 mM potassium 
phosphate, pH 7.5, 300 mM NaCl, 5 mM MgCl2, 200 µM TCEP, 20 mM 
imidazole) and lysed by sonication. The supernatant was applied to a 5 
mL HisTrap IMAC column (GE Healthcare). The (His)6-tagged 
LlaHisZGS eluted as a single peak with an imidazole gradient of 20 
mM to 500 mM over ten column volumes. The fractions containing 
LlaHisZGS were pooled and buffer exchanged into SEC buffer (50 mM 
potassium phosphate, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 200 µM 
TCEP) and loaded onto the SEC column. The purified protein was 
concentrated to 5-10 mg/mL and either stored at -80 °C or used for 
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crystal screens. The same methodology was employed for the 
purification of LlaHisZ, with the omission of LlaHisGS. This protocol 
was also employed to purify (His)6-tagged LlaHisGS in the absence of 
LlaHisZ however the protein precipitated during the first 
chromatography step.  
 
6.2.3 Determination of the Quaternary Structure of LlaHisZGS 
and LlaHisZ by Analytical SEC 
 
 Analytical SEC, using a Superdex 200 10/300 GL column (GE 
Healthcare), was employed to determine the multimeric states of 
LlaHisZGS and LlaHisZ. Samples (500 µL) and protein standards 
(Sigma Aldrich and GE Healthcare) were eluted in LlaHisZGS SEC 
buffer.  
 
6.2.4 SAXS Data Collection 
 
 SAXS data was collected at the Australian Synchrotron 
SAXS/WAXS beamline equipped with a Pilatus detector. The 
wavelength of the X-rays was 1.0332 Å and the sample detector 
distance was 1600 mm. Scattering data was collected from LlaHisZGS 
(approximately 1 mg/mL) following elution from a Superdex 200 5/150 
SEC equilibrated with SEC buffer with or without the addition of 1 
mM histidine. 2D intensity plots from the SEC peak were radially 
averaged, normalised to sample transmission, and the background was 
subtracted. 
 
6.2.5 SAXS Data Processing 
 
Primary data reduction was performed using the scatterbrain 
software (Australian Sycnchrotron). Guinear fits were made using 
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Primus.68 All plots were checked for increasing intensity at low s, 
which is indicative of an aggregated sample. Indirect Fourier 
transformation was performed using GNOM to generate the P(r) 
function, which shows the relative probabilities of distances between 
scattering centres and Dmax. Crysol69 was used to generate the 
theoretical scattering curves from the atomic coordinates (PDB 1Z7N, 
1Z7M, and 1USY) compared to the experimental scattering curves. The 
fits were evaluated by comparing the χ2 values. 
 
6.2.6 Ab initio Modelling  
 
 Ab initio shaped determination of the histidine bound 
LlaHisZGS was performed by running GASBOR.72 The ATSAS server 
was used to perform 20 iterations of GASBOR with P1, P2, and P4 
symmetry imposed. The ab initio models were averaged using the 
Damaver program suite. Supcomb was employed to superimpose the X-
ray crystal structures onto the most probable models. Crysol69 was 
used to generate the theoretical scattering curves from the average 
models compared to the experimental scattering curve. The fits were 
evaluated by analysing the χ2 values. 
 
6.2.7 Rigid Body Modelling 
 
 Coral was used to construct models of histidine-bound 
LlaHisZGS.74 Individual PDB files of each of the eight chains in the 
LlaHisZGS crystal structure (PDB 1Z7N) were created and the LlaHisZ 
and LlaHisGS dimer interfaces were fixed. Models were generated with 
imposed P1, P2, and P4 symmetry. Crysol69 was used to generate the 
theoretical scattering curves from the rigid body models compared to 
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the experimental scattering curve. The fits were evaluated by 
analysing the χ2 values. 
 
6.2.8 Isothermal Titration Calorimetry 
 
 Histidine binding to LlaHisZ and LlaHisZGS was monitored by 
ITC. ITC experiments were performed using a VP-ITC 
microcalorimeter (MicroCal). Contamination of the MilliQ resulted in 
precipitation of the potassium phosphate buffers normally used in 
LlaHisZGS experiments. LlaHisZ and LlaHisZGS samples were 
therefore buffer exchanged into 50 mM Tris-HCl pH 7.5 with 150 mM 
NaCl, 5 mM MgCl2, and 200 µM TCEP. Histidine samples were 
prepared in the identical buffer. The samples of histidine and protein 
were degassed under vacuum for 15 minutes prior to use. The sample 
cell was filled with 1.46 mL of protein sample (50 µM LlaHisZGS or 47 
µM LlaHisZ) and the syringe was filled with 250 µL of histidine (2 mM 
for binding to LlaHisZGS and 0.8 mM for binding to LlaHisZ). To 
monitor histidine binding to LlaHisZGS 10 µL of ligand was injected 
into the sample cell every 600 seconds, and 5 µL injections every 300 
seconds were used to monitor histidine binding to LlaHisZ. The heat of 
dilution was determined by injecting the histidine sample into buffer 
and was subtracted from the experimental data.  All experiments were 
performed at 25 °C. KA and n values were determined by fitting the 
data to a one site model in Origin.  
 
6.2.9 Crystallisation Trials  
 
 Freshly purified LlaHisZGS was used in sitting drop vapour 
diffusion crystal trials with a Mosquito® LCP crystallisation robot. A 
range of commercial screens, including JCSG-plusTM HT-96, PACT 
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premierTM HT-96, and Clear StrategyTM Screens 1 & 2 HT-96 
(Molecular Dimension) were employed with protein concentrations of 5 
mg/mL, 8 mg/mL, and 10 mg/mL and 400 nL drop size. In addition 
crystal trials were performed using hanging drop vapour diffusion in a 
24 well format with the ProPlex (Molecular Dimensions) screen. 
Crystals were screened for diffraction at the MX1 beamline at the 
Australian Synchrotron. The best crystal conditions were optimised by 
systematically altering the concentrations of precipitant, protein, salt, 
and the addition of histidine or histidine and AMP. Optimisation of 
crystal conditions was performed using hanging drop vapour diffusion 
in a 24 well format with a drop size of 2 µL or 4 µL. The most 
promising crystals were obtained by hanging drop vapour diffusion 
with 4 µL drops, 4 mg/mL LlaHisZGS (concentration in the drop) and a 
well solution of 100 mM Tris-HCl pH 7.3-8, 1.5 mM sodium acetate, 
and 2-8 % (v/v) PEG 4000, 1 mM histidine. Diffraction of 4.6 Å to 10 Å 
was measured at the MX1 beamline at the Australian Synchrotron. 
 
6.2.10  Kinetic Characterisation 
 
 The standard enzyme kinetics assay, with a protein 
concentration of 3.2 µM, was employed to determine the KMPRPP and 
KMATP. The response to histidine inhibition was determined with a 
PRPP concentration of 50 µM and an ATP concentration of 10 mM.  
 
6.3 Chapter Three Methods 
6.3.1 PCR amplification of EcohisGL 
 
 EcohisGL was amplified from E. coli gDNA using two rounds of 
nested PCR. The first round amplified the EcohisGL gene from gDNA 
and incorporated part of the TEV cleavage site at the 5’ end. The 
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purified PCR product was used as a template for the second 
amplification, which installed the remainder of the TEV recognition 
site as well as the attB sites for cloning into pDONR221 using 
Gateway® Technology (Invitrogen). Both PCR reactions employed a 
three-step thermocycling protocol with a 55 °C annealing temperature 
and a 30 second extension time. 
 
Primers designed to amplify EcohisGL 
Reaction 1 







6.3.2 Gateway® cloning of EcohisGL 
 
 The purified EcohisGL PCR product was introduced into 
pDONR221 using the standard procedure for BP clonaseTM. The BP 
clonase reaction consisted of 100 ng of PCR product, 150 ng of 
pDONR221 and Tris-EDTA buffer (10 mM Tris-HCl, pH 8.0, 1 mM 
EDTA) and 2  µL BP clonaseTM enzyme mix, made up to a total volume 
of 10 µL. The reaction mixture was incubated at 25 °C for 60 minutes 
followed by the addition of 1 µg of Proteinase K, which was incubated 
at 37 °C for ten minutes to terminate the reaction.  
 
 EcohisGL was cloned into pDEST-17, with an N-terminal (His)6-
tag using the standard procedure for LR clonaseTM. The sequence 
verified EcohisGLpDONR221 construct (100 ng) was incubated with 
150 ng pDEST-17, and 2 µL LR clonaseTM in Tris-EDTA buffer (total 
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volume 10 µL). The reaction mixture was incubated at 25 °C for 60 
minutes followed by the addition of 1 µg of Proteinase K, which was 
incubated at 37 °C for ten minutes to terminate the reaction. 
 
6.3.3 Purification of EcoHisGL 
 
 The cell pellet from a 1 L culture of EcoHisGL in E. coli 
Chaperone 3 cells was resuspended in 20 mL lysis buffer (50 mM 
potassium phosphate pH 7.5, 50 mM NaCl, 5 mM MgCl2, 5 mM 
imidazole) and lysed by sonication. The supernatant was applied to a 5 
mL HiTrap Talon Crude IMAC column (GE Healthcare) and eluted 
with an imidazole gradient of 5 mM to 250 mM. The fractions 
containing EcoHisGL were pooled and buffer exchanged into SEC buffer 
(20 mM Tris-HCl pH 8.5, 50 mM NaCl, 5 mM MgCl2). The sample was 
diluted to approximately 1 mg/mL in SEC buffer and the N-terminal 
(His)6-tag was cleaved by the addition of TEV protease in a 10 : 1 
EcoHisGL : TEV (w/w) ratio. The TEV cleavage mixture was incubated 
at 37 °C for one hour followed by 4 °C for three days. SEC was used to 
purify the untagged EcoHisGL. The purified EcoHisGL was 
concentrated to 5-10 mg/mL and stored at -80 °C. To test for ATP-
PRTase activity 1-20 µL samples 5 mg/mL EcoHisGL were introduced 
into the standard enzyme kinetic assay with 10 mM ATP and 1 mM 
PRPP. 
 
6.3.4 Determination of the Quaternary Structure of EcoHisGL 
by Analytical SEC 
 
Analytical SEC, using a Superdex 200 10/300 GL column (GE 
Healthcare), was employed to determine the multimeric state of 
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EcoHisGL. Samples (1 mL) and protein standards (Sigma Aldrich and 
GE Healthcare) were eluted in EcoHisGL SEC buffer. 
 
6.3.5 SAXS Data Collection 
 
 SAXS data was collected at the Australian Synchrotron 
SAXS/WAXS beamline equipped with a Pilatus detector. The 
wavelength of the X-rays was 1.0332 Å and the sample detector 
distance was 1600 mm. Static solution sample detection was performed 
using a 96 well plate. Samples were prepared at concentrations of 0.3 
mg/mL, 0.75 mg/mL, 1.5 mg/mL, and 3 mg/mL in SEC buffer (20 mM 
Tris-HCl pH 8.5, 50 mM NaCl, 5 mM MgCl2, 500 µM TCEP) with or 
without the addition of histidine, AMP, PRPP, or ATP (1 mM).  
 
6.3.6 SAXS Data Processing 
 
Primary data reduction was performed using the scatterbrain 
software (Australian Sycnchrotron). Guinear fits were generated using 
Primus.68 All plots were checked for increasing intensity at low s, 
which is indicative of an aggregated sample. Indirect Fourier 
transformation was performed using GNOM to calculate the P(r) 
function, which shows the relative probabilities of distances between 
scattering centres and Dmax. Crysol69 was used to generate the 
theoretical scattering curves from the atomic coordinates (PDB 1H3D 
and 1Q1K) compared to the experimental scattering curves. The fits 
were evaluated by comparing the χ2 values. 
6.3.7 Cloning and Expression of EcoHisGcore 
 
 EcohisGcore was amplified from the EcohisGLpDONR221 
construct using two rounds of nested PCR. The first round amplified 
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the gene and part of the TEV cleavage site and the second round 
installed the attB sites for cloning using Gateway® technology. The 
purified PCR product was cloned into pDONR221 using the standard 
procedure for BP clonaseTM. Following sequence verification the 
EcohisGcore was cloned into pDEST-17 using the standard procedure for 
LR clonaseTM.  
 
Primers used to amplify EcohisGcore 
Reaction 1 







 Expression trials of both EcoHisGcore were performed in E. coli 
BL21*(DE3) and Chaperone 3 cells grown in 500 mL LB cultures at 37 
°C and 23 °C. The cell pellets were resuspended in 20 mL of lysis buffer 
(50 mM potassium phosphate pH 7.5, 50 mM NaCl, 5 mM MgCl2) and 
lysed by sonication. To test for ATP-PRTase activity 5-50 µL samples of 
the soluble fractions were introduced into the standard enzyme kinetic 
assay with 10 mM ATP and 1 mM PRPP.  
 
6.3.8 Cloning of NmehisZ and NmehisGS 
 
 NmehisGS was amplified from the N. meningitidis gDNA using 
two rounds of nested PCR. The first round amplified the gene and part 
of the TEV cleavage site and the second round installed the attB sites 
for cloning using Gateway® technology. PCR amplification was 
achieved using a three-step thermocycling protocol with an annealing 
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temperature of 45 °C for round one and 50 °C for round 2. The purified 
PCR product was cloned into pDONR221 using the standard procedure 
for BP clonaseTM. Following sequence verification, NmehisGS was 
cloned into pDEST-17 and pDEST-15 using the standard procedure for 
LR clonaseTM. 
 









 The Gateway® system was also used to clone NmehisGS into 
pDEST-14 with no tag. The pDEST-14 vector does not contain a 
ribosome binding site. The NmehisGS gene was amplified from the 
NmehisGSpDONR221 construct via two rounds of nested PCR. The 
first round incorporated the Shine-Delgarno sequence and the second 
round installed the attB sites for cloning using Gateway® technology. 
A three step thermocycling protocol with a 55 °C annealing 
temperature was employed for both reactions. The NmehisGS PCR 
product was introduced into pDONR221 using the standard procedure 
for BP clonaseTM. The sequence verified NmehisGSpDONR221 
construct was used to clone NmehisGS into pDEST-14 using the 
standard procedure for LR clonaseTM.  
 
Primers used to clone NmehisGS into pDEST-14: 
Reaction 1 








 NmehisGS was also subcloned into pET-21a using the InFusion® 
HD cloning kit. NmehisGS was amplified from the 
NmehisGSpDONR221 construct using primers designed to incorporate 
the overlapping regions for the InFusion® reaction. The pET-21a 
vector was digested with NdeI-HF and XhoI-HF (New England 
Biolabs).  
 
Primers designed to clone NmehisGS into pET-21a 
NmeHisG_pET21_F aaggagatatacatatgcaggataatgctttgaccatcgcct 
NmeHisG_pET21_R ggtggtggtgctcgaggacgtctcattacttcgccttcactgcgccgc  
 
 NmehisZ was cloned into multiple cloning site I of pRSFDuet-1 
with an N-terminal (His)6-tag. NmehisZ was amplified from the 
NmehisZpBSK vector purchased from Epoch Life Science using 
primers designed for cloning using the InFusion® enzyme. A two step 
thermocycling protocol with a 60 second extension time was employed. 
The pRSFDuet-1 vector was digested with BamHI-HF and HindIII-HF. 
Following sequence verification; NmehisGS was cloned into multiple 
cloning site II of the NmehisZpRSFDuet-1 construct. NmehisGS was 
amplified from the NmehisGSpDONR221 construct using primers 
designed to incorporate the complementary region for the InFusion® 
reaction. A two step thermocycling protocol was employed with a 30 
second extension time. The NmehisZpRSFDuet-1 vector was digested 
with NdeI-HF and AatII-HF (New England Biolabs).  
 









6.3.9 Purification of NmeHisZGS 
 
 Numerous purification protocols were employed, which are 
discussed in chapter three. This section reports the most successful 
purification protocol. The pellets from 500 mL cultures of 
NmehisZpRSFDuet-1 in BL21*(DE3) cells and NmehisGSpET-21a in 
Chaperone 3 cells were combined and resuspended in 20 mL lysis 
buffer (50 mM potassium phosphate pH 7.0, 300 mM NaCl, 5 mM 
MgCl2, 500 µM TCEP, 20 µM imidazole) and lysed by sonication. The 
supernatant was applied to a 5 mL HisTrap (GE Healthcare) and 
eluted with an imidazole gradient of 20 mM to 500 mM imidazole. The 
fractions containing NmeHisZGS were pooled, buffer exchanged, and 
loaded onto the size exclusion column pre equilibrated with SEC buffer 
(50 mM potassium phosphate pH 8.0, 100 mM NaCl, 5 mM MgCl2, 500 
µM TCEP). The fractions corresponding to NmeHisZGS and NmeHisGS 
were pooled separately and stored at -80 °C. 
 
 NmeHisZ was purified serendipitously while attempting to 
purify the NmeHisZGS complex. The pellet from a 1 L culture of 
NmehisZGSpRSFDuet-1 was resuspended in 20 mL lysis buffer (20 mM 
Tris-HCl pH 8.5, 100 mM NaCl, 5 mM MgCl2, 5 mM imidazole) and 
lysed by sonication. The supernatant was applied to a 5 mL HiTrap 
Talon Crude (GE Healthcare) IMAC column. The (His)6-tagged protein 
was eluted over an imidazole gradient of 5 mM to 250 mM.  The 
fractions containing NmeHisZGS were pooled, buffer exchanged, and 
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loaded onto the size exclusion column pre equilibrated with SEC buffer 
(20 mM Tris-HCl pH 8.5, 100 mM NaCl, 5 mM MgCl2, 5 mM 
imidazole). The fractions corresponding to NmeHisZ were pooled, 
concentrated to 10 mg/mL and stored at -80 °C. 
 
6.3.10  Determination of the Quaternary Structure of 
NmeHisZGS, NmeHisZ, and NmeHisGS by Analytical SEC 
 
Analytical SEC, using a Superdex 200 10/300 GL column (GE 
Healthcare), was employed to determine the multimeric state of 
NmeHisZGS, NmeHisZ and NmeHisGS. Samples (1 mL) and protein 
standards (Sigma Aldrich and GE Healthcare) were eluted in 
NmeHisZGS SEC buffer. 
 
6.3.11  Crystallisation Trials 
 
Freshly purified NmeHisZ was used in sitting drop vapour 
diffusion crystal trials with a Mosquito® LCP crystallisation robot. A 
range of commercial screens, including JCSG-plusTM HT-96, PACT 
premierTM HT-96, and Clear StrategyTM Screens 1 & 2 HT-96 
(Molecular Dimension) were employed with protein concentrations of 5 
mg/mL and 10 mg/mL and 400 nL drop size. In addition crystal trials 
were performed using hanging drop vapour diffusion in a 24 well 
format with the ProPlex (Molecular Dimensions) screen. Crystals were 
screened for diffraction at the MX1 beamline at the Australian 





6.3.12  Preliminary Kinetic Characterisation 
 
The standard enzyme kinetics assay was employed to determine 
the KMPRPP for NmeHisZGS (6 µM). The ATP concentration was held 
constant at 10 mM and the PRPP concentration was varied from 1 µM 
to 50 µM. The decision was made not to continue kinetic 
characterisation as the estimated kcat was three fold lower than that of 
LlaHisZGS and analytical SEC revealed aggregation of NmeHisZGS. 
 
6.4 Chapter Four Methods 
6.4.1  PCR Amplification of LmehisZGFusion 
 
 LmehisZGFusion was amplified from the LmehisZGFusionpBSK 
vector purchased from Epoch Life Science. Primers were designed to 
clone LmehisZGFusion into pET-28a, digested with NdeI and EcoRI, 
using the InFusion enzyme. A two-step thermocycling protocol was 






 The pET-28a vector was digested with NdeI-HF and EcoRI-HF 
(New England Biolabs). Both the linearised vector and PCR products 
were gel purified prior to incubation with the InFusion enzyme.  
 
6.4.2 Purification of LmeHisZGFusion 
 
 The pellet from a 1 L culture of LmeHisZGFusion in E. coli 
BL21*(DE3) cells was resuspended in 20 mL lysis buffer (50 mM 
potassium phosphate pH 7.5, 150 mM NaCl, 5 mM MgCl2, 200 µM 
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TCEP, 20 mM imidazole) and lysed by sonication. The supernatant 
was applied to a 5 mL HisTrap column (GE Healthcare) and the (His)6-
tagged LmeHisZGFusion was eluted by running an imidazole gradient 
from 20 mM to 500 mM over ten column volumes. The fractions 
corresponding to the A280nm peak were analysed by SDS-PAGE. The 
fractions containing LmeHisZGFusion were pooled, buffer exchanged, and 
loaded onto the Superdex S200 26/60 column (GE Healthcare) pre 
equilibrated with SEC buffer (50 mM potassium phosphate pH 7.5, 150 
mM NaCl, 5 mM MgCl2, 200 µM TCEP). The purified protein was 
concentrated to 5 mg/mL and stored at -80 °C.  
 
6.4.3 Construction of LlaHisZGFusion by PCR 
 
The amino acid sequence of the LlaHisZGFusion(long) construct is 
shown below. The TEV cleavage site is highlighted in cyan, the linker 
between the TEV site and LlaHisZ is underlined, and the linker 













To generate the LlahisZGFusion(long) PCR product, LlahisZ was 
amplified from the LlahisZpBSK vector with primers designed to 
incorporate 21 base pairs of the 63 base pair linker at the 3’ end of the 
PCR product (reaction 1). The purified product from reaction 1 was 
used as a template for the second PCR reaction that installed a further 
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33 base pairs of the linker (reaction 2). The same forward primer was 
used in both PCR reactions 
 









 LlahisGS was amplified from the LlahisGSpBSK vector using 
primers designed to incorporate 21 base pairs of the 63 base pair linker 
at the 5’ end of the PCR product (reaction 3). The purified PCR product 
was used as a template for an additional PCR reaction that installed a 
further 21 base pairs of the linker region (reaction 4). The same 
reverse primer was used in both amplifications.  
 










 Each of the PCR reactions used to amplify LlahisZ employed a 
two-step thermocycling protocol with a 60 second extension. PCR 
amplification of LlahisGS was achieved using a two-step thermocycling 
protocol with an extension time of 30 seconds. 
 
The LlahisZ and LlahisGS PCR products were stitched together 
by the addition of both purified PCR products, in an equimolar ratio, to 
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a standard PCR reaction, without primers. A two-step thermocycling 
protocol with a 90 second extension was run for 10 cycles prior to the 
addition of primers. The reaction proceeded for a further 30 cycles 
following the addition of the LlahisZ forward primer and LlahisGS 
reverse primer (reaction 5). The purified LlahisZGFusion(long) PCR 
product was used as a template for the final PCR step that installed 
the recognition sequence for cloning into pET-28a using the InFusion 
enzyme (reaction 6).  
 





LlaHisZG_Fusion_Inf_F cgcgcggcagccatatggagaatctgtacttccagg  
LlaHisZG_Fusion_Inf_R gacggagctcgaattctcatcagttggtctgagcgtcttc 
 
 The pET-28a vector was linearised with NdeI-HF and EcoRI-HF 
(New England Biolabs). The LlahisZGFusion(long) PCR product was 
introduced into pET-28a using the standard protocol for the InFusion 
system. 
 
 The amino acid sequence of LlaHisZGFusion(short), coloured in 













 The LlahisZpBSK construct was used as a template for the 
amplification of LlahisZ. Primers were designed to incorporate 17 
bases of the 30 base pair linker at the 3’ end of the PCR product 
(reaction 1). LlahisGS was amplified from the LlahisGSpBSK vector 
using primers designed to install 23 base pairs of the linker region at 
the 5’ end of the PCR product (reaction 2). The purified product from 
reaction 2 was used as a template for the third PCR reaction that 
introduced a further 17 base pairs of the linker at the 5’ end of the PCR 
product.  
 
Reaction 1  
LlaHisZG_Fusion_HisZ_f catatggagaatctgtacttccagg 
LlaHisZG_FusionS_rxn1_R acaatcggttcctgcggatcttcttccagctcctggcgtt 








 The purified LlahisZ and LlahisGS PCR products were 
combined, in an equimolar ratio, to amplify the fusion construct, as 
described for the formation of the LlahisZGFusion(long) PCR product. 
The LlahisZGFusion(short) PCR product was used as a template in the 
final PCR reaction, which installed the overlapping sequences for 










The pET-28a vector was linearised with NdeI-HF and EcoRI-HF 
(New England Biolabs). The LlahisZGFusion(short) PCR product was 
introduced into pET-28a using the standard protocol for the InFusion 
enzyme. 
 
6.4.4 Expression of LlaHisZGFusion 
 
 Expression trials of both LlaHisZGFusion constructs were 
performed in E. coli BL21*(DE3) and Chaperone 3 cells grown in 500 
mL LB cultures at 37 °C and 23 °C. The cell pellets were resuspended 
in 20 mL of lysis buffer (50 mM potassium phosphate pH 7.5, 150 mM 
NaCl, 5 mM MgCl2, 200 µM TCEP, 20 mM imidazole) and lysed by 
sonication. A 600 µL sample of each supernatant was applied to a His 
SpinTrap (GE Healthcare) and the (His)6-tagged protein was eluted 
with 500 mM imidazole. SDS-PAGE was used to analyse the fractions 
from the His SpinTrap in addition to the soluble and insoluble 
fractions from the lysis trial. To test for ATP-PRTase activity 5-50 µL 
samples of the soluble fractions and the His SpinTrap eluents were 
introduced into the standard enzyme kinetic assay with 10 mM ATP 
and 1 mM PRPP.  
 
6.4.5 PCR Amplification of LlahisGS-CjeACT 
 
 The amino acid sequence of the LlaHisGS-CjeACT chimera is 
shown below. The TEV protease cleavage site is highlighted in cyan, 
the linker between the TEV site and LlaHisGS is underlined, the 
LlaHisGS sequence is highlighted in green and the CjeACT domain 











 The LlahisGS gene was amplified from the LlahisGSpBSK vector 
using primers designed to install part of the TEV protease cleavage 
site at the 5’ end of the PCR product and a 14 base pair sequence 
complementary to the CjeACT sequence at the 3’ end (reaction 1). The 
purified PCR product was used as a template for the second PCR 
reaction to install the remainder of the TEV cleavage site (reaction 2). 
 








 The CjeACT sequence was amplified from the 
CjehisGLpDONR221 sequence using primers designed to include a 24 
base pair overlap with the LlahisGS sequence (reaction 3). A two-step 
thermocycling protocol with a 30 second extension time was employed 
for all amplifications.  
 
Primers designed to amplify the CjeACT sequence: 
 
Reaction 3 
LlaCje_Chimera_ACT_F cgaaatggttgaacgtgtagcaggagtaatgcaagcaaga  
LlaCje_Chimera_ACT_R tcatcactttaacattttttctataggcag 
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The purified LlahisGS and CjeACT PCR products were 
introduced into a PCR reaction without primers. A two-step 
thermocycling protocol was employed with a 30 second extension. The 
thermocycling protocol was run for 10 cycles at which point the 
protocol was paused and primers were added to amplify the LlahisGS-
CjeACT chimera (reaction 4). The purified product from reaction four 
was used as a template for the final amplification to install the 
recognition sequence for cloning into pET-28a using the InFusion 
enzyme (reaction 5).  
 









 The pET-28a vector was digested with NdeI-HF and EcoRI-HF 
(New England Biolabs). The final purified LlahisGS PCR product was 
cloned into pET-28a using the standard protocol for the InFusion 
enzyme.  
6.4.6 Expression of the LlaHisGS-CjeACT Chimera 
 
 Expression trials of the LlaHisGS-CjeACT chimera were 
performed in E. coli BL21*(DE3) and Chaperone 3 cells, grown in 500 
mL LB cultures at 37 °C and 23 °C. The cell pellets were resuspended 
in 20 mL of lysis buffer (50 mM potassium phosphate pH 7.5, 150 mM 
NaCl, 5 mM MgCl2, 200 µM TCEP, 20 mM imidazole) and lysed by 
sonication. A 600 µL sample of each supernatant was applied to a His 
SpinTrap (GE Healthcare) and the (His)6-tagged protein was eluted 
with 500 mM imidazole. SDS-PAGE was used to analyse the fractions 
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from the His SpinTrap in addition to the soluble and insoluble 
fractions from the lysis trial. To test for ATP-PRTase activity 5-50 µL 
samples of the soluble fractions and the His SpinTrap eluents were 
introduced into the standard enzyme kinetic assay with 10 mM ATP 
and 1 mM PRPP.  
 
6.4.7 E. coli BW25113ΔhisG Complementation Studies 
 
 E. coli BW25113ΔhisG cells from the Keio collection97 were 
provided by Dr Wayne Patrick from the University of Otago. This 
strain is devoid of the hisG gene and is auxotrophic for histidine. A 
kanamycin resistance cassette has replaced the hisG gene. The strain 
may therefore be grown selectively in the presence of kanamycin and 
either an exogenous supply of histidine or complementation of a 
functional ATP-PRTase. The cells were made chemically competent 
prior to use. 
 
Sterile solutions of agar, M9 salts, MgSO4, CaCl2, glucose, 
antibiotics, and either IPTG or histidine, were combined to make M9 
minimal media plates. 1.5 g of agar was mixed with 80 mL MilliQ and 
autoclaved. The agar was melted and incubated at 60 °C prior to use. A 
5× solution of M9 salts consisting of Na2HPO4 (34g/L), KH2PO4 (15 
g/L), NaCl (2.5 g/L), and NH4Cl (0.5 g/L) was prepared in MilliQ and 
autoclaved at 121 °C, 15 psi for 20 minutes. Solutions of MgSO4 (1 M), 
CaCl2 (0.1 M) and 20 % (w/v) glucose, IPTG (100 mM), and histidine (2 
g/L) were filter sterilised prior to use. M9 minimal media plates were 





Table 6.1 Recipe for M9 Minimal Media Agar Plates 
Component Stock Concentration Volume Added Final Concentration 
M9 Salts 5× 20 mL 1× 
MgSO4 1 M 200 µL 2 mM 
CaCl2 0.1 M 100 µL 0.1 mM 
Glucose 20 % 2 mL 0.4 % 
Ampicillin* 100 g/L 100 µL 0.1 g/L 
Kanamycin* 50 g/L 100 µL 0.05 g/L 
IPTG** 100 mM 1 mL 0.1 mM 
Histidine** 2 g/L 1 mL 0.002 g/L 
* Antibiotics were added as appropriate for the strain. The E. coli BW25113ΔhisG strain is 
kanamycin resistant therefore all M9 plates included kanamycin. The pET-28, pET-24 and 
pRSFDuet-1 vectors are kanamycin resistant, therefore cells that were transformed with these 
plasmids were grown on M9 plates containing only kanamycin. The pDEST-14/15/17 and pET-
21 vectors are ampicillin resistant; therefore cells that were transformed with these plasmids 
were grown on M9 plates containing both kanamycin and ampicillin. **M9 plates were made 
with either IPTG, to induce protein expression, or histidine as a positive control.  
 
 The E. coli BW25113ΔhisG cells were transformed with 
plasmids encoding functional and putative ATP-PRTase enzymes as 
per Table 6.2. An untransformed strain was used as both a positive 
and negative control. M9 minimal media plates were streaked with 5 
µL of transformation mixture and incubated at 37 °C. Plates were 
inspected each day for a maximum of three days to detect growth. The 



















NmeHisZGS NmehisGSpET-21a + NmehisZpRSFDuet-1 
LlaHisZGS LlahisGSpET-21a + LlahisZpRSFDuet-1 
NmeHisGS+LlaHisZ NmehisGSpET-21a + LlahisZpRSFDuet-1 
















LlaHisZGS SAXS Crysol Fits 
 
Crysol was used to fit the LlaHisZGS SAXS data to the X-ray 
crystal structures of LlaHisZGS (PDB 1Z7N), shown in Chapter Two, 




Figure I.1 (Left) Crysol fit of the LlaHisZGS SAXS data (blue) to the theoretical scattering obtained from 
the X-ray crystal structure of LlaHisZGS (PDB 1Z7M) (χ2 = 0.87). (Right) Crysol fit of the LlaHisZGS + 
histidine SAXS data (red) to the theoretical scattering obtained from the X-ray crystal structure of 
LlaHisZGS (PDB 1Z7M) (χ2 = 11). 
 
Figure I.2 (Left) Crysol fit of the LlaHisZGS SAXS data (blue) to the theoretical scattering obtained from 
the X-ray crystal structure of TmaHisZGS (PDB 1USY) (χ2 = 5.5). (Right) Crysol fit of the LlaHisZGS + 
histidine SAXS data (red) to the theoretical scattering obtained from the X-ray crystal structure of 




Complementation Studies with E. coli 
BW25113ΔhisG::kan 
 
 E. coli BW25113ΔhisG::kan cells from the Keio collection were 
transformed with plasmids encoding both functional and putative 
ATP-PRTase enzymes, and plated on M9 agar plates supplemented 
with either histidine or IPTG, as discussed in chapter four. The 




Figure II.1 The untransformed E. coli BW25113ΔhisG::kan strain plated on M9 + histidine agar plates and 
M9 + IPTG plates to form a positive and negative control respectively. Cell growth was observed on the 




Figure II.2 Complementation studies of the wild type long form ATP-PRTase proteins. Colonies were 
observed on all three experimental plates with EcoHisGL resulting in more growth than either Cje or 




Figure II.3 Complementation studies of the wild type short form ATP-PRTase proteins. Growth was 
observed on the LlaHisZGS and NmeHisZGS plates, indicating that these are both functional ATP-PRTase 
proteins. LmeHisZGS was unable to rescue the strain. 
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Figure II.4 Complementation studies of the combination of NmeHisZ with LlaHisGS and LlaHisZ with 
NmeHisGS, both of which were able to restore ATP-PRTase activity. 
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Figure II.5 Complementation studies of NmeHisGS, LlaHisGS and the HisGcore proteins. The HisGS and 
EcoHisGcore proteins were able to rescue the strain, however CjeHisGcore was not, although this may be due 




Figure II.6 Complementation studies of the LlaHisZGSFusion proteins and the LlaHisGS-CjeACT chimera, 
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